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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing loss of 
synaptic contacts and cognitive decline. It is widely believed that AD is initiated by synaptic 
dysfunction caused by production of A peptides. Therefore, understanding how the progression 
of amyloidogenesis alters synaptic function is imperative in developing effective therapeutics for 
disease intervention. 
While many studies have focused on how A peptides and the progression of AD affect 
frequency-dependent long-term potentiation and long-term depression (LTP/LTD), it is unclear 
whether synaptic dysfunction is at the level of induction or expression of synaptic plasticity 
mechanisms. Here we report that there is an age-dependent alteration in synaptic plasticity at the 
Schaffer collateral inputs to CA1 of APPswe;PS1deltaE9 AD transgenic (Tg) mice. Young pre-
amyloidogenic Tgs showed enhanced LTP at the expense of LTD, while adult post-
amyloidogenic Tgs showed enhanced LTD at the expense of LTP. The apparent shift in plasticity 
was mediated by altered LTP/LTD expression mechanisms, and in particular due to an absence of 
a normal age-dependent shift in pull-push metaplasticity. These results suggest that the main 
synaptic deficit in AD Tg mice is due to their inability to developmentally regulate LTP/LTD 
expression in accord with the pull-push metaplasticity model.    
Current AD therapeutics provide only temporary symptomatic relief, but need to strive to 
mitigate the long term progression of the disease by targeting the specific cellular mechanisms 
that become disrupted. Recognizing that cognitive decline during AD is correlated with loss of 
dendritic spine density, we examined two novel therapies that increase dendritic spine density 
through a Ras/ERK dependent mechanism. We found that the increase in dendritic spine density 
was better correlated with cognitive performance than the absolute magnitude of LTP. While 
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these therapies were investigated in wild type mice, they both exhibit potential as drug candidates 
for AD treatment and warrant further studies to determine their effects in mouse models of AD. 
In summary, this project provides a novel mechanistic viewpoint in understanding the 
synaptic dysfunction seen in AD that can lead to the development of more effective therapeutics 
by specifically targeting the fundamental cellular mechanisms that are disrupted, such as pull-
push metaplasticity.  
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Chapter 1: Introduction 
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H. Wang*; A. Megill*; K. He; A. Kirkwood; H-K. Lee (2012) Neural Plasticity 2012: 272374 
*These authors contributed equally to this work  
 
Note: Some parts of this work have been updated to include recent references and discoveries. 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing loss of 
synaptic contacts and cognitive decline. It is widely believed that AD is initiated by synaptic 
dysfunction, which may be the basis for memory loss in early stages of the disease (Walsh and 
Selkoe, 2004; Shankar and Walsh, 2009). Current theories implicate the production of amyloid 
beta (Aβ) as a key molecular event that ultimately leads to neuronal degeneration and the clinical 
pathology seen in AD (Hardy and Selkoe, 2002). Aβ is produced by sequential proteolytic 
cleavage of amyloid precursor protein (APP) by two endoproteolytic enzymes, β- and γ-secretase 
(Fig 1.1). Therefore, inhibiting the activity of these enzymes has surfaced as one of the major 
disease-modifying approaches for AD (Citron, 2004a). However, in order to develop effective 
therapeutics, a detailed molecular and cellular understanding of the role of both secretases in 
synaptic function is necessary. In addition, since accumulating evidence suggests that the initial 
pathology of AD is a result of synaptic dysfunction (Walsh and Selkoe, 2004; Shankar and 
Walsh, 2009), understanding how Aβ production alters normal synaptic function and what types 
of synaptic functions are differentially affected by Aβ becomes important in developing effective 
therapeutics for disease intervention. This introduction summarizes a number of experimental 
observations that address how Aβ affects synaptic function, and review data obtained from 
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genetically altered mice developed to test the feasibility of blocking APP processing enzymes 
which unveiled functional roles for these enzymes in normal synaptic transmission and plasticity. 
It also discusses a body of work, which investigates how synaptic function is affected by 
currently available therapies that target APP processing enzymes. Before this, a brief introduction 
to the topic and current understanding of synaptic plasticity, which are relevant for the later 
discussions.  
 
Section 1: Synaptic plasticity and memory formation 
It is widely believed that long-term changes in the strength of synaptic transmission 
underlie the formation of memories. Hebb is often recognized as the first person to crystallize this 
Figure 1.1. A diagram of amyloid precursor protein (APP) processing pathways. 
  
The transmembrane protein APP (membrane indicated in blue) can be processed by two pathways, the 
nonamyloidogenic α-secretase pathway and the amyloidogenic β-secretase pathway. In the 
nonamyloidogenic pathway, α-secretase cleaves in the middle of the β-amyloid (Aβ) region (red) to 
release the soluble APP-fragment sAPP- α. The APP C-terminal fragment 83 (APP-CTF83) is then 
cleaved by γ-secretase to release the APP intracellular domain (AICD) and P3 fragment. In the 
amyloidogenic pathway, β-secretase cleaves APP to produce the soluble fragment sAPP-β. APP-CTF99 




idea by proposing that coincident activity of pre- and postsynaptic neurons strengthens synaptic 
connections (Hebb, 1949). It was subsequently recognized that uncorrelated activity between two 
neurons should decrease the strength of synaptic transmission between them (Stent, 1973). The 
strengthening of synaptic connections is termed long-term potentiation (LTP), and is 
experimentally produced by high frequency stimulation (Bliss and Lomo, 1973), while the 
weakening of synaptic connections, produced by low frequency stimulation (Dudek and Bear, 
1992; Mulkey and Malenka, 1992), is called long-term depression (LTD). Since their initial 
discovery, both LTP and LTD have been found to occur in a diverse set of synapses across many 
different brain areas [reviewed in (Malenka and Bear, 2004)]. These long lasting forms of 
synaptic plasticity share similar mechanisms of induction, expression, and maintenance with 
those of long-term consolidation of several forms of memory (Lisman, 1989; Bailey et al., 1996; 
Bear, 1996; Martin et al., 2000; Paulsen and Sejnowski, 2000; Bliss et al., 2003; Lynch, 2004; 
Barco et al., 2006; Morris, 2006). Moreover, long-term alterations in synaptic transmission, 
similar to characteristics of LTP and LTD, have been observed in vivo during various learning 
paradigms (Rioult-Pedotti et al., 1998; Rodrigues et al., 2004; Schafe et al., 2005; Stefan et al., 
2006; Whitlock et al., 2006; Garner et al., 2012; Liu et al., 2012; Ramirez et al., 2013; Nabavi et 
al., 2014), which further suggests that LTP and LTD may be cellular substrates for memory 
formation. 
While LTP and LTD are effective models for mediating synapse-specific changes 
required for memory formation, theoretical considerations indicate that maintaining the stability 
of the nervous system requires additional homeostatic plasticity mechanisms that operate at a 
slower time scale (hours to days) (Bienenstock et al., 1982; Bear et al., 1987; Abraham and Bear, 
1996; Turrigiano et al., 1998; Turrigiano and Nelson, 2004). For example, without homeostatic 
regulation, the increase in postsynaptic activity after LTP might result in a vicious cycle of 
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potentiation that not only degrades the capacity of neural circuits to store specific information, 
but could also culminate in a run-away excitation of the neural network. There are several 
mechanisms of homeostasis that can stabilize the nervous system: adjusting excitatory synaptic 
transmission postsynaptically (Bienenstock et al., 1982; Bear et al., 1987; Turrigiano et al., 1998; 
Abbott and Nelson, 2000; Turrigiano and Nelson, 2004), modulating the excitability of neurons 
(Desai et al., n.d.; Aizenman et al., 2003; Maffei et al., 2004), changing inhibitory circuits 
(Kilman et al., 2002; Morales et al., 2002; Maffei et al., 2004, 2006), and altering presynaptic 
function (Burrone et al., 2002; Thiagarajan et al., 2002, 2005). While most studies of synaptic 
plasticity related to memory formation focus on LTP and LTD, it is prudent to understand that 
alterations in homeostatic plasticity can also affect learning and memory.  
 
Section 2: Molecular mechanisms of synaptic plasticity: a brief overview 
While LTP and LTD have been observed in many different brain areas, the majority of 
knowledge about their molecular mechanisms comes from studies in the hippocampus. This is 
partly because the hippocampus is an area of the brain that is critically involved in the formation 
of long-term memories [reviewed in (Lynch, 2004)]. In addition, the hippocampus is one of the 
areas highly susceptible to amyloid pathology in most AD brains [reviewed in (Walsh and 
Selkoe, 2004)]. Therefore, a brief review of the mechanisms of synaptic plasticity in the 
hippocampus is provided. 
In the hippocampus, two major forms of LTP and LTD are observed: one that is 
dependent on NMDA receptor (NMDAR) activation and another that is independent of NMDARs 
(Nicoll and Malenka, 1995; Lynch, 2004). The most widely studied forms of LTP and LTD are 
those dependent on NMDARs in the CA1 region; hence, their mechanisms have been fairly well 
characterized. Therefore, most of this discussion will focus on the NMDAR-dependent forms of 
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LTP and LTD. NMDARs, due to activity-dependent relief of their Mg2+ block (Malenka and 
Nicoll, 1999), act as coincident detectors for pre- and postsynaptic activity. In addition, activation 
of NMDARs allows influx of Ca2+ (Connor et al., 1999; Yuste et al., 1999; Kovalchuk et al., 
2000), which can act as a second messenger to activate various downstream effectors in the 
postsynaptic neuron. It is thought that both the magnitude and temporal pattern of Ca2+ increase 
determines the expression of either LTP or LTD, by differentially regulating the activity of 
protein kinases and phosphatases (Lisman, 1989). One of the key downstream events of LTP and 
LTD is the regulation of synaptic AMPA receptors (AMPARs) [for review see (Malinow and 
Malenka, 2002; Lee, 2006; Lee and Kirkwood, 2011)]. AMPARs are the major mediators of fast 
excitatory synaptic transmission in the central nervous system (CNS); therefore, their function 
directly dictates synaptic strength. Several studies demonstrated that LTP increases the synaptic 
content of AMPARs, predominantly by an activity-dependent insertion of receptors containing 
the GluA1 subunit (GluR1) (Shi et al., 1999, 2001; Hayashi et al., 2000). This requires 
concomitant activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) and 
phosphorylation of the AMPAR subunit GluA1 at serine 818 (S818) (Boehm et al., 2006) and 
serine 845 (S845) (Esteban et al., 2003). GluA1-S818 is a protein kinase C (PKC) 
phosphorylation site (Boehm et al., 2006) while GluA1-S845 is a protein kinase A (PKA) 
phosphorylation site (Roche et al., 1996). In addition to these two sites, phosphorylation of 
GluA1-S831, which can be phosphorylated by both PKC (Roche et al., 1996) and CaMKII 
(Barria et al., 1997a; Mammen et al., 1997), has been shown to correlate with LTP (Barria et al., 
1997b; Lee et al., 2000a). However, this site is not necessary for LTP (Lee et al., 2010a) nor 
synaptic trafficking of AMPARs (Hayashi et al., 2000). Many studies confirm that CaMKII, 
PKC, and PKA are involved in NMDAR-dependent LTP [reviewed in (Lee, 2006; Lu and Roche, 
2012; Henley and Wilkinson, 2013)]. Consistent with a dominant role for GluA1 in mediating 
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synaptic potentiation, GluA1 knockout mice (Zamanillo et al., 1999), as well as mice lacking 
specific phosphorylation sites on GluA1 (Lee et al., 2003), display LTP deficits. On the other 
hand, NMDAR-dependent LTD is associated with an activity-dependent removal of synaptic 
AMPARs (Carroll et al., 2001). This process depends on endocytosis of GluA2-containing 
receptors (Lüthi et al., 1999; Daw et al., 2000; Lin et al., 2000; Man et al., 2000; Osten et al., 
2000; Kim et al., 2001a; Lee et al., 2004), but also requires dephosphorylation at GluA1-S845 
(Lee et al., 1998, 2000a, 2003). 
While regulation of synaptic AMPARs, through synaptic targeting and phosphorylation, 
is involved in the initial expression of LTP and LTD, maintenance of these forms of plasticity 
involve additional mechanisms. Collectively, data from many studies report that blocking new 
protein synthesis inhibits the late phase of long-term synaptic plasticity (Krug et al., 1984; 
Stanton and Sarvey, 1984; Frey et al., 1988; Huber et al., 2000; Manahan-Vaughan et al., 2000; 
Kelleher et al., 2004). This parallels the requirement for new protein synthesis in the formation of 
long-term memory in intact animals (Flexner et al., 1963; Davis and Squire, 1984) [see review 
(Sutton and Schuman, 2006)]. Transcriptional activation is also necessary for the maintenance of 
some forms of long-term synaptic plasticity (Nguyen et al., 1994). So far, it is known that 
multiple transcription factors are activated immediately after induction of LTP. Increased 
transcription of several immediate early genes (IEG) is especially important (Tischmeyer and 
Grimm, 1999) since they enhance new protein synthesis (Lynch, 2004; Barco et al., 2006). 
Interestingly, some, if not all, of these transcriptional regulators are also required for long-term 
memory formation. Disruption of cAMP Response Element-Binding Protein (CREB) levels, a 
Ca2+-dependent transcription factor, in either the hippocampus or the amygdala has been found to 
impair specific long-term memory but not initial acquisition or short-term memory formation 
(Guzowski and McGaugh, 1997; Lamprecht et al., 1997; Silva et al., 1998). Inhibiting the 
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expression of Arc/Arg 3.1 (activity-regulated cytoskeletal protein/activity regulated gene 3.1), an 
IEG, in the hippocampus also impairs long-term memory consolidation (Guzowski et al., 2000).  
 
Section 3: Exogenous Aβ application alters synaptic function 
Much of the molecular understanding of AD came from studying familial AD (FAD)-
linked mutations, which have been found in genes encoding APP and presenilin 1 and 2 (PS1 and 
2) in AD patients. These mutations are linked to elevated Aβ production (Scheuner et al., 1996; 
Lendon et al., 1997). For example, the FAD-linked APPswe mutation makes APP a more favorable 
substrate for the amyloidogenic cleavage pathway leading to increased A production. Since 
Figure 1.2. Concentration-dependent effects of Aβ on synaptic function.  
 
At normal physiological levels (picomolar range), Aβ peptides have positive effects on synaptic function: 
they can positively regulate presynaptic release probability and facilitate learning and LTP in CA1 by 
activating α7-nAChRs. However, when the concentration of Aβ peptides is lower than normal, 
presynaptic function is impaired. On the other hand, under pathological conditions, such as increased 
neuronal activity, stress, or the presence of familial Alzheimer’s disease (FAD) mutations, the increase in 
Aβ peptide concentration produces pathological effects, including decreased presynaptic neurotransmitter 
release, reduced postsynaptic responsiveness, LTP impairment, and LTD facilitation. Therefore, 
maintaining the concentration of Aβ peptides within a normal physiological range is essential and should 




FAD patients often harbor multiple mutations, many of the AD mouse models also carry several 
FAD mutations. However, depending on the combination of the mutations and their variants, 
distinct phenotypes are observed across age and brain regions studied [for an extensive recent 
review on electrophysiological studies of various AD transgenic (Tg) mouse models see 
(Marchetti and Marie, 2011)]. 
Although different AD mouse models show deficits in synaptic function, it cannot be 
taken for granted that these deficits are caused directly by the enhanced production of Aβ 
peptides (especially Aβ42, which is the major component of extracellular senile plaques). In order 
to directly test the role of Aβ in altering synaptic function, many studies have investigated 
synaptic properties and synaptic plasticity following exogenous application of various Aβ 
peptides.  
In vitro studies done in either the medial perforant path to dentate granule cells or the 
Schaffer collateral inputs to CA1 neurons, reported that application of subneurotoxic 
concentrations of Aβ peptides (i.e. Aβ42, Aβ40, or Aβ25-35) inhibits LTP induction without 
affecting basal synaptic transmission (Chen et al., 2000, 2002; Zhao et al., 2004). A similar result 
was found in an in vivo study, where naturally secreted Aβ collected from cells expressing 
mutated APP (V717F mutation in APP751) was injected into the CA1 region of hippocampus 
which prevented stable LTP maintenance (Walsh et al., 2002). This study further showed that 
soluble Aβ oligomers, not monomeric Aβ, or Aβ fibrils, are responsible for blocking LTP (Walsh 
et al., 2002). In addition, in vivo injection of Aβ peptides (i.e. Aβ42 or the C-terminal of APP 
which contains the Aβ fragment) is reported to facilitate LTD and LTP reversal (called 
depotentiation) in the CA1 region (Kim et al., 2001b). A majority of studies suggest that while 
fibrillar Aβ accumulation is found in senile plaques that are a hallmark of AD, it is the soluble Aβ 
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oligomers that disturb synaptic function and lead to neurodegeneration in AD (Walsh et al., 2002; 
Tanzi, 2005).  
Subsection 1: Postsynaptic alterations by Aβ 
Soluble Aβ oligomers in AD brains have been found to bind to neuronal surfaces (Gong 
et al., 2003), specifically to a subset of synapses where they colocalize with a postsynaptic 
density marker PSD95 (Lacor et al., 2004), suggesting that Aβ may regulate postsynaptic 
function directly. One candidate target of Aβ is NMDARs. It was found that synthetic Aβ40 
peptides can selectively augment NMDAR currents, without affecting AMPAR currents, in the 
dentate gyrus of acute hippocampal slices (Wu et al., 1995). Consistent with this, APPInd (V717F 
mutation) Tg mice show an enhancement in the ratio of NMDAR-to-AMPAR-mediated synaptic 
transmission in the CA1 region (Hsia et al., 1999). However, contradictory results are reported 
from later studies. A recent study showed that both application of synthetic Aβ42 peptides and 
naturally secreted Aβ, from APPSwe (K670N/M671L mutation) Tg mice, promote endocytosis of 
surface NMDARs and hence depress NMDAR currents in wild type cultured cortical neurons 
(Snyder et al., 2005). Moreover, they also found reduced surface expression of NMDARs in 
cultured cortical neurons from APPSwe Tg mice (Snyder et al., 2005). Other studies found down-
regulation of surface AMPARs in neurons overexpressing either wild type or APPSwe, or when 
wild type neurons were treated with exogenous Aβ42 peptides (Almeida et al., 2005; Hsieh et al., 
2006). This is mediated not only by endocytosis of synaptic AMPARs via mechanisms shared by 
LTD (Hsieh et al., 2006), but also through a reduction in basal levels of GluA1-S845 
phosphorylation by activating the calcium-dependent phosphatase, calcineurin, as well as 
interrupting extrasynaptic delivery of AMPARs (Miñano-Molina et al., 2011). Contradictory 
results on the effects of Aβ on AMPAR and NMDAR regulation may be due to several variables. 
First, there is evidence that Aβ40 and Aβ42 peptides may have distinct functions in AD pathology. 
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For example, a majority of FAD-linked PS1 mutations cause a reduction in Aβ1-40 peptides and 
therefore an increase in the Aβ42/Aβ40 ratio (Borchelt et al., 1996; Thinakaran and Sisodia, 2006). 
Second, there are differences in experimental preparations. Both Wu et al. (Wu et al., 1995) and 
Hsia et al. (Hsia et al., 1999) were working with acute adult hippocampal slices, while Snyder et 
al. (Snyder et al., 2005), Almeida et al. (Almeida et al., 2005), Hsieh et al. (Hsieh et al., 2006) and 
Minano-Molina et al. (Miñano-Molina et al., 2011) were using either cultured neurons from 
embryonic mice or organotypic hippocampal slice cultures prepared from early postnatal mice. 
Third, the presence or absence of APP itself may have also affected the results. Indeed, there is 
evidence that uncleaved full-length APP may promote synapse formation and enhance excitatory 
synaptic function [see (Hoe et al., 2012) for a recent review]. 
In any case, Aβ mediated alterations in NMDAR function suggests that Aβ will affect 
downstream Ca2+-dependent signaling pathways. Calcineurin, a Ca2+-activated protein 
phosphatase, may be one of the downstream signaling molecules affected by Aβ, since it is 
required for the inhibition of perforant pathway LTP (Chen et al., 2002), endocytosis of surface 
AMPARs (Hsieh et al., 2006), as well as dephosphorylation of GluA1-S845 (Miñano-Molina et 
al., 2011). In addition to activating calcineurin, Aβ prevents the activation of CaMKII, a Ca2+-
dependent protein kinase necessary for LTP, and decreases the synaptic clustering of CaMKII, 
which correlates with a reduction in the phosphorylation of GluA1-S831, surface expression of 
GluA1, and AMPAR mediated EPSCs (Zhao et al., 2004; Gu et al., 2009). Together, these data 
are consistent with the idea that Aβ oligomers impair LTP and facilitate LTD (Lee et al., 2000a; 
Knobloch et al., 2007; Li et al., 2009).  
A has also been found to modify regulation of gene expression. Aβ peptides have been 
found to alter CREB signaling, causing synaptic dysfunction and memory deficits [reviewed in 
(Saura and Valero, 2011)]. In addition, treating cultured hippocampal neurons with soluble Aβ 
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oligomers induces rapid expression of the IEG Arc/Arg 3.1 (Lacor et al., 2004), which is 
implicated in synaptic plasticity (Guzowski et al., 2000; Steward and Worley, 2001; Shepherd et 
al., 2006). Because overexpression of Arc/Arg 3.1 causes learning deficits (Guzowski, 2002), 
possibly via reducing surface expression of GluA1-containing AMPARs (Shepherd et al., 2006), 
this would suggest that Aβ oligomer-induced Arc/Arg3.1 expression may in fact interfere with 
normal synaptic plasticity. However, this study is seemingly at odds with the results of Echeverria 
and colleagues, which reported a strong inhibition of BDNF-induced increase in Arc expression 
in cultured cortical neurons treated with Aβ oligomers (Echeverria et al., 2007). Similarly, there 
is also a report that synaptic plasticity related genes, including Arc/Arg3.1, are reduced in 
transgenic mice expressing FAD-linked mutations in APP and PS1 (Dickey et al., 2003). The 
apparent differences in Arc expression caused by A could be due to different experimental 
systems, or to the differential effects of different concentrations of A oligomers. 
Subsection 2: Presynaptic alterations by Aβ 
Besides influencing postsynaptic function, Aβ is also implicated in presynaptic 
modifications. A recent study reported that 8 nM Aβ42 globulomer (a highly stable globular 
oligomeric Aβ) could directly inhibit presynaptic P/Q type Ca2+ channels and decrease vesicle 
release (Nimmrich et al., 2008). Moreover, application of synthetic Aβ to cultured hippocampal 
neurons causes a down-regulation of dynamin, a protein critical for synaptic vesicle endocytosis, 
and interrupts synaptic vesicle recycling (Kelly et al., 2005; Kelly and Ferreira, 2007). This result 
is consistent with the observed reduction in dynamin levels in human AD brains (Yao et al., 
2003). These findings may explain the observation that Aβ42 globulomer causes a decrease in 
basal synaptic transmission at the Schaffer collateral to CA1 synapses in hippocampal slice 
culture (Nimmrich et al., 2010). Recently, Kelly et al. reported that the reduction in dynamin is 
dependent on Ca2+ influx through activated NMDARs as well as activation of a calcium-activated 
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intracellular cysteine protease, calpain (Kelly et al., 2005; Kelly and Ferreira, 2006). These results 
not only suggest that there may be retrograde signaling from postsynaptic to presynaptic 
terminals, but also establish an interesting relationship between Aβ, NMDARs and calpain. It has 
been found that Aβ42 peptides can activate calpain-mediated cleavage of p35 to p25 (Lee et al., 
2000b), which then upregulates mRNA and protein expression of β-secretase (BACE1) (Wen et 
al., 2008; Liang et al., 2010), a critical enzyme for Aβ formation (discussed in the following 
sections). This indicates that there is a positive feedback between Aβ production and calpain 
activation. Calpain inhibitors can fully prevent deficits in basal synaptic transmission caused by 
Aβ globulomer application in hippocampal slice culture to a comparable level as using an 
NMDAR antagonist memantine (Nimmrich et al., 2010). This suggests that Aβ acts through 
NMDARs and calpain: a potential signaling cascade being NMDAR-medicated Ca2+ influx 
activating intracellular calpain, which then promotes p25/cdk5 dependent transcription of 
downstream genes, including BACE1 (Wen et al., 2008).  
Subsection 3: Other targets of Aβ that affect synaptic plasticity 
Recent studies suggest that the α7-nicotinic acetylcholine receptor (α7-nAChR), a Ca2+-
permeable homopentameric ion channel highly expressed in the hippocampus and cerebral cortex 
(Séguéla et al., 1993), is another potential target of Aβ. High affinity binding between Aβ42 
peptides and α7-nAChRs (Wang et al., 2000a, 2000b) either inhibit (Guan et al., 2001; Liu et al., 
2001a; Pettit et al., 2001; Chen et al., 2006) or activate α7-nAChR signaling (Dineley et al., 
2001). It is possible that Aβ42 peptides may facilitate α7-nAChRs at low concentrations, but may 
inhibit α7-nAChRs when the burden of Aβ increases (Dineley et al., 2001; Dougherty et al., 
2003). This concentration-dependent role of Aβ peptides is suggested from studies showing that 
at normal concentrations (picomolar range), Aβ peptides positively regulate presynaptic release at 
hippocampal synapses and facilitate CA1 LTP and learning by activating α7-nAChRs; whereas 
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when the level of Aβ is low or high (nanomolar range), Aβ peptides cause either deficits in 
presynaptic function or abolish hippocampal LTP and learning via its interaction with α7-
nAChRs (Puzzo et al., 2008; Abramov et al., 2009; Palop and Mucke, 2010a). 
Moreover, the concentration-dependent effect of Aβ is also reflected by its ability to 
regulate reactive oxygen species (ROS). ROS have been found to have physiological roles in 
maintaining normal synaptic plasticity. However, high levels of ROS have been found in both AD 
animal models and human patients, leading to oxidative damage related to AD pathology 
[reviewed in (Massaad and Klann, 2011)]. Recently, Ma and colleagues found that exogenous 
treatment of Aβ42 (500 nM) increased mitochondria superoxide, which they reported is a cause of 
synaptic dysfunction induced by Aβ. In particular, decreasing mitochondrial superoxide levels 
reversed Aβ-induced CA1 LTP impairments (Ma et al., 2011). Given the normal physiological 
role of Aβ and ROS at intermediate levels, this finding suggests that ROS imbalance, caused by 
Aβ toxicity, may lead to synaptic dysfunction in AD. It also implies that Aβ levels exceeding the 
normal range may initiate the abnormalities in synaptic function (Fig 1.2).  
In summary, pathologically high levels of Aβ can disturb the ROS balance and interfere 
with both pre- and postsynaptic function, presumably by affecting NMDARs, presynaptic P/Q 
Ca2+ channels, and/or α7-nAChRs, thereby interrupting subsequent Ca2+ signaling leading to 
altered synaptic function. 
 
Section 4: Neuronal activity can regulate APP processing and Aβ levels 
Data from both transgenic mice and exogenous Aβ application studies suggest that 
alterations in Aβ levels change neuronal activity and synaptic function. In vivo two-photon Ca2+ 
imaging of APP23xPS45 mice showed that cortical neurons near amyloid plaques are 
hyperactive, while the percentage of hypoactive cortical neurons is enhanced at locations further 
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away from a plaque (Busche et al., 2008, 2012). The disparate change in neuronal activity caused 
by the location of a neuron relative to amyloid plaques may reflect differences in local Aβ 
concentration. It is now evident that neuronal activity itself can also regulate APP processing 
leading to alterations in Aβ production. In 1993, a study reported that electrical stimulation not 
only increases neurotransmitter release in rat hippocampal slices, but also enhances the release of 
APP cleavage products (Nitsch et al., 1993). In agreement with this finding, ten years later, 
Kamenetz and colleagues (Kamenetz et al., 2003) found that neuronal activity can bidirectionally 
control Aβ levels in organotypic hippocampal slice cultures from APPSwe Tg mice. Blocking 
neuronal activity in this preparation by tetrodoxin (TTX) treatment reduced Aβ levels, while 
increasing neuronal activity with picrotoxin (PTX) enhanced Aβ secretion (Kamenetz et al., 
2003). The experimental paradigm used by Kamenetz et al. to manipulate neuronal activity is 
reported to produce homeostatic synaptic plasticity termed “synaptic scaling” (Turrigiano et al., 
1998), which globally up- or down-regulates all excitatory synapses following prolonged 
decrease or increase, respectively, in neuronal activity (Turrigiano and Nelson, 2004). Indeed, a 
recent paper from our lab showed that the absence of A in mice lacking BACE1 (-secretase) 
result in an inability to appropriately scale synapses in response to experience-dependent changes 
in activity (Petrus and Lee, 2014). This suggests that Aβ may play a role in regulating 
homeostasis of excitatory synapses in normal brains. In addition, the cellular mechanism 
responsible for regulating APP processing and Aβ production in response to neuronal activity, is 
possibly through enhancing the accessibility of APP to γ-secretase cleavage (Kamenetz et al., 
2003) and/or depressing γ-secretase function (Lesné et al., 2005). It has recently been shown that 
PS1, the catalytic subunit of the γ-secretase complex, is necessary to scale up excitatory synapses 
following reduced network activity and that PS1 knockout mice show deficits in synaptic scaling 
(Pratt et al., 2011b). Moreover, Wu and colleagues have reported that the immediate early gene 
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Arc is required for the activity-dependent increase in Aβ production (Wu et al., 2011). They 
found that Arc directly binds the N terminus of PS1 and plays an important role in trafficking the 
γ-secretase complex to early endosomes where APP is processed through the amyloidogenic 
pathway to produce Aβ peptides. In addition, Arc contributes to Aβ levels and plaque load in 
APPswe;PS1deltaE9 mice, and Arc expression is elevated in the medial frontal cortex of AD 
patients (Wu et al., 2011). These results provide a cellular mechanism coupling Aβ generation to 
neuronal activity, and may explain why people who suffer from hypoxia, which usually causes an 
abnormal enhancement in neuronal activity (Talos et al., 2006), have a higher risk for developing 
AD (Desmond et al., 2002).   
Consistent with the idea that Aβ induces homeostatic adaptation to increases in activity, 
in vivo studies have also shown that either electrical stimulation or endogenous whisker activity 
proportionally regulate interstitial fluid (ISF) Aβ levels in Tg2576 mice, which overexpress 
human APP carrying the Swedish (K670N/M671L) mutation (Cirrito et al., 2005, 2008; Bero et 
al., 2011). However, there are also contradictory results. Tampellini et al. have shown that 
synaptic activity decreases intracellular Aβ in primary neuronal culture, as well as in the barrel 
cortex of 4-month old Tg19959 mice, which overexpress human APP carrying the Swedish 
(K670N/M671L) and Indiana (V717F) mutations (Li et al., 2004), likely by enhancing Aβ 
degradation (Tampellini et al., 2009). Zhang et al. have reported that prolonged olfactory 
deprivation facilitates amyloid plaque deposition in the olfactory bulb and piriform cortex of 7-
24-month old Tg2576 mice (Zhang et al., 2010c). These contradictions may be due to age, region, 
and paradigm differences. Another possibility is that normal neuronal activity regulates Aβ levels 
by balancing Aβ release and degradation, and that either hyperactivity or hypoactivity may break 




Section 5: Physiological roles of APP and Aβ 
Proteolytic processing of APP not only produces Aβ peptides, but also other products. 
Some functions of these products have been identified [reviewed in (Pearson and Peers, 2006; 
Chow et al., 2010; Zhang et al., 2011)]. For example, the cytoplasmic tail of APP, APP 
intracellular domain (AICD), is shown to participate in transcriptional regulation (Cao and 
Südhof, 2001). To evaluate other normal physiological roles of APP, mice lacking APP were 
generated. APP knockouts show enhanced excitatory synaptic activity and neurite growth (Priller 
et al., 2006), which is consistent with the finding that APP-deficient mice are more susceptible to 
glutamate-induced toxicity (Steinbach et al., 1998). Similar to APP, Aβ peptides also have normal 
physiological functions. Normal levels (picomolar range) of Aβ peptides regulate synaptic 
function by positively increasing presynaptic release at hippocampal synapses and facilitating 
learning and LTP in CA1 (Puzzo et al., 2008; Abramov et al., 2009; Palop and Mucke, 2010a). 
Moreover, normal levels of Aβ may be essential for neurons, because preventing Aβ production 
by adding β- or γ-secretase inhibitors in cultured neurons causes cell death, which can be rescued 
by applying synthetic Aβ peptides to culture medium (Plant et al., 2003). In addition, activity-
dependent changes in Aβ may in fact play a role in maintaining homeostasis by acting as a 
negative feedback regulator of excitatory synaptic transmission (Kamenetz et al., 2003).  
Collectively, these data suggest that proteolytic processing of APP and the presence of a 
normal physiological dose of Aβ may be required for maintaining proper neuronal activity and 
brain function. While the therapeutic benefits of targeting APP processing and Aβ production are 
still attractive, it should be noted that AD pathology is most likely triggered only when Aβ levels 
exceed the normal range, and that the physiological processing of APP and Aβ production may be 
important in maintaining normal brain functions. Therefore, partial inhibition, but not complete 
blockade, of Aβ production might be a useful approach for AD therapeutics. A recent study 
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supports this view. Immunizing APPInd Tg mice against Aβ, which lowered Aβ levels, decreased 
senile plaque formation, and rescued loss of neuronal integrity seen previously in aged mice 
(Buttini et al., 2005). However, Aβ-immunotherapy in clinical trials reported severe 
complications, which must be overcome [for review articles on this topic please see (Schenk et 
al., 2001; Lemere, 2009; Town, 2009; Spencer and Masliah, 2014)]. 
 
Section 6: Role of BACE1 in synaptic function 
As mentioned above, Aβ peptides are generated by sequential cleavage of APP by β- and 
-secretase (Fig 1.1). In the brain, BACE1, a transmembrane aspartic protease, has been found to 
be the major neuronal β-secretase (Vassar et al., 1999; Cai et al., 2001; Luo et al., 2001; Roberds 
et al., 2001). Mice lacking the BACE1 gene show no β-secretase activity and essentially no Aβ 
(Aβ40 and Aβ42) production in the brain compared to wild type littermates. Initial characterization 
of BACE1 knockouts (BACE1 -/-) showed that they are viable and fertile, with no gross 
differences in behavior or development (Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001; 
Ohno et al., 2004). Furthermore, knocking out the BACE1 gene in mouse models of AD was able 
to rescue hippocampus-dependent memory deficits (Ohno et al., 2004, 2006; Laird et al., 2005) 
and ameliorate impaired hippocampal cholinergic regulation of neuronal excitability (Ohno et al., 
2004). These findings were quite encouraging and suggested that BACE1 may be a good 
therapeutic target for treating AD (Citron, 2002, 2004a, 2010; Vassar, 2002). 
However, recent studies have found that BACE1 has normal physiological functions in 
synaptic transmission and plasticity in both CA1 and CA3 regions of the hippocampus (Table 
1.1). Laird et al. found that BACE1 -/- mice display deficits in both synaptic transmission and 
plasticity at the hippocampal Schaffer collateral to CA1 synapses (Laird et al., 2005). While 
BACE1 -/- mice display normal AMPAR- and NMDAR-mediated synaptic transmission, these 
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synapses show a larger paired-pulse facilitation (PPF) ratio compared to wild type littermates 
when tested with paired-pulse stimuli at a 50 ms interstimulus interval (Laird et al., 2005). 
Changes in PPF ratio are linked to alterations in presynaptic function (Manabe et al., 1993). 
Therefore, the increase in PPF ratio observed in BACE1 -/- mice indicates a reduction in 
presynaptic function, which is consistent with the high expression of BACE1 in presynaptic 
terminals (Laird et al., 2005). In addition to reflecting presynaptic changes, recent data suggest 
that alterations in PPF ratio can also be caused by postsynaptic modifications, such as by varying 
the subunit composition of AMPARs (Rozov et al., 1998). Therefore, it is possible that knockout 
of BACE1 may also affect postsynaptic AMPAR function. Besides alterations in PPF ratio, 
BACE1 -/- mice also showed a larger de-depression (reversal of LTD) induced by high frequency 
theta burst stimulation (TBS) at the Schaffer collateral inputs to CA1 (Laird et al., 2005). In 
contrast, the same TBS protocol induced-LTP remained unchanged (Laird et al., 2005). As LTP 
and de-depression have separate underlying mechanisms (Lee et al., 2000a), these data suggest 
BACE1 may play a regulatory role in the de-depression pathway, while not affecting the 
mechanisms that lead to LTP. Laird and colleagues also found evidence that the enhanced de-
depression is due to larger summation of responses during TBS, specifically following LTD 
induction. Enhanced summation of synaptic responses during the induction of de-depression 
despite normal basal synaptic transmission suggests that BACE1 may play a specific role in 
activity-dependent high frequency information transfer across synapses. Also, the abnormal 
increase in the magnitude of de-depression reflects that LTD expression may be easily disrupted 
when knocking out BACE1, which could interfere with memory formation and storage. 
Consistent with this interpretation, detailed behavioral studies of BACE1 -/- mice reported 
problems in both cognitive and emotional memory tests (Harrison et al., 2003; Laird et al., 2005; 
Ma et al., 2007). 
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Although the majority of studies characterizing synaptic function of BACE1 -/- mice 
have been performed in the CA1 region of the hippocampus (Ohno et al., 2004; Laird et al., 2005; 
Ma et al., 2007), the expression of BACE1 is most prominent in the mossy fiber terminals that 
synapse onto CA3 pyramidal neurons (Laird et al., 2005; Zhao et al., 2007). Recently, our lab 
reported that BACE1 -/- mice display severe deficits in presynaptic function at these synapses, 
including a reduction in presynaptic release and an absence of mossy fiber LTP, which is 
normally expressed by a long-term increase in presynaptic release (Wang et al., 2008; Nicoll and 
Schmitz, 2005). 
Moreover, BACE1 -/- mice exhibited a slightly larger mossy fiber LTD, which could not 
be reversed (Wang et al., 2008). These results suggest that BACE1 function is crucial for normal 
synaptic transmission and activity-dependent presynaptic potentiation at these synapses. We 
further found evidence that the presynaptic dysfunction in BACE1 -/- mice is likely at the level of 
presynaptic Ca2+ signaling, because the mossy fiber LTP deficit in BACE1 -/- mice could be 
recovered by increasing the extracellular Ca2+ concentration. This suggests that the signaling 
downstream of Ca2+ is more or less intact in BACE1 -/- mice, which was confirmed by the fact 
that the magnitude of presynaptic potentiation resulting from direct activation of the cAMP 
signaling pathway is normal in BACE1 -/- mice (Wang et al., 2008). Therefore, it is possible that 
manipulations that enhance presynaptic Ca2+ may overcome the synaptic deficits caused by 
inhibiting BACE1 activity. In line with this, our lab recently showed that activation of Ca2+-
permeable α7-nAChRs, by nicotine or α7-nAChRs agonist, can restore PPF ratio and mossy fiber 
LTP in BACE1 -/- mice (Wang et al., 2010). The cellular mechanism of nicotine-induced rescue 
is dependent on the recruitment of Ca2+-induced Ca2+-release (CICR) from intracellular Ca2+ 
stores through ryanodine receptors (Wang et al., 2010). These results suggest that nicotine and 
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α7-nAChR agonists may be a potential pharmacological means to circumvent the synaptic 
dysfunctions caused by BACE1 inhibition. 
Since synaptic deficits are seen in both the CA1 and CA3 regions of BACE1 -/- mice, it 
indicates that BACE1 may play a general role in regulating presynaptic function. Reduced Aβ 
levels have been shown to produce deficits in presynaptic function (Abramov et al., 2009), which 
may explain the synaptic phenotype seen in BACE1 -/- mice. However, whether presynaptic 
deficits in BACE1 -/- mice are solely due to a lack of APP processing is unclear. An alternative 
possibility is that the synaptic dysfunction seen in BACE1 -/- mice may arise from abnormal 
processing of substrates other than APP (Fig 1.3). 
It has been shown that the auxiliary β2 subunit of the voltage-gated sodium channel 
(Nav1), is a substrate of BACE1 (Wong et al., 2005; Kim et al., 2007). The β2 subunit of the Nav1 
channel is important for plasma membrane expression of functional Na+ channels, which are 
critical for generating action potentials. Among the ten different types of Nav1 channels, Nav1.1, 
Nav1.2, Nav1.3 and Nav1.6 are expressed mainly in the CNS (Lai and Jan, 2006). BACE1 
regulates the surface expression of these types of Nav1 channels by cleaving the β2 subunit. In 
transgenic mice overexpressing BACE1, there is an increase in the Nav1.1 α-subunit mRNA and 
protein levels, but a decrease in the surface expression of functional Nav1.1 channels due to 
cleavage of the β2 subunits (Kim et al., 2007; Kim and Kovacs, 2011). The interpretation is that 
the full-length β2 subunit promotes surface expression of Nav1.1 channels, but the β2-intracellular 
domain (ICD), which is produced by a sequential cleavage by BACE1 and γ-secretase, increases 
transcription of the Nav1.1 α-subunit gene. Consistent with this, BACE1 -/- mice display a 
decrease in Nav1.1 α-subunit mRNA and protein (Kim et al., 2011). However, there is a 
compensatory increase in the surface expression of Nav1.2 in BACE1 -/- mice, which correlates 
with the hyperexcitability and seizure phenotypes seen in these mice (Hu et al., 2010). These 
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results suggest that the ability of BACE1 to regulate the Nav1 family of Na+ channels is rather 
complex, but suggests a role for BACE1 in regulating neuronal excitability. 
Another candidate substrate for BACE1 is neuregulin-1 (NRG1), which is an axonal 
signaling molecule critical for regulating myelination (Lemke, 2006). Willem and colleagues 
found that BACE1 -/- mice show hypomyelination in the peripheral nerves (Willem et al., 2006), 
while another study detected loss of myelination in the central nerves (Hu et al., 2006b). Both of 
these studies showed an accumulation of unprocessed NRG1 and a reduction in its cleavage 
products, suggesting that NRG1 is a potential substrate for BACE1 cleavage and that this process 
is important for myelination of axons (Hu et al., 2006b; Willem et al., 2006). Recently, it has 
been shown that the absence of NRG1 processing in BACE1 -/- mice decreased postsynaptic 
function of ErbB4, a receptor for NRG1 (Savonenko et al., 2008). NRG1/ErbB4 signaling has 
been suggested to regulate synaptic function and plasticity, mainly via regulation of postsynaptic 
glutamate receptors (Huang et al., 2000; Gu et al., 2005; Li et al., 2007). Additionally, abnormal 
processing of NRG1 may also affect presynaptic release by regulating the expression of α7-
nAchRs (Liu et al., 2001b; Zhong et al., 2008) which allows Ca2+ influx. Indeed, presynaptic 
nAchRs can increase glutamate release (McGehee et al., 1995; Gray et al., 1996; Maggi et al., 
2003), likely via the α7 containing nAchRs (Le Magueresse et al., 2006). These results suggest 
that a lack of NRG1 cleavage resulting from BACE1 inhibition can alter synaptic function both 
pre- and postsynaptically. 
Accumulating data on the biological roles of BACE1, particularly evidence that complete 
inhibition of BACE1 activity has a deleterious effect on normal neuronal function, suggests 
caution for using BACE1 inhibitors as a treatment for AD. In order to improve the development 
of effective therapeutics that target this enzyme, we need to identify ways to avoid the synaptic 
dysfunction associated with complete knockdown of BACE1, which may include partial  
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Table 1.1: Summary of known synaptic effects of altering BACE1. 






LTP LTD Reference 




ratio (CA1 and 
CA3) 
Normal LTP (4x 
TBS) but larger 
dedepression in 
CA1; no mossy 
fiber LTP (3x 100 




(paired- pulse 1Hz) 
in CA1, but 
slightly larger LTD 
(paired-pulse 1 Hz) 
in CA3 
(Laird et al., 2005; 
Wang et al., 2008) 
BACE1 KO + 
activation of 
α7-nAChRs 




fiber LTP (CA3) 
(3x 100 Hz) 





66% decrease in 
A40 and 57% in 




78% and anterior 





Restored LTP to 
WT control levels 
(CA1) (3x TBS) 




12 - 14 mo 
30% decrease in 
A42 
No change  
Improved the 
impaired LTP 




 (Gong et al., 2010) 
23 
 
inhibition strategies.  
Subsection 1: Partial inhibition or conditional knockdown of BACE1 
It has been shown that Aβ burden is dose-dependent on BACE1 activity; therefore, partial 
inhibition or conditional knockdown of BACE1 may be beneficial for AD treatment. To test this, 
Kimura and colleagues crossed BACE1 heterozygous mice with a line of transgenic mice 
carrying a combination of 5 FAD-linked mutations in human APP and PS1 (5XFAD). They 
found that partial reduction of BACE1 improved remote and recent memory and restored CA1 
LTP (Kimura et al., 2010). Researchers have also successfully suppressed BACE1 activity by 
using RNA interference (RNAi) in vitro (Kao et al., 2004; Hu et al., 2006a) and in vivo (Laird et 
al., 2005; Singer et al., 2005). Lentiviral BACE1 siRNA delivered into the hippocampus has been 
found to effectively reduce Aβ production, neurodegeneration, and behavioral deficits in APP 
transgenic mice (Laird et al., 2005; Singer et al., 2005). Characterizing synaptic function in the 
BACE1 siRNA knockdown models may provide information about acute effects of inhibiting 
BACE1 function. In addition, siRNA knockdown of BACE1 in APP transgenic lines will better 
approximate clinical situations, hence allowing us to better estimate the feasibility of developing 
an effective treatment for AD using BACE1 inhibition.   
Subsection 2: BACE1 inhibitors 
Since the identification of BACE1, the development of BACE1 inhibitors has been 
initiated. However, the progress was slow, likely due to the difficulty of identifying small 
molecules that could bind and inhibit the large catalytic pocket of BACE1, penetrate the blood 
brain barrier, maintain high stability, and possess good pharmacokinetics (Citron, 2004b; Ghosh 
et al., 2008a). To date, numerous BACE1 inhibitors have been discovered, but not many have 
been able to advance in human clinical trials due to toxicity concerns [see review (Ghosh et al., 
2008a; Luo and Yan, 2010; Yan and Vassar, 2014)]. MK-8931 has advanced the farthest to Phase 
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2/3 clinical trials, which are expected to conclude in 2017 and 2018 (Yan and Vassar, 2014). 
Many BACE1 inhibitors have been shown to decrease soluble Aβ production, amyloid plaque 
deposition, as well as improve cognitive function in AD animal models (Hussain et al., 2007; 
Ghosh et al., 2008c; Fukumoto et al., 2010; Takahashi et al., 2010; Zhu et al., 2010; Chang et al., 
2011). Surprisingly, none of them have been tested to determine their ability to improve synaptic 
dysfunction, the cellular mechanism that correlates with cognitive decline. A critical question is 
whether these inhibitors can recover synaptic deficits seen in AD models, or whether they may 
produce additional defects as seen in BACE1 -/- mice.  
Subsection 3: Transcriptional and miRNA regulation of BACE1  
There are several reports of transcriptional regulation of BACE1. Nie et al. have shown 
that activation of α4β2 nAChR can decrease BACE1 transcription through the ERK1-NFκB 
pathway in vitro (Nie et al., 2011); Wen and colleagues reported that overexpression of p25, an 
Figure 1.3. The roles of BACE1 in synaptic function.  
 
Besides cleaving APP to produce Aβ peptides, BACE1 has been found to have other substrates. It can 
process the β2 subunit of the voltage-gated sodium (Na+) channels, which can regulate Na+ channel 
surface expression and in turn modulate neuronal excitability. In addition, BACE1 can cleave NRG1, 
which plays a crucial role in myelination and NRG1/ErbB4 signaling. Recently, it has been showed that 




activator of cdk5, can increase BACE1 mRNA and protein levels likely through interactions of 
signal transducer and activator of transcription (STAT3) with the BACE1 promoter (Wen et al., 
2008). In addition, in the brains of sporadic AD patients, an increase in BACE1 levels is 
correlated with a decrease in a subset of microRNAs (miRNA), especially the miR-29a/b-1 
miRNA cluster (Hébert et al., 2008). miRNAs regulate mRNA translation. Therefore, it is 
possible that an increase in specific miRNA levels can decrease BACE1 protein expression and 
decrease Aβ burden. These findings provide various ways to regulate BACE1 expression. 
Subsection 4: Endogenous BACE1 activity modulators 
Recently, studies have shown that during sporadic AD or in AD animal models, the 
activities of certain endogenous molecules are modified, causing an increase in BACE1 activity. 
For example, sphingosine-1-phosphate (S1P) phosphorylation of the translation initiation factor 
eIF2α and calpain activity are increased in AD, which can lead to an increase in BACE1 activity 
(O’Connor et al., 2008; Liang et al., 2010; Nimmrich et al., 2010; Ill-Raga et al., 2011; Takasugi 
et al., 2011). On the other hand, decreased activity in conjugated linoleic acid (CLA), 
acetylcholinesterase inhibitor galantamine (Gal), copper chaperone for superoxide dismutase 
(CCS), PPARγ co-activator-1α (PGC-1α), the trafficking molecule GGA3, as well as Fbx2-E3 
ligase during AD can lead to increased BACE1 protein levels (Tesco et al., 2007; Sarajärvi et al., 
2009; Gong et al., 2010; Gray et al., 2010; Kang et al., 2010; Li et al., 2010, 2011; Katsouri et al., 
2011). So far, only the effect of Fbx2 on synaptic plasticity has been tested. Adenoviral-Fbx2 
transfection significantly improves CA1 LTP in Tg2576 mice without affecting basal synaptic 
transmission (Gong et al., 2010). While these molecules may be potential targets for controlling 
BACE1 activity, further studies need to verify whether synaptic function can be improved by 




Section 7: Presenilin: its physiological roles and relationship with Alzheimer’s disease 
Presenilin 1 (PS1) is the catalytic component of the γ-secretase complex. Following 
BACE1 cleavage, γ-secretase cleaves the transmembrane domain of APP, releasing A peptides 
(Fig 1.1). The active γ-secretase complex is composed of four different proteins, all of which are 
required for the protease to function [for a good review on the composition of γ-secretase, see (De 
Strooper, 2003)]; however, PS1 receives the most attention stemming from its identification as 
the major locus for early onset FAD (Sherrington et al., 1995). Since the accumulation and 
deposition of extracellular Aβ has been emphasized in the progression of AD (Tanzi, 2005), the 
identification of several FAD-linked mutations in PS1 led to many studies investigating how 
dysfunction of this protein contributes to AD. FAD-linked mutations in PS1 facilitate the 
production of the more pathogenic A42 peptide (Borchelt et al., 1996; Scheuner et al., 1996), 
which is the major constituent of senile plaques found in the brains of AD patients. This section 
will briefly summarize the functions of presenilins and focus on how they play a role in normal 
synaptic regulation and also during AD. Key points are summarized in Table 1.2. 
To investigate the normal physiological functions of PS1, many genetic knockout 
experiments have been conducted. Knockout of PS1 causes abnormal development and perinatal 
death (Shen et al., 1997; Wong et al., 1997; De Strooper et al., 1998; Donoviel et al., 1999; 
Marjaux et al., 2004). FAD-linked mutations have also been discovered in Presenilin 2 (PS2), 
which is highly similar to PS1 in both sequence and structure (Levy-Lahad et al., 1995); however, 
PS2 knockout mice are viable and fertile with only mild age-dependent pulmonary fibrosis and 
hemorrhage (Herreman et al., 1999). This suggests PS1 is sufficient to maintain the majority of 
regular physiological activities and that these two homologs share little overlapping function. 
Another study using PS1+/-;PS2-/- mice found that they could live normally until 6- months of 
age, after which most developed an autoimmune disease and benign skin hyperplasia  
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Table 1.2: Summary of alterations in synaptic function by altering presenilin or γ-secretase activity. 
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(Aoki et 
al., 2009) 
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Table 1.2: Continued. 
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Table 1.2: Continued. 
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soluble A levels 
Partial recovery 
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(Tournoy et al., 2004). The lethal effect of knocking out PS1 is not surprising considering that γ-
secretase is involved in the processing of many other substrates beside APP (Uemura et al., 2003; 
Kopan and Ilagan, 2004; Lleó, 2008), one of the most important being the Notch receptor, a 
protein that is critical in cell differentiation during embryonic development (Shen et al., 1997; 
Handler et al., 2000; Uemura et al., 2003; Kopan and Ilagan, 2004).  
Figure 1.4. The roles of presenilin 1 in synaptic function.  
 
Two main functions of presenilin 1 (PS1) focused on in this section are its ability to function as part of 
the γ-secretase cleavage complex and also to function as an ER Ca2+ leak channel. The γ-secretase 
complex is responsible for the final cleavage of APP in the production of Aβ peptides. The γ-secretase 
complex has also been shown to regulate spontaneous neurotransmitter release and is crucial for the 
regulation of the notch signaling pathway especially during early development. The PS1 holoprotein has 
been proposed to function as an ER Ca2+ leak channel. It is responsible for regulating intracellular 
calcium dynamics and calcium homeostasis required for proper signaling and neurotransmitter release. In 
addition to these two main functions, knockout studies have shown that the PS1 protein is important for 
synaptic scaling, proper NMDAR-mediated responses, as well as cell adhesion mediated by N-cadherin. 




γ-Secretase still remains to be a promising candidate for AD drug targets because it is 
thought that the function of PS1 might not be as critical in the adult brain, unlike during 
embryonic development, and/or partial inhibition of the enzymatic activity may still be feasible. 
Encouragingly, mice with conditional knockout (cKO) of PS1, in which PS1 expression was 
eliminated in most neurons of the cerebral cortex in the postnatal brain, were viable and had 
nearly normal phenotypes, including normal basal synaptic transmission and plasticity, with only 
mild deficits in long-term spatial memory (Yu et al., 2001; Saura et al., 2004). A40 and A42 
levels were also reduced in the cortex of PS1 cKO mice, providing evidence in support of 
targeting PS1 as a potential anti-amyloid therapy in AD. Another promising finding was that 
regulation of Notch activity in the adult brain was unaffected and independent of PS1, contrasting 
the dependency of Notch signaling during embryonic brain development. This suggests PS2 may 
be able to compensate for the loss of PS1 in the adult brain, and leads one to question whether 
knockout of both PS1 and PS2 will lead to more extreme deficits. To test this hypothesis, Saura 
and colleagues (Saura et al., 2004) generated forebrain specific PS1/PS2 conditional double 
knockout (PS cDKO) mice. These mice exhibit cognitive impairments as well as deficits in 
hippocampal synaptic plasticity, which appear earlier than in the PS1 cKO mice. PS cDKO mice 
also developed age-dependent and progressive neurodegeneration, including loss of dendritic 
spines and presynaptic terminals (Saura et al., 2004). Together, this suggests that in the adult 
brain the role of PS1 in regulating Notch signaling may not be as important, but that presenilins 
are required for normal hippocampal synaptic plasticity, memory formation, and age dependent 
neuronal survival. 
It is encouraging that conditional inactivation of PS1 is able to decrease A levels in the 
adult brain, without effecting Notch signaling (Yu et al., 2001). In order to examine the 
possibility of using inactivation of PS1 as a therapy for AD, PS1 cKO mice have been crossed 
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with transgenic mice expressing different FAD-linked mutations in APP. The first study 
developed postnatal neuron-specific inactivation of PS1 (PS1-/-) in transgenic mice 
overexpressing human APP with the London mutation (V717I), APPxPS1(-/-) (Dewachter et al., 
2002). This group had previously shown that APP(V717I) mice had increased levels of A42 
peptides as early as 2 months, leading to plaque development at 13-months old, as well as 
cognitive impairment and reduced hippocampal LTP (Moechars et al., 1999). APPxPS1(-/-) mice 
showed reduced A and amyloid plaque formation, even at 18 months. While hippocampal CA1 
LTP was rescued in APPxPS1(-/-) mice, they still showed impaired cognition. A second study 
used the forebrain-specific PS1 cKO mice, mentioned previously (Yu et al., 2001; Saura et al., 
2004), to inactivate PS1 in an APP transgenic that overexpressed human APP containing the 
Swedish (K670N/M671L) and Indiana (V717F) mutations to generate PS1 cKO;APP Tg (Saura 
et al., 2005). Similar to the previous study, these mice also had reduced amyloid-phenotypes 
compared to APP Tg mice, but there was still no long-term improvement in cognitive function. 
Conditional inactivation of PS1 was only able to rescue learning and memory deficits seen in 
young but not old mice (Saura et al., 2005). Together, these data indicate a causative role for A 
peptides in LTP deficits and demonstrate that inactivation of PS1 in Tg mice can decrease the 
amyloid pathology of AD and restore LTP impairments in young mice. One question elicited 
from the above studies is that, if conditional knockout of PS1 is able to reduce amyloid 
pathologies and rescue certain LTP impairments, why is it not able to rescue cognitive deficits 
seen in these AD mice, and why is it not able to sustain LTP improvements in older mice? One 
possible explanation is the age-dependent accumulation of the APP C-terminal fragments (CTFs) 
caused by a lack of γ-secretase activity after conditional inactivation of PS1, leading to the 
buildup of γ-secretase substrates (Saura et al., 2005). Another explanation is the non γ-secretase 
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functions of PS1 may be involved in aspects of memory formation, storage, or consolidation, by 
regulating intracellular calcium dynamics.  
In addition to its proteolytic activity, PS1 is implicated in regulating neurotransmitter 
release (Zhang et al., 2009; Pratt et al., 2011a) and intracellular calcium dynamics (Bezprozvanny 
and Mattson, 2008; Supnet and Bezprozvanny, 2010; Zhang et al., 2010b) (Fig 1.4). It has been 
proposed that the full length PS1 can act as a passive endoplasmic reticulum (ER) Ca2+ leak 
channel (Tu et al., 2006), and that some FAD-linked PS1 mutations lack this property. However, 
it remains controversial (Thinakaran and Sisodia, 2006; Gandy et al., 2006; Shilling et al., 2012) 
whether Ca2+ dysregulation that occurs during AD can be directly linked to alterations in ER Ca2+ 
leak channels formed by PS1. While the exact mechanism may be unknown, there is ample 
evidence that FAD-linked mutations in PS1 contribute to augmented cytosolic Ca2+ 
concentrations resulting from changes in intracellular ER Ca2+ dynamics (Smith et al., 2005; 
Stutzmann et al., 2006; Bezprozvanny and Mattson, 2008; Cheung et al., 2010; Supnet and 
Bezprozvanny, 2010; Zhang et al., 2010a, 2010b). FAD-linked mutations in PS1 appear to 
influence Ca2+ homeostasis by causing enhanced Ca2+ responses of ryanodine receptors (RyRs) 
(Smith et al., 2005; Stutzmann et al., 2006, 2007; Supnet et al., 2006; Chakroborty et al., 2009; 
Goussakov et al., 2010) and inositol-1,4,5-triphosphate receptors (IP3Rs) (Stutzmann et al., 2004; 
Cheung et al., 2008, 2010) found in the ER (Berridge, 1998), enhanced filling of ER Ca2+ stores 
(Leissring et al., 1999; Green et al., 2008), and attenuation of capacitive Ca2+ entry (CCE) stores 
(Leissring et al., 2000; Yoo et al., 2000; Smith et al., 2002; Herms et al., 2003). Presenilins have 
also been found to play a normal physiological role in regulating sarco ER Ca2+-ATPase 
(SERCA) pumps that help maintain low cytosolic Ca2+ concentrations by pumping Ca2+ into ER 
stores (Green et al., 2008). SERCA activity also influences A production, such that increased 
SERCA activity increases A production (Green et al., 2008). 
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Synaptic transmission and plasticity are important cellular mechanisms underlying 
cognitive functions, and there is evidence that presenilins play a role in these mechanisms. Mice 
with PS1 cKO in the cortex, showed normal basal synaptic transmission, LTP, and LTD in the 
hippocampal Schaffer collateral pathway (Yu et al., 2001), suggesting that in the adult brain, 
activity of PS2 is sufficient to maintain normal synaptic properties when PS1 is absent. In 
contrast to PS1 cKO mice, PS1/PS2 conditional double knockout (PS cDKO) show reduced LTP 
and a decreased PPF ratio at these synapses as early as 2 months of age. By 6 months, PS cDKO 
mice showed even greater synaptic deficits, including loss of presynaptic inputs and enhanced 
basal synaptic transmission, in addition to reduced LTP and PPF ratio (Saura et al., 2004). These 
synaptic impairments may explain the age-dependent deterioration in the cognition of the PS 
cDKO mice (Saura et al., 2004). Collectively, these studies suggest that presenilins are essential 
for synaptic plasticity as well as learning and memory in the adult brain.  
What is the cellular mechanism that mediates the effects of PS1 on synaptic plasticity? 
Saura et al. (Saura et al., 2004) found a reduction in the postsynaptic NMDAR-mediated response 
in PS cDKO mice, which correlated with a decrease in the cortical levels of synaptic NMDAR 
expression. Saura et al. also found that synaptic localization and delivery of NMDARs may 
depend on certain interactions with presenilins. Therefore, the downregulation of postsynaptic 
NMDARs is a reasonable explanation for why LTP and memory are impaired in PS cDKO mice. 
Loss of presenilin function also decreased the expression of both dendritic and synaptic αCaMKII 
levels as well as multiple CRE-dependent genes (Saura et al., 2004), which are all involved in the 
downstream signaling of NMDAR activation associated with LTP and memory formation [for a 
review on LTP and memory and the involved molecules, see (Lynch, 2004)]. This indicates that 
presenilins not only exert regulatory effects on NMDARs, but also the signaling cascades that 
lead to LTP and memory formation. Surprisingly, later studies that looked specifically at CA1 
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neurons in the hippocampus, revealed that, at 2 months, PS cDKO mice show an unexpected 
increase in the number of pre- and postsynaptic sites labeled for the NR2A subunits of NMDARs 
(Aoki et al., 2009). This increase is not accompanied by synapse loss or alterations in spine size, 
in agreement with previously documented morphology of PS cDKO mice at this age (Saura et al., 
2004). The authors (Aoki et al., 2009) suggested that NMDARs become trapped at the synaptic 
membrane leading to excitotoxicity and eventual neurodegeneration that is present in PS cDKO 
mice at 6 months (Saura et al., 2004). In addition, they suggested that LTP impairments are not 
due to a reduction in NMDAR number, but may be more tightly linked to the reduced levels of 
αCaMKII present in the dendritic spines (Aoki et al., 2009).  
As previously mentioned, presynaptic function was also altered in PS cDKO mice: a 
reduced PPF ratio, which was attributed to abnormal presynaptic Ca2+ signaling, and a reduction 
in presynaptic release probability was observed (Zhang et al., 2009, 2010a). In addition, there was 
a loss of presynaptic inputs in older PS cDKO mice suggesting that certain signals necessary for 
maintaining axon terminals may be missing. PS1 has been found to localize at the synapse and 
regulate adhesive contact of pre- and postsynaptic compartments, mediated by N-cadherin 
(Uemura et al., 2003), the major molecule that mediates Ca2+-dependent cell-cell interaction 
(Tepass et al., 2000). The diminution of N-cadherin-mediated cell-cell adhesion when presenilins 
are inhibited might cause the presynaptic defects in PS cDKO mice. One study sought to address 
the temporal progression of pre- and postsynaptic impairments in the Schaffer collateral pathway 
of PS cDKO mice (Zhang et al., 2010a). They found that the decrease in presynaptic calcium-
dependent facilitation and neurotransmitter release preceded postsynaptic impairments in 
NMDAR-mediated responses and LTP. Previous experiments in which presenilins were 
conditionally knocked out in either presynaptic, CA3, or postsynaptic, CA1 neurons (Zhang et al., 
2009), demonstrated that loss of presynaptic presenilin is sufficient to cause impaired glutamate 
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neurotransmitter release and LTP, due to altered intracellular calcium signaling. However, loss of 
pre- or postsynaptic presenilin alone was not sufficient to cause impairments in NMDAR-
mediated responses (Zhang et al., 2009). The authors propose a “trans-synaptic mechanism” to 
explain the alterations in postsynaptic NMDAR function (Zhang et al., 2010a). In any case, 
presenilins are likely essential for regulating the intracellular calcium signals required for proper 
neurotransmitter release to insure normal short- and long-term plasticity. Indeed, several recent 
studies have found that PS1 function is important in regulating homeostatic plasticity (Pratt et al., 
2011b) and neuronal ER Ca2+ homeostasis (Zhang et al., 2010b), as well as a novel function of 
the γ-secretase complex in regulating spontaneous neurotransmitters release (Pratt et al., 2011a). 
Therefore, presynaptic dysfunction and altered calcium dynamics may be an early event leading 
to neuronal degeneration and pathogenesis in AD.  
Subsection 1: Gamma-secretase inhibitors and modulators 
The γ-secretase complex is critical in the formation of A peptides, hence it is one of the 
key therapeutic targets for stopping the progression of AD. Although many classes of compounds 
exist that target the γ-secretase complex, not many have investigated their effects on synaptic 
transmission and plasticity. Numerous studies have documented the ability of different classes of 
γ-secretase inhibitors (GSI) and modulators (GSM) to reduce A levels in the brain (Dovey et al., 
2001; Eriksen et al., 2003; Yan et al., 2003; Imbimbo et al., 2007, 2011; Wolfe, 2008; Martone et 
al., 2009; Basi et al., 2010; Kounnas et al., 2010; Pettersson et al., 2011), as well as their effects 
on cognitive function in hippocampal dependent memory task such as the Morris water maze or 
contextual fear conditioning (Comery et al., 2005; Dash et al., 2005; Kukar et al., 2007; Imbimbo 
et al., 2009). There are two studies (Townsend et al., 2010; Balducci et al., 2011) that looked at 
the effects of drug treatment on synaptic plasticity in a mouse model of AD. Both studies used 
Tg2576 mice to investigate the ability of the GSI, MRK-560 (Townsend et al., 2010), or the 
37 
 
GSM, CHF5074 (Balducci et al., 2011), to restore hippocampal memory and synaptic plasticity. 
Each study used different initial starting times and durations of treatment. To understand the 
interaction between the age dependent increase in A and its effect on basal synaptic transmission 
and plasticity in the CA1 region of the hippocampus, Townsend et al. (Townsend et al., 2010) 
compared synaptic activity across three different ages, young (3-4 months), middle (6-7 months), 
and old (14-15 months) mice. Basal synaptic transmission was assessed by measuring the 
input/output activity in CA1. Even though A levels continue to increase with age, the greatest 
synaptic deficits in Tg2576 mice were seen at 6-7 months, and in particular LTP was impaired at 
this middle age, but was normal in both young and old mice (Townsend et al., 2010). This 
suggests that soluble A is inversely correlated with LTP, until plaque deposition occurs, when 
soluble A can no longer predict LTP impairments (Townsend et al., 2010). Since 6-7 month old 
mice showed the greatest deficits, they were given oral doses for 1, 3, or 7 days with the GSI, 
MRK-560. After 1 day, A levels were significantly reduced and LTP began to improve. LTP 
improvements reached significance after 3 days of dosing. After 7 days of treatment, basal 
synaptic transmission began to recover but did not reach significance. This supports the theory 
that lowering A levels can recover synaptic plasticity in 6-7 month old Tg2576 mice, before 
plaque deposition. Balducci et al. (Balducci et al., 2011) also focused on how the GSM, CHF5074 
may be able to rescue synaptic deficits seen in plaque-free Tg2576 mice. After acute 
subcutaneous treatment with the GSM, CHF5074, 5-month old Tg2576 mice showed 
significantly reduced contextual memory impairments (Balducci et al., 2011). At 6-months old, 
after receiving a 4-week subchronic oral treatment, which reduced intraneuronal A level, the 
impairments in recognition memory and hippocampal LTP were reversed.  
To determine if aged mice would also show improvements after treatment, daily doses of 
the GSI, MRK-560 were given to Tg2576 mice from 12-15 months of age (Townsend et al., 
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2010). Since LTP was similar to wild type mice at this age, the focus was on basal synaptic 
transmission. Similar to middle aged animals, treatment with MRK-560 significantly reduced A 
levels; however, there was no improvement in basal synaptic transmission. The lack of functional 
recovery in the older age group was also seen in APP Tg mice crossed with PS1 cKOs (Saura et 
al., 2005). These results reveal that even though conditional inactivation of PS1 can successfully 
reduce A production and the amyloid associated neuropathological alterations, it does not 
prevent the impairments in both synaptic and cognitive functions (Saura et al., 2005). 
Collectively, these studies suggest that the effects of A on basal synaptic transmission and 
plasticity differ with age, and that successful reduction of A levels by targeting APP processing 
enzymes may not recover synaptic dysfunction. 
 
Section 8: Conclusion 
It is clear that successful AD treatments will need to do more than just lower A 
production, they will need to rescue cognitive as well as synaptic dysfunctions. Increasing 
evidence suggests the cognitive syndromes found in AD patients are preceded by changes in 
synaptic efficacy [reviewed in (Selkoe, 2002; Shankar and Walsh, 2009)]. Therefore, examining 
whether different strategies that target APP processing enzymes rescue synaptic dysfunctions 
associated with AD is important. Several current reviews state why certain APP processing drug 
therapies have failed in recent clinical trials and why current trials have not been able to generate 
more beneficial or significant results (Imbimbo et al., 2010; Sastre and Gentleman, 2010; 
Galimberti and Scarpini, 2011). Testing the effects of potential AD therapeutics on synaptic 
function, in addition to behavioral analyses, will provide a better mechanistic understanding of 
the potential problems. It is also important to remember how different animal models may affect 
the outcome of results. For example, in mouse studies, genetic background has been shown to 
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influence the effectiveness of certain γ-secretase targeting drugs (Czirr et al., 2007; Page et al., 
2008; Hahn et al., 2011). In addition, many AD mouse models have been generated from FAD-
linked mutations, and may not fully recapitulate sporadic AD cases. In sum, a mechanistic 
understanding of the normal synaptic functions of APP processing enzymes will benefit the 
development of more effective treatments for AD.  
 
Section 9: Overview 
It is clear from the above summary of current literature that a further basic understanding 
of AD pathology at a cellular level is needed to design effective therapeutics. The phenotype of 
synaptic deficits seen in various AD mouse models has yielded controversial results on how 
FAD-linked mutations alter LTP and LTD (Marchetti and Marie, 2011). The ability to regulate 
these forms of plasticity is termed metaplasticity and states that synaptic modification is governed 
by the recent synaptic history of a cell (Abraham and Bear, 1996), such that previously low levels 
of synaptic activity will facilitate later LTP induction, while previously high levels of synaptic 
activity will inhibit its induction. Therefore, metaplasticity is triggered by integrated prior 
neuronal activity and acts to provide stability in neuronal function within a dynamic range (Bear 
et al., 1987; Bear, 1995). When synapses lose their ability to modify subsequent neuronal 
responses, based on previous synaptic activity, synaptic weights may become stuck at extremes 
within the LTP/LTD dynamic range. An inability to regulate metaplasticity would limit the 
responsiveness of synapses to further subsequent modification following a plasticity-inducing 
activity pattern. The resulting synaptic phenotypes may be just as detrimental as a complete lack 
of plasticity and may explain synaptic dysfunction seen in many FAD-linked mutants. In this 
work, we investigate two different models for regulating metaplasticity in APPswe;PS1deltaE9 
AD Tg mouse model: the sliding threshold and pull-push models. Regardless of which model is 
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mediating the metaplasticity, getting stuck at different set points for inducing plasticity within this 
dynamic range will result in LTP/LTD deficits.  
The main goal of this study is to test the hypothesis that amyloidogenic progression leads 
to defective metaplasticity of NMDAR-dependent LTP and LTD. Typically, this has been studied 
in various AD Tg mouse models using frequency-dependent LTP/LTD induction protocols (i.e. 
high and low frequency stimulations). However, these studies have only focused on changes in 
the absolute magnitude of LTP/LTD, rather than changes in metaplasticity. To our knowledge, no 
one has tried to explain AD in terms of defects in metaplasticity or to target metaplasticity for 
normalizing synaptic function. In addition, in most studies it is unclear whether the synaptic 
deficits found in various AD models are related to changes in LTP/LTD induction and/or 
expression mechanisms. The rationale for choosing the APPswe;PS1deltaE9 AD Tg mouse model 
is because they exhibit an accelerated amyloidogenic phenotype [e.g. accumulation of A and 
amyloid plaques by 6 months of age (Jankowsky et al., 2004; Garcia-Alloza et al., 2006)]. They 
not only express high levels of A and amyloid plaques, but also other pathological phenotypes 
of AD, including synaptic dysfunction, increased inflammation, cognitive deficits, 
hyperphosphorylated tau in dystrophic neurites, and cholinergic axon breakdown (Tomidokoro et 
al., 2001; Kurt et al., 2003; Jankowsky et al., 2005; Samura et al., 2006; Reiserer et al., 2007; 
Ding et al., 2008; Crouch et al., 2009; Phillips et al., 2011; Cramer et al., 2012; Wu et al., 2014). 
Since LTP/LTD are cellular substrates for learning and memory and important for encoding new 
information, deficits in metaplasticity may be relevant to other phenotypes, such as cognitive 
deficits, seen in this AD model.  
This study also seeks to investigate how novel therapeutics for AD may affect synaptic 
function and plasticity in both wild type and AD mice, and compare their effects to compounds 
that inhibit APP processing enzymes, discussed previously. Drugs that target APP processing 
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enzymes have not been as successful as originally anticipated. This is largely due to mechanism-
based toxicity caused by adverse side effects related to other proteins processes by these 
enzymes, besides APP. Hence, an alternative approach may be needed. The above discussion also 
emphasizes a lack of sufficient investigation into the effect of novel therapeutics on basic 
synaptic function and plasticity. To gain a complete understanding of new drug therapies, initial 
testing should include investigation of not only their ability to decrease A peptide and plaques 
levels, but also their effects on cognitive and synaptic function. Current therapies provide only 
temporary symptomatic relief and do not alter the progression of AD pathogenesis. A 
comprehensive understanding like this, that includes functional data, will enable a better 
mechanistic approach to overcome synaptic deficits that occur early in AD, when treatment may 
be most effective. Understanding how bidirectional synaptic plasticity becomes altered 
throughout the progression of AD will help to determine the specific synaptic events that underlie 
the synaptic dysfunction associated with cognitive decline in AD patients. In addition, an 
understanding of these basic mechanisms will not only lead to the development of more effective 
therapeutics, but also enable progress by overcoming the unforeseen side effects produced by 
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Section 1: Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder causing a loss of 
synaptic contacts and cognitive decline. Current theories implicate the production of A peptides 
as the key molecular event that ultimately leads to neurodegeneration and clinical pathologies 
(Hardy and Selkoe, 2002; Walsh and Selkoe, 2004; Shankar and Walsh, 2009). It is widely 
believed that cognitive deficits in AD patients are preceded by synaptic dysfunction, which may 
be the basis for memory loss in early stages of the disease (Walsh and Selkoe, 2004; Shankar and 
Walsh, 2009). 
Much of the molecular understanding of AD comes from studying FAD-linked 
mutations, which have been found in genes encoding APP and PS1 and PS2 in AD patients. 
Numerous Tg mouse models have been generated to study AD; however, depending on the 
combination of the FAD-linked mutations and their variants, distinct phenotypes are observed 
across age and brain regions studied. In addition, in many of these studies, it is unclear whether 
synaptic dysfunction is at the level of induction or expression of synaptic plasticity mechanisms.  
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Hippocampal LTP and LTD are effective models for mediating synapse-specific changes 
required for memory formation (Dudek and Bear, 1992; Mulkey and Malenka, 1992; Paulsen and 
Sejnowski, 2000; Lynch, 2004; Malenka and Bear, 2004; Whitlock et al., 2006). Bidirectional 
modifications in synaptic strength allow synapses to adjust the strength of their synaptic 
connections based on incoming activity. However, the induction threshold of LTP and LTD is not 
static but is itself adjusted by past neuronal activity by a metaplasticity process termed the 
“sliding threshold” (Bear, 2003; Yashiro and Philpot, 2008). NMDAR activation is important for 
determining the magnitude and polarity of plasticity. In addition, activity-dependent alterations in 
the NMDAR subunit composition have been shown to be responsible for sliding the threshold for 
inducing frequency-dependent LTP and LTD, due to their different electrophysiological 
properties (Philpot et al., 2001b; Bear, 2003a; Yashiro and Philpot, 2008; Gray et al., 2011). 
Therefore, a shift in NMDAR subunit composition can mediate a shift in the synaptic 
modification threshold (crossover point for LTD/LTP).  
An alternative process to the sliding threshold, which can result in similar metaplasticity, 
is called the “pull-push” hypothesis (Huang et al., 2012), which demonstrates that distinct 
neuromodulatory systems promote LTP and LTD by acting on their expression mechanisms. One 
mechanism of pull-push metaplasticity has been shown to be due to the ability of specific G-
protein coupled receptors (GPCRs) to promote the expression of LTP/LTD by changing 
phosphorylation states of AMPARs. For example, adenylyl cyclase (AC) coupled signaling 
cascades, leading to PKA activity promote LTP, while phospholipase C (PLC) signaling 
cascades, leading to PKC activity promote LTD. A key difference between the sliding threshold 
model and pull-push model of metaplasticity is that the former is traditionally supported by 
changes in NMDAR gain that are responsible for changing plasticity induction mechanisms. 
However, the pull-push model states that metaplasticity results from regulating LTP/LTD 
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expression mechanisms by effecting signaling that is downstream of NMDAR activation and 
therefore, downstream of plasticity induction mechanisms (Seol et al., 2007; Huang et al., 2012).  
Alterations in memory networks have been seen early in AD patients, prior to clinical 
pathologies, and manifest as increases in activity within these systems (Sperling et al., 2010). In 
addition, A-induced increases in activity have also been seen in mouse models of AD, 
suggesting that aberrant excitatory neuronal activity may be an early symptom leading to 
cognitive decline seen in AD patients (Palop et al., 2007; Palop and Mucke, 2009). Metaplasticity 
is triggered by integrated prior neuronal activity, and acts to provide stability in neuronal function 
(Bear et al., 1987; Bear, 1995). Numerous studies have focused on how A peptides and the 
progression of AD effects frequency-dependent LTP/LTD; however, changes in LTP/D are not 
always the best correlate of behavioral deficits (Marchetti and Marie, 2011). Perhaps it is not just 
the change in LTP/LTD magnitude that is driving cognitive deficits, but the inability of the 
system to adequately adapt to changes in neural activity to produce metaplasticity. Therefore, we 
determined whether changes in frequency-dependent synaptic plasticity seen in 
APPswe;PS1deltaE9 Tg mice are due to altered metaplasticity. Our results indicate that there is a 
differential contribution of FAD-linked mutations on LTP/LTD magnitude in young versus adult 
Tg mice, but the major defect is in the developmental regulation of metaplasticity leading to 
altered expression mechanisms of LTP/LTD across age. 
 
Section 2: Materials and Methods 
Subsection 1: Animals 
 Young 1-month and adult 6-month old APPswe;PS1deltaE9  Tg and wild type (WT)  
mice (129/C57BL6 mixed background) were used. Genotypes were distinguished by polymerase 
chain reaction (PCR) of isolated genomic DNA obtained from each pup after weaning.  Young 
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pre-adolescent mice were of either sex, while adult older mice were only male. 
APPswe;PS1deltaE9 Tg mice have accelerated amyloid pathologies and have a substantial 
number of plaque deposits by 6 months of age (Jankowsky et al., 2004; Savonenko et al., 2005). 
Therefore, these mice were used at both pre- and post-amyloidogenic ages. The Institutional 
Animal Care and Use Committees of Johns Hopkins University approved all procedures 
involving animals. 
Subsection 2: Preparation of acute hippocampal slices  
Acute hippocampal slices were prepared from 1-month and 6-months old WT and 
APPswe;PS1deltaE9 Tg mice as described previously (Lee et al., 2003). Briefly, each mouse was 
euthanized by decapitation following overdose of isoflurane. Hippocampi were rapidly removed 
and sectioned into either 300-μm (for whole-cell recording) or 400-μm (for field potential 
recording) slices on a vibratome (Vibratome 3000 series, Ted Pella Inc.) Hippocampi were 
dissected using oxygenated ice-cold dissection buffer (composition in mM: 212.7 sucrose; 2.6 
KCl; 1.23 NaH2PO4; 26 NaHCO3; 10 dextrose; 3 MgCl2; and 1 CaCl2) and recovered at room 
temperature in artificial cerebrospinal fluid (ACSF, composition in mM: 124 NaCl; 5 KCl; 1.25 
NaH2PO4; 26 NaHCO3; 10 dextrose; 1.5 MgCl2; and 2.5 CaCl2).  
Subsection 3: Field potential recordings from Schaffer collateral inputs to CA1 
All recordings were done in a submersion recording chamber perfused with ACSF (29–
30°C, 2 ml/min) bubbled with 95% O2-5% CO2. For field potential (FP) recordings, synaptic 
responses were delivered through a bipolar glass stimulating electrode placed to activate the 
Schaffer collaterals with a 0.2 ms duration pulse (baseline stimulation at 0.0333 Hz), and 
recorded from the dendritic field of CA1. Synaptic responses were digitized and stored on-line 
using IGOR Pro software (WaveMetrics). Input-output curves were generated by measuring 
extracellular field potential responses with varying stimulus intensities. For measurement of 
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paired-pulse facilitation (PPF), 25, 50, 100, 200, 400, 1000, and 2000 ms interstimulus intervals 
(ISIs) were used. LTP was induced using a theta burst stimulation [TBS: four trains, each 
consisting of ten 100-Hz bursts (four pulses) given at 5 Hz, repeated at 10-s intervals] (Larson et 
al., 1986). LTD in young mice was induced using 1Hz, 900 pulses stimulation protocol. LTD in 
adult mice was induced using a paired-pulse 1 Hz (50 ms ISI), 900 pluses stimulation. An 
intermediate stimulation frequency of 10 Hz, 900 pulses, was chosen because it was close to the 
modification threshold.  
For certain experiments 10 μM TBOA was used to induce spillover of glutamate. In these 
experiments CA3 was cut away during dissection and high divalents were added to the ACSF (4 
mM MgCl2 and 4 mM CaCl2) in addition to 100 μM D,L-APV, 2.5 μM Gabazine. Field potential 
slopes were measured, and data are expressed as mean ± SE of mean. 
Subsection 4: Whole-cell recording of evoked NMDAR-mediated excitatory  
postsynaptic currents (EPSC) and their sensitivity to a GluN2B antagonist  
Slices were visualized using an upright microscope (E600 FN, Nikon) with infrared (IR) 
oblique illumination. NMDAR-mediated EPSCs were pharmacologically isolated by adding 20 
μM Bicuculline and 10 μM NBQX to the ACSF [(ACSF, composition in mM: 124 NaCl; 2.5 
KCl; 1.25 NaH2PO4; 26 NaHCO3; 5 dextrose; 4 MgCl2; and 4 CaCl2), (30 ±1°C, saturated with 
95% O2 and 5% CO2)], which was continually perfused at a rate of 2 ml/min. Target cells in CA1 
were identified by the pyramid-shaped soma. These neurons were patched using a whole-cell 
patch pipette (tip resistance 3–5 MΩ), which was filled with internal solution (in mM: 120 Cs-
methanesulfonate, 5 MgCl2, 8 NaCl, 1 EGTA, 10 HEPES, 2 Mg-ATP, 0.5 Na3GTP, and 1 QX-
314; pH 7.3, 280–290 mOsm). NMDAR-mediated currents were measured at +40 mV. A double-
barrel glass stimulating electrode filled with ACSF was placed in the stratum radiatum of CA1 to 
activate Schaffer collateral inputs. To test the portion of these currents mediated by GluN2B 
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containing NMDARs, 3 μM of the GluN2B antagonist, ifenprodil, was added to the ACSF. To 
evaluate the amplitude and decay kinetics of the NMDAR-EPSCs in a given condition, 20-40 
traces were averaged and normalized. The decay was then fitted with two exponentials; one fast 
and one slow, using Igor. To measure the decay, a weighted time constant (τw) was calculated 
according to the following equation as described (Rumbaugh and Vicini, 1999; Philpot et al., 
2001a): τw = τf (If /(If+Is)) + τs (Is /(If+Is)), where τf and τs are the time constant for the fast and 
slow components, while If and Is are their respective amplitudes. Only the cells and recording 
conditions that met the following criteria were studied: no obvious multiple EPSCs or 
polysynaptic waveforms, Rinput ≥ 125 MΩ and Rseries ≤ 30 MΩ, and Rinput or Rseries changed less 
than 25% during the course of the experiment. Data are the means ± SE.  Comparison between 
the two conditions was done using paired Student’s t test.  
Subsection 5: Whole-cell recording of miniature GABAAR-mediated IPSCs (mIPSCs) 
For mIPSC from CA1 pyramidal cells, the recording pipette was filled with intracellular 
solution (in mM: 140 CsCl, 8 KCl, 10 EGTA, 10 HEPES, and 0.01 QX-314 (pH 7.3, 275-285 
mOsm) in the presence of 1 μM TTX, 100 μM D,L-APV, and 10 μM NBQX in the ACSF to 
isolate GABAR-mediated currents. The Axon patch-clamp amplifier 700B (Molecular Devices) 
was used for voltage-clamp recordings. Cells were held at -70 mV, and the recorded mIPSC data 
were digitized at 10 kHz with a data acquisition board (National Instruments) and acquired 
through custom-made programs using the Igor Pro software (WaveMetrics). The MiniAnalysis 
program (Synaptosoft) was used to analyze the acquired mIPSCs. The threshold for detecting 
mIPSCs was set at three times the root mean square (RMS) noise. Recordings were excluded 
from analysis if the series resistance was >25 MΩ or input resistance was <100 MΩ. To minimize 
the impact of dendritic filtering, we adopted the standard approach of excluding mIPSCs with a 
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rise time of > 5 ms. 300-400 hundred consecutive mIPSCs that met the rise-time criteria were 
analyzed from each cell. 
Subsection 6: Golgi staining and morphological analysis of dendritic spines 
To analyze dendritic spine density in vivo, Golgi staining was performed using FD Rapid 
GolgiStain Kit (FD NeuroTechnologies) according to the manufactures protocol, as previously 
described (Megill et al., 2013). Brains from 1-month old WT and APPswe;PS1deltaE9 Tg mice 
(n = 3 per group) or from 6-month old WT and APPswe;PS1deltaE9 Tg mice (n = 3 per group) 
were immersed in Solution A and B for 2 weeks and then transferred into Solution C for 24 hr. 
After 24 hr of incubation, it was replaced with fresh Solution C and kept at 4°C for 3 days. After 
the 3-day incubation, the brains were sliced using a Vibratome at 150-μm thickness. Images were 
acquired using an Axioplan 2 microscope (Zeiss) under bright-field illumination. Dendritic spines 
(0.2 to 2 µm in length) from apical oblique (AO) and basal shaft (BS) dendrites were counted 
manually in a blinded manner.  
Subsection 7: Western blot analysis of major AMPAR and NMDAR subunits 
The hippocampus from 1-month and 6-month old WT and APPswe;PS1deltaE9 Tg mice 
was homogenized in ice-cold 0.2% SDS/1% Triton X-100 immunoprecipitation buffer (TX-IPB; 
20 mM Na3PO4, 150 mM NaCl, 10 mM EDTA, 10 mM EGTA, 10 mM Na4P2O7, 50 mM NaF,  
and 1 mM Na3VO4, pH 7.4; with 1 μM okadaic acid and 10 kIU/ml aprotinin), sonicated and 
centrifuged for 10 min at 13,200 × g, at 4°C. Protein concentration of the supernatant was 
normalized to 0.6 – 3.0 mg/ml. The total homogenate from WT and Tg mice of the same age was 
run on one gel and processed for immunoblot analysis using GluA1 (sc-55509, Santa Cruz 
Biotechnology), GluN2A (07–632, Millipore), and GluN2B (71–8600, Invitrogen) antibodies.  
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GluA1-phosphorylation site-specific antibodies were previously generated as described 
(Mammen et al., 1997). AMPAR blots were probed simultaneously with GluA1 and either of the 
phospho-antibodies. GluA1-phosphorylation sites and NMDAR subunit blots were developed 
using enhanced chemifluorescence substrate (ECF substrate, GE Healthcare), while GluA1 was 
developed with a second antibody linked to Cy5. All blots were scanned using Typhoon 9400 
(GE Healthcare), and quantified using Image Quant TL software (GE Healthcare). For each gel, a 
Figure 2.1. Basal synaptic function in young WT and APPswe;PS1deltaE9 Tg mice. 
 
(A-B) Increase in input-output function with stimulation intensity in 1-month Tg mice. A. Field 
Potential (FP) slope plotted against stimulus intensity (ANOVA, *p < .001). B. Fiber Volley (FV) 
amplitude plotted against stimulus intensity (ANOVA, *p < .001). (C-D) Average data when data 
points in Graph B were fit with sigmoidal curves. C. Increase in the maximal FV/axonal response 
(WT: 0.45 ± 0.07; Tg: 0.88 ± 0.15; t test, *p < 0.02). D. No change in the rate at which axons are 
recruited (WT: 9.07 ± 1.16; Tg: 10.78 ± 1.26; t test, p = 0.328). E. FP slope normalized to FV 




control WT and Tg sample was loaded at three different concentrations to determine the linear 
range of signal for quantification. Only the samples that produced a signal within the linear range 
were used for analysis. The signal of each sample on a blot was normalized to the average signal 
from the WT group to obtain the percentage of average WT values, which were compared across 
groups using unpaired Student’s t test.  
 
Section 3: Results 
Subsection 1: Basal synaptic function and dendritic spine density in young 
APPswe;PS1deltaE9 Tg mice 
We examined synaptic function in hippocampal CA1 using field potential recording in 
acute hippocampal slices from WT and APPswe;PS1deltaE9 Tg mice at two ages. Given the 
inconclusiveness in the field (Marchetti and Marie, 2011) we first wanted to see what basic 
phenotypes these mice displayed in our hands, given our experimental conditions and paradigms. 
At the Schaffer collateral inputs to CA1 young, 1-month old Tg mice show an increase in input-
output function with stimulus intensity (Fig 2.1 A&B). Fiber volley (FV) amplitude data (Fig 2.1 
B) were fit with sigmoidal curves to determine if this increase was due to an increase in maximal 
FV response, or a difference in the rate at which axons were recruited. There was an increase in 
the maximum FV amplitude (Fig 2.1 C) without a change in the rate at which axons are recruited   
(Fig 2.1 D). This suggests that there was an increase in the total number of axons or increased 
axon density in the stratum radiatum of CA1. There was no change in the input-output function 
when synaptic transmission was normalized to the FV amplitude (Fig 2.1 E), which suggests that 
the strength of synaptic transmission per activated axon fiber is normal in the young Tg mice.  
To determine if the increase in axonal density was associated with an increase in   
dendritic spine density, we measured spine density in CA1 and cortical layers II/III using Golgi  
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staining (Fig 2.2).  We found that total spine density in young Tg mice was increased compared 
to young WT mice in CA1 and cortical layers II/III. In CA1, the increase in dendritic spine  
Figure 2.2. Dendritic spine density in CA1 and cortical II/III of young WT and 
APPswe;PS1deltaE9 Tg mice. 
 
(A-B) Increase in dendritic spine density in CA1 of 1-month Tg mice. A. Left, Spine density in 
hippocampal basal shaft (BS) dendrites (n = 3 mice; t test, *p < 0.01). Middle, Spine density in 
hippocampal apical oblique (AO) dendrites (n = 3 mice; t test, *p < 0.01). Right, Total spine density (BS 
+ AO) in hippocampal dendrites (n = 3 mice; t test, *p <0.01). B. Representative BS and AO dendrites 
from hippocampal CA1 neurons from WT and Tg mice, as indicated. (C-D). Increase in dendritic spine 
density in cortical layers II/III. C. Left, Spine density in cortical II/III basal shaft (BS) dendrites (n = 3 
mice; t test, *p < 0.01). Middle, Spine density in hippocampal apical oblique (AO) dendrites (n = 3 
mice; t test, p = 0.095). Right, Total spine density in hippocampal dendrites (n = 3 mice; t test, *p 
<0.01). D. Representative BS and AO dendrites from cortically layers II/III neurons from WT and Tg 




density was not restricted to the apical oblique (AO) dendrites, but was also see in the basal shaft 
(BS) dendrites (Fig 2.2 A&B). This suggests that there is a global increase in excitatory synapse 
number in the 1-month old Tg mice across different brain areas. 
Subsection 2: Basal synaptic function and dendritic spine density in adult 
APPswe;PS1deltaE9 Tg mice 
Figure 2.3. Basal synaptic function in adult WT and APPswe;PS1deltaE9 Tg mice.  
 
(A-B) No change in input-output function with stimulation intensity in 6-month Tg mice. A. FP slope 
plotted against stimulus intensity. B. FV amplitude plotted against stimulus intensity. (C-D) Average 
data when data points in Graph B were fit with sigmoidal curves. C. No change in the maximal 
FV/axonal response (WT: 0.69 ± 0.10; Tg: 0.53 ± 0.08; t test, p = 0.253). D. No change in the rate at 
which axons are recruited (WT: 8.43 ± 0.84; Tg: 6.31 ± 0.82; t test, p = 0.086). E. FP slope normalized 





Figure 2.4. Dendritic spine density in CA1 and cortical II/III of adult WT and 
APPswe;PS1deltaE9 Tg mice. 
 
(A-B) Selective decrease in dendritic spine density of basal dendrites in CA1 of 6-month Tg mice. A. 
Left, Spine density in hippocampal basal shaft (BS) dendrites (n = 3 mice; t test, *p < 0.01). Middle, 
Spine density in hippocampal apical oblique (AO) dendrites (n = 3 mice; t test, p = 0.595). Right, Total 
spine density (BS + AO) in hippocampal dendrites (n = 3 mice; t test, *p < 0.05). B. Representative BS 
and AO dendrites from hippocampal CA1 neurons from WT and Tg mice, as indicated. (C-D) Selective 
decrease in dendritic spine density of basal dendrites in cortically layers II/III of 6-month Tg mice. C. 
Left, Spine density in cortically II/III basal shaft (BS) dendrites (n = 3 mice; t test, *p < 0.01). Middle, 
Spine density in cortical II/III apical oblique (AO) dendrites (n = 3 mice; t test, p = 0.817). Right, Total 
spine density in cortical II/III dendrites (n = 3 mice; t test, *p < 0.001). D. Representative BS and AO 




To examine how the progression of amyloidogenesis and other FAD-linked factors affect    
basal synaptic transmission adult, 6-month old Tg mice were studied. In contrast to the young, 1-
month old Tg mice, there was no change in input-output function with stimulus intensity (Fig 2.3 
A&B), the maximal FV response (Fig 2.3 C), or the rate at which axons were recruited (Fig 2.3 
D). Also, there was no change in synaptic transmission when normalized to the presynaptic FV 
amplitude (Fig 2.3 E). Consistent with the rather normal basal synaptic transmission at the 
Schaffer collateral to CA1, we found that the dendritic spine density of apical oblique dendrites of 
CA1 neurons, which receive Schaffer collateral inputs, is also normal in adult Tg mice (Fig 2.4 
A&B). Interestingly, we found a selective decrease in dendritic spine density at BS dendrites in 
CA1 and cortical layers II/III in adult Tg mice (Fig 2.4), which suggests that the inputs to BS 
dendrites may be more vulnerable at this age across different brain areas. 
Subsection 3: Paired pulse facilitation in young and adult APPswe;PS1deltaE9 Tg 
mice 
To determine whether there is any alteration in presynaptic function, we measured the 
paired pulse facilitation (PPF) ratio. This form of short-term plasticity occurs when two 
stimulation pulses are given very close to one another allowing for summation of calcium in the 
presynaptic terminal causing the second response to be larger than the first. The PPF ratio is the 
ratio of the slope of the second field potential (FP) response over the slope of the first FP, and it is 
commonly used as a correlate of the release probability of the presynaptic cell. Young Tg mice 
showed no change in PPF ratio over all interstimulus intervals (ISIs) (Fig 2.5 A).  In contrast,  
PPF ratio was decreased at early ISIs in adult Tg mice (Fig 2.5 B), which could suggest 
enhancement in presynaptic function. An alternative explanation is that altered calcium dynamics 
lead to an inability to summate the responses, resulting in decreased facilitation.  




To determine whether changes in frequency-dependent synaptic plasticity seen in 
APPswe;PS1deltaE9 Tg mice are due to altered metaplasticity, we measured synaptic plasticity  
Figure 2.5. PPF ratio in young and adult WT and APPswe;PS1deltaE9 Tg mice. 
 
A. No change in paired pulse facilitation (PPF) ratio in 1-month Tg mice. Left, PPF ratio at different 
interstimulus intervals (ISI). Right, Representative traces at 50 ms ISI (WT: n = 20 slices, 6 mice; Tg: n 
= 30 slices, 6 mice.) B. Decreased PPF ratio at shorter ISIs (25, 50, and 100 ms) in 6-month Tg mice. 
Left, PPF ratio at different ISIs. Right, Representative traces at 50 ms ISI (WT: n = 22 slices, 7 mice; 




using standard LTP/LTD protocols, as well as an intermediate simulation frequency close to the 
modification threshold. In young Tg mice, high frequency theta burst induced LTP is increased 
(Fig 2.6 C), while low frequency stimulation induced LTD is decreased (Fig 2.6 A). An 
intermediate frequency (10 Hz, 900 pulses) produced reliable LTD in young WT mice but no 
long-term change in young Tg mice (Fig 2.6 B). This is consistent with the modification 
threshold for inducing plasticity being shifted to the left in favor of LTP (Fig 2.6 D). In adult Tg 
mice, high frequency theta burst induced LTP is decreased (Fig 2.6 G), while low frequency 
stimulation induced LTD is increased (Fig 2.6 E). Despite the fact that synaptic changes at an 
intermediate stimulation frequency did not reach statistical significance (Fig 2.6 F), our data are 
consistent with the modification threshold for inducing plasticity being shifted to the right to 
promote LTD (Fig 2.6 H). Taken together, these data suggest that metaplasticity is altered in both 
young and adult Tg mice, but in opposite directions. 
Figure 2.6. Frequency-dependent plasticity in young and adult WT and APPswe;PS1deltaE9 Tg 
mice. 
 
A. A decrease in the magnitude of LTD following 1 Hz, 900 pulses protocol in 1-month Tg mice (WT: 
71.11 ± 3.67% of baseline at 1-hour after onset of 1 Hz, n = 9 slices, 3 mice; Tg: 80.19 ±1.91%, n = 15 
slices, 5 mice; t test, *p < 0.05). Top, Representative traces (baseline: thin line, post-LTD: thick line). B. 
Significant difference in plasticity following an intermediate 10 Hz, 900 pluses protocol in 1-month Tg 
mice (WT: 87.98 ± 2.98% of baseline at 1-hour after onset of 10 Hz, n = 15 slices, 5 mice; Tg: 98.88 ± 
2.91%, n = 16 slices, 5 mice; t test, *p < 0.05). Top, Representative traces (baseline: thin line, post-LTD: 
thick line). C. An increase in the magnitude of LTP following 4xTBS protocol in 1-month Tg mice 
(WT: 124.26 ± 3.75% of baseline at 1-hour after 4xTBS, n = 11 slices, 5 mice; Tg: 141.38 ± 5.95%, n = 
10 slices, 6 mice; t test, *p < 0.05). Top, Representative traces (baseline: thin line, post-LTD: thick line). 
D. The modification threshold for LTP/D is shifted to the left in young, 1-month Tg mice, which shows 
enhanced LTP at the expense of LTD compared to WT mice. E. An increase in the magnitude of LTD 
following pp-1 Hz, 900 pulses protocol in 6-month Tg mice (WT: 92.20 ± 2.18% of baseline 1-hour 
after onset of pp-1 Hz, n = 11 slices, 4 mice; Tg: 81.97 ± 2.41%, n = 12 slices, 4 mice; t test, *p < 0.01). 
Top, Representative traces (baseline: thin line, post-LTD: thick line). F. No significant difference in 
plasticity following an intermediate 10 Hz, 900 pluses protocol in 6-month Tg mice (WT: 111.73 ± 
3.82% of baseline 1-hour after onset of 10 Hz, n = 14 slices, 5 mice; Tg: 102.22 ± 3.26%, n = 15 slices, 
5 mice; t test, p= 0.069). Top, Representative traces (baseline: thin line, post-LTD: thick line). G. A 
decrease in the magnitude of LTP following 4xTBS protocol in 6-month Tg mice (WT: 172.31 ± 
11.68% of baseline at 1-hour after 4xTBS, n = 10 slices, 6 mice; Tg: 139.34 ± 7.24%, n = 12 slices, 5 
mice; t test, *p < 0.05). Top, Representative traces (baseline: thin line, post-LTD: thick line). H. The 
modification threshold for LTP/D is shifted to the right in adult 6-month Tg mice, which shows impaired 







We also observed an unexpected phenomenon when looking at plasticity across 
development in WT and Tg mice. While WT mice show a developmental increase in frequency-
dependent LTP, Tg mice lacked this developmental change (Fig 2.7). Therefore, Tg mice produce 
similar magnitudes of LTP/LTD in both young and adult ages, despite having larger LTP than 
Figure 2.7. Deficit in developmental regulation of metaplasticity in APPswe;PS1deltaE9 Tg mice. 
 
A. WT mice show a reduction in the magnitude of LTD with age. Magnitude of LTD following 1 Hz 
protocol does not change over development from 1-month to 6-month Tg mice (n = same as Fig 2.6, t 
test, *p <0.001). B. WT mice show a developmental change in the polarity of 10 Hz-induced plasticity. 
In contrast, the magnitude of plasticity following an intermediate 10 Hz protocol does not change over 
development from 1-month to 6-month Tg mice (n = same as Fig 2.6, t test, *p <0.001). C. The 
magnitude of LTP induced with 4xTBS increased with age in WT mice, which is absent in Tg mice (n = 
same as Fig 2.6, t test, *p <0.01). D. WT mice show a shift in their modification threshold during 
development. Tg mice appear to be unable to regulate metaplasticity during development and do not 





WT at 1-month of age and smaller LTP than WT at 6-months of age. Therefore, in WT mice the 
modification threshold is shifted to the left during development; however, Tg mice do not 
undergo this developmental shift (Fig 2.7 D). This suggests that the developmental regulation of 
metaplasticity is altered in Tg mice.  
Subsection 5: NMDAR gain and other factors that control induction threshold in 
young and adult APPswe;PS1deltaE9 Tg mice 
Due to our sparse sampling of frequency-dependent plasticity, the alterations in 
metaplasticity observed in Tg mice at either age, can be explained by either the sliding threshold 
or pull-push models. To differentiate which mode of metaplasticity is altered, we looked at 
NMDAR gain in young and adult mice. In young Tg mice, the summation of synaptic responses 
during high frequency LTP induction was increased (Fig 2.8 A). This suggests an altered 
induction mechanism for LTP in young Tg mice. Enhanced NMDAR function during induction 
of LTP could be attributed to a decrease in the GluN2A/GluN2B ratio as suggested by the sliding 
threshold model. To directly test whether alterations in the ratio of NMDAR subunit composition 
may be mediating the changes associated with sliding the threshold for inducing plasticity in 
young Tg mice, we biochemically measured if there were changes in the expression of the 
NR2A/NR2B ratio. There was no difference in the NR2A/NR2B ratio between young WT and Tg   
mice (Fig 2.8 B). To verify that there was no change in synaptic NMDAR function, we 
pharmacologically isolated NMDAR current and tested their sensitivity to a GluN2B subunit 
antagonist, ifenprodil. There was no change in the decay constant (Fig 2.8 C, middle) or the 
percent of the response blocked by ifenprodil (Fig 2.8 C, left). This suggests that NMDAR 
subunit composition is similar between WT and Tg mice at this age. Therefore, changes in the 




Other factors such as inhibitory synaptic transmission, also have a large influence on 
plasticity induction (Steele and Mauk, 1999). However, we saw no change in mIPSC amplitude 
(Fig 2.8 D), frequency (Fig 2.8 F), or charge transfer (Fig 2.8 E), suggesting that there is no 
significant change in inhibitory synaptic transmission in young Tg mice. Together, this suggests 
that the resulting changes in plasticity induction mechanisms in young Tg mice are likely via 
mechanisms other than regulation of NMDARs or inhibitory function.  
In adult Tg mice, there was no change in the summation of synaptic responses during  
high frequency LTP induction (Fig 2.8 G). There was also no change in NR2A/NR2B ratio 
expression (Fig 2.8 H). This would indicate that induction mechanisms are not altered in adult Tg 
mice, and hence it rules out the sliding threshold model of metaplasticity. 
Figure 2.8. NMDAR gain and inhibitory synaptic transmission in young and adult WT and 
APPswe;PS1deltaE9 Tg mice. 
 
A. Increase in the summation of synaptic responses during 4xTBS induction protocol in 1-month Tg 
mice (ANOVA, *p < 0.01). Top, Representative traces (WT: black line, Tg: grey line). B. No difference 
in total NR2A/NR2B ratio in 1-month mice (WT: 100.82 ± 3.22% of average WT, n = 10 mice; Tg: 
78.05 ± 11.16% of average WT, n = 10 mice; t test, p = 0.077). (C) No difference in the NMDAR-
mediated response blocked by GluN2B antagonist ifenprodil (3 μM) in 1-month Tg mice. C. Left, 
Percent of the response amplitude blocked by ifenprodil (WT: 48.03 ± 8.64%, n = 7 cells, 5 mice; Tg: 
47.66 ± 5.95%, n = 10 cells, 5 mice; t test, p = 0.973). Middle, Average changes in the decay constant 
(WT: control = 183.23 ±38.77 ms, ifenprodil = 97.02 ± 13.87 ms, n = 7 cells, 5 mice; Tg: control = 
163.41 ± 18.02 ms, ifenprodil = 92.48 ± 13.99 ms, n = 10 cells, 5 mice; t test before, p = 0.654; t test 
after, p = 0.821). Right, Pharmacologically isolated NMDAR-mediated EPSCs recorded before (black 
line) and after bath application of ifenprodil (dark grey line). The normalized responses after ifenprodil 
are also included (light grey line). The traces are normalized to the peak amplitude in control ACSF and 
represent averages across all cells recorded in each condition (20-40 responses per cell). (D-F). No 
difference in whole-cell recording of miniature GABAAR-mediated IPSCs (mIPSCs). D. No change in 
average mIPSC amplitude of CA1 pyramidal cells from 1-month Tg mice (WT: 42.28 ± 5.19 pA, n = 15 
cells, 10 mice; Tg: 48.07 ± 4.19 pA, n = 15 cells, 9 mice; t test, p = 0.393). Right, Average mIPSC trace 
from each group. E. No change in charge transfer as measured by area under the curve in 1-month Tg 
mice (WT: 222.10 ± 33.57 fC, n = 12 slices, 10 mice; Tg: 276.74 ± 52.71 fC, n = 15 slices, 9 mice; t test, 
p = 0.391). F. No change in average mIPSC frequency of CA1 pyramidal cells from 1-month Tg mice. 
Left, Comparison of average mIPSC frequency (WT: 15.19 ± 1.18 Hz, n = 15 cells, 10 mice; Tg: 14.32 
± 1.24 Hz, n = 15 cells, 9 mice; t test, p = 0.615). Right, representative mIPSC traces taken from cells of 
each group. G. No change in the summation of synaptic responses during 4xTBS induction protocol in 
6-month Tg mice. Top, Representative traces (WT: grey line, Tg: black line). H. No difference in total 
NR2A/NR2B ratio in 6-month mice (WT: 91.16 ± 12.06%, n = 8 mice; Tg: 102.11 ± 15.18%, n = 8 







Subsection 6: Regulation of AMPA receptors in young and adult APPswe;PS1deltaE9 
Tg mice 
Changes in frequency-dependent plasticity especially in adult Tg mice appear to be 
mediated by dysregulation of pull-push metaplasticity, leading to altered expression mechanisms  
for controlling LTP/LTD. The pull-push model states that neuromodulators acting on specific G-
protein coupled receptors (GPCRs) promote the expression of LTP/LTD by changing 
phosphorylation states of AMPARs, thereby priming the synapse for LTP or LTD. Therefore, a       
key feature of the pull-push model is the size of the perisynaptic AMPAR population and the 
regulation of AMPAR phosphorylation. To measure the former, we used TBOA, a glutamate 
transporter inhibitor, to induce spill over of glutamate that will activate perisynaptic AMPARs 
(Fig 2.9 A&B). While the amplitude of FP recordings increased after TBOA application in WT 
and Tg mice at both ages, there was no significant difference between genotypes at either age  
(Fig 2.9 A&B). This suggests that the size of the perisynaptic pool is similar between WT and Tg 
mice. We noted that there might be a developmental increase in the size of the perisynaptic pool  
Figure 2.9. Quantification of perisynaptic AMPAR population and major AMPAR 
phosphorylation sites in young and adult WT and APPswe;PS1deltaE9 Tg mice. 
 
A. Amplitude of FP recordings from CA1 of 1-month WT and Tg mice is similar following 10 μM 
TBOA (WT: 105.83 ± 3.99% of baseline at 40-min post-TBOA, n = 12 slices, 4 mice; Tg: 106.30 ± 
2.76%, n = 10 slices, 4 mice; t test, p = 0.922). Top, Representative traces (before TBOA: thin line, after 
TBOA: thick line). B. Amplitude of FP recordings from CA1 of 6-month WT and Tg mice is similar 
following 10 μM TBOA (WT: 112.63 ± 2.74% of baseline at 40-min post-TBOA, n = 13 slices, 4 mice; 
Tg: 117.46 ± 4.63%, n = 13 slices, 4 mice; t test, p = 0.380). Top, Representative traces (before TBOA: 
thin line, after TBOA: thick line). (C-D). Top, representative immunoblots. Bottom, average data of 
glutamate receptor signal normalized to average WT control. C. No difference in total GluA1 (WT: 
97.15 ± 2.88%, n = 7 mice; Tg: 77.83 ± 10.16%, n = 11 mice; t test, p = 0.093), decrease in total 
S845/GluA1 ratio (WT: 103.34 ± 5.31% of average WT, n = 7 mice; Tg: 80.73 ± 6.60% of average WT, 
n = 10 mice; t test, *p < 0.05), and increase in total S831/GluA1 ratio (WT: 102.88 ± 6.30%, n = 8 mice; 
Tg: 208.39 ± 29.09%, n = 9; t test, *p < 0.01) in hippocampal samples from 1-month Tg mice. D. No 
difference in total GluA1 (WT: 101.10 ± 7.86%, n = 10 mice; Tg: 81.93 ± 7.85%, n = 10 mice; t test, p = 
0.102), S845/GluA1 ratio (WT: 99.41 ± 4.82%, n = 9 mice; Tg: 133.93 ± 18.54%, n = 10 mice; t test, p 
= 0.101), and S831/GluA1 ratio (WT: 101.28 ± 6.25%, n = 8 mice; Tg: 109.11 ± 5.44%, n = 8 mice; t 




as measured as changes in FP after TBOA, however only the Tg mice showed a significant 
difference between young and adult mice (ANOVA, *p < 0.05; Fig 2.9 A&B). 
Specific phosphorylation sites on AMPAR subunit GluA1, such as GluA1-S845 and 
GluA1-S831, have been correlated with LTP and LTD (Lee et al., 2000a, 2003). It has also been 
proposed that soluble A peptides can alter AMPAR endocytosis by modulating downstream 
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kinases and phosphatases, leading to decreased GluA1-S845 phosphorylation and cell surface 
AMPARs (Miñano-Molina et al., 2011). Furthermore, changes in GluA1-S845 and S831 
phosphorylation sites have been correlated with pull-push model of metaplasticity (Seol et al., 
2007; Huang et al., 2012). Young Tg mice show a decrease in the S845/GluA1 ratio (Fig 2.9 C) 
but an increase in the S831/GluA1 ratio (Fig 2.9 C) compared to WT mice, with no difference in 
total GluA1 (Fig 2.9 C). This suggests a possible correlation between GluA1-S831 
phosphorylation and increased LTP magnitude. In adult Tg mice, there was no change in total 
GluA1, S845/GluA1 ratio, and S831/GluA1 ratio (Fig 2.9 D). Together these data support a 
change in the expression mechanisms of LTP/LTD in the Tg mice, which supports a defect in the 
pull-push model as a way to explain the observed altered metaplasticity in young and adult Tg 
mice.  
 
Section 4: Discussion 
We investigated age-dependent alterations in basal synaptic function and plasticity in 
APPswe;PS1deltaE9 Tg mice. We observed altered metaplasticity in young and adult Tg mice 
(Fig 2.6). In young Tg mice, a shift in the modification threshold to the left favors LTP, but in 
adult Tg mice, a shift in the modification threshold to the right promotes LTD. Despite enhanced 
summation of synaptic responses in young Tg mice (Fig 2.8 A), conventional induction 
mechanisms for controlling the sliding threshold of metaplasticity were normal in both young and 
adult Tg mice (Fig 2.8). Most interesting was that Tg mice appear to be developmentally stuck 
and unable to regulate metaplasticity with age (Fig 2.7). Therefore, we suggest dysregulation of 
pull-push metaplasticity, leads to altered expression mechanisms for controlling LTP/LTD in Tg 
mice across ages (Fig 2.9).  
Subsection 1: Differential contribution of FAD-linked mutations across age 
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Mouse models have been generated expressing FAD-linked mutations in APP, PS1, or 
PS2 in order to study synaptic transmission and plasticity changes associated with AD. While 
many of these studies have focused on hippocampal plasticity, specifically frequency-dependent 
LTP, there is still no clear picture of how synaptic dysfunction progresses in these AD Tg mouse 
models (Marchetti and Marie, 2011). The resulting inconclusiveness is likely due to differences in 
FAD-linked contributing factors seen across synaptic parameters studied. It is important to 
consider how, and if, different FAD-linked mutations will result in different synaptic phenotypes, 
which may become important when generating effective therapies and may lead to the need for 
personalized medicine. For example, the APP and PS1 FAD mutations in our mouse model may 
contribute differently to synaptic dysfunction due to a difference in their relative contribution to 
synaptic phenotypes with age. In young, 1-month old animals, the contribution of A peptides to 
synaptic phenotypes is small and therefore any phenotypes seen in young mice may be due 
exclusively to the FAD-linked mutation in PS1. In addition to enhanced LTP (Fig 2.6 C), we 
observed an increase in basal synaptic function (Fig 2.1) and dendritic spine density (Fig 2.2). 
These phenotypes have been shown by others to occur in single PS1 Tg mice at this age (Zaman 
et al., 2000; Dewachter et al., 2008; Inoue et al., 2009; Jung et al., 2011; Marchetti and Marie, 
2011), so we conclude that these phenotypes may be attributed to the FAD-linked mutation in 
PS1.   
In adult, 6-month old animals, the impact of A peptides would now be evident in 
addition to effects of altered PS1. Reduced LTP (Fig 2.6 G) and decreased dendritic spine density 
(Fig 2.4) have been seen in other mouse models expressing mutated APP protein (Chapman et al., 
1999; Fitzjohn et al., 2001; Trinchese et al., 2004; Spires et al., 2005; Jacobsen et al., 2006; Palop 
et al., 2007). We believe this phenotype can be attributed to A accumulation since these 
phenotypes are not observed in adult PS1 Tg mice. The observed differences in presynaptic 
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function in adult Tg mice (Fig 2.5 B) is likely due to altered calcium dynamic caused by the 
FAD-linked mutation in PS1, which is known to enhance the ER Ca2+ leak channel function of 
PS1 (Tu et al., 2006). In addition, mice expressing a single APPswe mutation at this age do not 
show changes in PPF ratio (Chapman et al., 1999; Palop et al., 2007; Harris et al., 2010). 
The opposite LTP/LTD phenotype seen in young versus adult Tg mice could be 
attributed to difference in amyloid load. This is in line with a recent study which showed that 
mild cognitive impairment (MCI) and AD patients display opposite gene expression profiles 
compared to normal aged controls (Berchtold et al., 2014). Perhaps pre- and post-amyloidogenic 
mice are also not on a continuum from WT mice, but display opposing phenotypes compared to 
WT mice, similar to MCI and AD patients. 
Subsection 2: Altered induction mechanisms for LTP/LTD in young 
APPswe;PS1deltaE9 Tg mice 
It remains unclear at what level cellular mechanisms for regulating plasticity are 
becoming disrupted, leading to the conserved deficits in synaptic plasticity. Enhanced LTP in 
young Tg mice is likely due to altered induction mechanisms since we observed an increase in 
response summation during TBS used for LTP induction (Fig 2.8 A). However, we saw no 
functional change in NMDAR subunit composition (Fig 2.8 C), no change in the NMDAR ratio 
(Fig 2.8 B), and no change in inhibitory synaptic transmission (Fig 2.8 D-F). Changes in 
NMDAR ratio and inhibition have been implicated as major mechanisms for mediating the 
sliding threshold of metaplasticity (Steele and Mauk, 1999; Bear, 2003). Here we find that an 
alternative mechanism is at play to regulate the induction mechanisms of LTP/LTD in young Tg 
mice. We surmise that this may be due to the observed changes in AMPAR function. GluA1-
S831 phosphorylation is known to selectively increase conductance of GluA1 homomers (Oh and 
Derkach, 2005), which are inward rectifying and Ca2+-permeable (Cull-Candy et al., 2006). 
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Inward rectifying AMPARs can summate responses better, because they do not produce outward 
current when the membrane is depolarized (Bowie and Mayer, 1995). Therefore, if the increase in 
GluA1-S831 phosphorylation (Fig 2.9 C), observed in young Tg mice, was found on inward 
rectifying GluA1 homomers, this could increase the summation of synaptic responses during LTP 
induction. In support of this idea, GluA1 phosphorylation at S845 and S831 has been shown to 
decrease the threshold for producing LTP (Makino et al., 2011; Hu et al., 2007), similar to what 
we observed in young Tg mice (Fig 2.6 D). In addition, the enhanced LTP in young Tg mice 
could be due to dysregulated intracellular calcium dynamics due to the FAD-linked mutation in 
PS1 (Cheung et al., 2010). Indeed, it has been shown that a rise in intracellular calcium alone is 
sufficient to alter the signaling cascades downstream of NMDARs (Horne and Dell’Acqua, 2007; 
Thore et al., 2004), like AC and PLC, involved in pull-push regulation of metaplasticity 
responsible for altering plasticity expression mechanisms.  
In addition to the altered induction mechanism, the reduction of LTD in young Tg mice 
could be due to the decrease in GluA1-S845 phosphorylation (Fig 2.6 A). S845 
dephosphorylation correlates with LTD expression (Lee et al., 1998, 2000a), and S845 
phosphorylation site is necessary for LTD (Lee et al. 2003; Lee et al. 2010). Therefore, reduced 
basal phosphorylation of S845 is predicted to occlude further LTD.  
Subsection 3: Altered expression mechanisms of LTP/LTD in adult 
APPswe;PS1deltaE9 Tg mice 
In adult Tg mice, we did not observe changes in the summation of synaptic responses 
during LTP induction (Fig 2.8 G) nor in NMDAR subunit composition (Fig 2.8 H). Therefore, it 
is clear that the synaptic deficits at this age are most likely due to altered expression mechanisms 
as suggested by the pull-push model. However, dysregulation of expression mechanisms is not at 
the level of changes in basal phosphorylation of AMPARs, as both the S831 and S845 
68 
 
phosphorylation on the GluA1 subunit were similar between adult WT and Tg mice. Instead, the 
defect may reflect an ineffective upstream neuromodulatory signal or lie downstream of AMPAR 
phosphorylation. A proposed key mechanism of LTP expression is synaptic recruitment and 
stabilization of AMPARs from a perisynaptic pool, but we did not observe a change in the size of 
the perisynaptic AMPAR pool in adult Tg (Fig 2.9 B). This suggests that the deficit in LTP is not 
due to insufficient AMPARs available for synaptic insertion. Rather, it suggests a failure to 
stabilize AMPARs at synapses following LTP induction. This is supported by our observation 
that the initial phase of LTP is normal in adult Tg mice, but it decays. Synaptic stabilization of 
AMPARs is thought to occur via interaction of AMPAR with a hypothetical “slot” protein at the 
PSD (Kessels and Malinow, 2009). We surmise that the ability to generate new “slots” during 
LTP is compromised in adult Tg mice, hence the newly inserted synaptic AMPARs are not 
stabilized. 
Subsection 4: Defective developmental change of LTP/LTD in APPswe;PS1deltaE9 Tg 
mice 
Finally, we observed an unexpected and interesting developmental deficit in the Tg mice 
(Fig 2.7). We found that the magnitude of frequency-dependent LTP/LTD in young Tg mice is 
similar to adult Tg mice and does not undergo enhancement as was seen during normal 
development in WT mice. Based on our electrophysiological and biochemical data, we provide a 
model in Figure 2.10. In WT mice, we observed a developmental increase in LTP magnitude (Fig 
2.7 C), which we surmise is due to enhanced synaptic recruitment and stabilization of AMPARs 
(Fig 2.10 A).  
In young Tg mice the perisynaptic pool of AMPARs is similar to that of WT (Fig 2.9 A); 
however, they show larger LTP. This suggests that the rate at which AMPARs are inserted into 




Figure 2.10. Working model of AMPAR regulation throughout development in WT and 
APPswe;PS1deltaE9 Tg mice.  
 
A. Development in WT mice. As WT mice age, the rate at which AMPARs are inserted at the synapse 
and the stability of inserted receptors increases with LTP. This increase is likely correlated with an 
increase in the basal phosphorylation of S831 on the GluA1 subunit (Lee et al., 2010). The result is a 
larger magnitude of LTP produced in adults, in part due to increased “slot” generation for which 
AMPAR can be inserted and anchored to the PSD. B. Development in Tg mice. Tg mice start with a 
higher rate of synaptic insertion and a small increase in the ability to generate more “slots” for 
stabilizing AMPARs at synapses with LTP. This results in a large transient increase in LTP followed by 
a small, but statistically significant, increase in overall LTP magnitude in young Tg mice. As Tg mice 
age, the rate at which AMPARs are inserted to synapses or the ability to generate “slots” with LTP does 
not increase, likely because the S831/GluA1 ratio remains the same. Hence, the magnitude and the shape 
of LTP in the adults remain the same as in young Tgs. This suggests a defect in developmental changes 




young WT mice, possibly due to an increase in GluA1-S831 phosphorylation (Fig 2.9 C) and 
presumably larger Ca2+ influx based on enhanced synaptic summation during LTP induction (Fig 
2.8 A). In adult Tg mice, there is no developmental increase in LTP magnitude even though the  
level of AMPAR phosphorylation and the perisynaptic AMPAR pool size is similar to those of 
adult WT mice. This suggests that the developmental deficit is not at the level of synaptic 
recruitment of AMPARs or the availability of perisynaptic AMPARs, but is likely due to an 
inability to anchor and stabilize the receptors at the PSD following LTP. Thus, we surmise the 
lack of developmental changes in LTP is due to an inability to developmentally up-regulate 
mechanisms for “slot” generation. Considering that the developmental downregulation of LTD 
magnitude is also defective in Tg (Fig 2.7 A), we propose that the main synaptic dysfunction of 
Tg mice is its initial “off-set” in LTP/LTD induction threshold and the inability to 
developmentally regulate LTP/LTD expression mechanisms. In a way, the Tg mice are “stuck” at 
a defective level of LTP/LTD, and are unable to change as the synapses mature (Fig 2.7 D). The 
parameters responsible for the sliding threshold model of metaplasticity did not correlate with 
observed changes in LTP/LTD, rather we observed changes in expression mechanisms. Hence we 
propose that the defect may lie at the inability to regulate the pull-push model of metaplasticity 
with age.  
Subsection 5: Conclusion 
Despite which FAD-linked factors may be mediating the differences in LTP/LTD 
plasticity in APPswe;PS1deltaE9 Tg mice, the novelty of our data is that the underlying 
mechanisms for both ages can be explained by noting that these animals are stuck at an altered set 
point for LTP/LTD induction, and the inability to regulate their metaplasticity mechanisms during 
development. Therefore, if we can determine a way to normalize this adaptation, we may be able 
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Section 1: Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by aggregated A 
plaques in the brain (Finder and Glockshuber, 2007). Extracellular A deposition deteriorates 
axons, reduces dendritic spine density, and increases oxidative stress (Subbarao et al., 1990), 
partially by direct interaction between cellular enzymes and A (Lustbader et al., 2004; Habib et 
al., 2010). Current therapies for AD, such as acetyl cholinesterase inhibitors and NMDA receptor 
antagonists (memantine), provide only temporary symptomatic relief without altering the long-
term progression of the disease. Other leading strategies seek to alter long-term disease 
progression, but are severely limited by their induction of widespread toxicity. While patients 
receiving A immunotherapy showed an apparent reduction in A plaque load and slowed 
cognitive decline, adverse side effects of the treatment have included vasogenic edema (Nicoll et 
al., 2003; Orgogozo et al., 2003). Likewise, while γ-secretase inhibitors can effectively decrease 
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A peptide levels and improve memory in a mouse model of AD, widespread inhibition of 
Notch-mediated signaling following treatment results in developmental defects (Loane et al., 
2009). Clearly, novel strategies must be developed in parallel both to treat the underlying 
pathology of the disease and to prevent the adverse side effects of current therapies. 
One novel strategy to overcome AD pathology is the use of small molecules to prevent 
aggregated A from interacting with cellular components in harmful ways (Selkoe, 2011). 
Members of the benzothiazole aniline (BTA) family of compounds are characterized as a class of 
small molecules that have shown great promise in preventing A-protein interactions. Yang et al. 
previously reported that a tetra-ethylene glycol derivative of BTA (BTA-EG4) inhibits A-
induced cellular damage by surrounding aggregated A with a bioresistive coating, preventing its 
association with cellular proteins (Inbar et al., 2006; Habib et al., 2010; Capule and Yang, 2012). 
BTA-EG4 is able to adhere to aggregated forms of A with high affinity (20 nM), cross the blood-
brain barrier, and has adequate solubility in aqueous solutions (Inbar et al., 2006). Thus, BTA-
EG4 is a promising candidate for further in vivo study. While the effects of BTA compounds on 
AD pathogenesis are areas of active investigation, it is also pertinent to understand their effects 
on normal brain activity and synaptic function. 
In the present study, we investigated the biological effects of BTA-EG4 on synaptic 
function in vitro and in vivo. We initially found that BTA-EG4-injected wild type mice exhibited 
increased dendritic spine formation, as well as improved memory. The spinogenic activity of 
BTA-EG4 is accompanied by an increase in the number of functional synapses, as evidenced by 
an elevated frequency of AMPA receptor-mediated mEPSCs. Furthermore, BTA-EG4 acts via 
APP to increase Ras activity as well as downstream Ras signaling, which is necessary for its 
ability to increase dendritic spine density. These data suggest that BTA-EG4 may be beneficial as 
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a therapeutic treatment for the neuronal and cognitive dysfunction seen in AD by targeting Ras-
dependent spinogenesis.  
 
Section 2: Materials and Methods 
Subsection 1: Synthesis of 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl  
toluenesulfonate 
In a clean, dry 1 L round-bottom flask equipped with a stirbar, tetra-ethylene glycol (10.0 
g, 51.5 mmol) was dissolved in 500 ml dry dichloromethane (DCM) and stirred at room 
temperature. After 5 min, potassium iodide (1.71 g, 10.3 mmol), Ag2O (17.9 g, 77.2 mmol), and 
p-toluenesulfonyl chloride (10.8 g, 56.6 mmol) were successively added to the reaction flask. The 
reaction mixture was stirred vigorously for 2 h, filtered through Celite to remove the solids and 
concentrated in vacuo. The residue was purified via silica column chromatography (100% DCM 
to 95:5 DCM/CH3OH) giving 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl toluenesulfonate as 
a colorless oil (13.2 g, 74%): 1H-NMR (400 MHz, CDCl3): δ = 7.74 (d, 8.0 Hz, 2H), 7.30 (d, 8.0 
Hz, 2H), 4.11 (t, 4.8 Hz, 2H), 3.66 –3.53 (m, 12H), 2.79 (s, 1H), 2.39 (s, 3H); 13C-NMR (100 
MHz, CDCl3); δ = 145.04, 133.17, 130.10 (2C), 128.19 (2C), 70.95, 70.79, 70.70, 69.49, 68.88, 
21.87. Electrospray ionization tandem mass spectrometry (ESI-MS) [mass-to-charge ratio (m/z)] 
was calculated for C15H24O7S [M]+ value of 348.1243; found values were [M+H]+ 348.96, 
[M+NH4]+ 365.94, and [M+Na]+ 371.08. 
Subsection 2: Synthesis of 2-(2-(2-(2-iodoethoxy)ethoxy)ethoxy)ethanol 
2-(2-(2-(2- Hydroxyethoxy)ethoxy)ethoxy)ethyl toluenesulfonate (12.01 g, 34.5 mmol), 
sodium iodide (20.7 g, 137.9 mmol), and 200 ml of dry acetone were combined in a clean, dry, 
round-bottom flask and heated to reflux with vigorous stirring. After 12 h, the reaction was 
cooled to room temperature and diluted with 100 ml of ethyl acetate. The organic phase was 
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washed with 10% Na2S2O3 (2x10 ml), deionized H2O (1x20 ml), and saturated NaCl (1x20 ml); 
dried over anhydrous Na2SO4; filtered; and concentrated in vacuo giving 2-(2-(2-(2-
iodoethoxy)ethoxy) ethoxy) ethanol as a pale yellow oil (5.61 g, 54%): 1H-NMR (400 MHz, 
CDCl3), δ = 3.73–3.58 (m, 14H), 3.24 (t, 2H), 2.59 (s, 1H); 13C-NMR (100 MHz, CDCl3), δ = 
72.70, 72.19, 70.90, 70.76, 70.58, 70.39, 61.94, 3.07. 
Subsection 3: Synthesis of BTA-EG4 
A microwave reaction tube was charged with 2-(2-(2-(2-iodoethoxy)ethoxy)ethoxy) 
ethanol (1.47 g, 4.83 mmol), benzothiazole aniline (3.49 g, 14.5 mmol), potassium carbonate 
(3.34 g, 24.2 mmol), and 20 ml of dry tetrahydrofuran (THF). The tube was then equipped with a 
small stirbar, sealed, and placed in a microwave reactor. The reaction was heated at 125°C for 2 
h. The reaction was cooled to room temperature and filtered to remove the solids. The solids 
washed several times with DCM until the filtrate was colorless. The combined organic layers 
were concentrated in vacuo and purified by column chromatography to give the desired BTA-EG4 
compound as a yellow solid (1.13 g, 56%): 1H-NMR (400 MHz, CDCl3), δ = 7.87 (d, 8.8 Hz, 
2H), 7.83 (d, 8.4 Hz, 1H) 7.63 (s, 1H) 7.23 (d, 8.4 Hz, 1H), 6.68 (d, 8.8 Hz, 2H), 3.76–3.64 (m, 
14H), 3.37 (t, 5.2 Hz, 2H), 2.47 (s, 3H); 13C-NMR (100 MHz, CDCl3), δ = 168.03, 152.64, 
150.92, 134.87, 134.47, 129.13 (2C), 127.70, 122.88, 122.03, 121.41, 112.82 (2C), 72.86, 70.88, 
70.69, 70.43 (2C), 69.64, 61.91, 43.32, 21.70. HR-ESI-MS (m/z) calculated for a C22H28N2O4SNa 
[M+Na] value of 439.1662; the found value for [M+Na]+ was 439.1660. 
Subsection 4: Cerebrovascular permeability and pharmacokinetic analysis of  
BTA-EG4 in wild type mice 
The partitioning of BTA-EG4 between plasma and brain was studied in male CD-1 mice. 
The mice were dosed with 10 mg/kg, i.p., BTA-EG4 (in 10% DMSO/90% PBS; n = 2 per time 
point), and the concentration of BTA-EG4 in the plasma and brain was measured over time. 
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Blood was collected via cardiac puncture and was pooled in EDTA tubes and centrifuged, and the 
plasma was isolated. The brain was collected from each mouse, snap frozen, and homogenized in 
2 ml of PBS. The concentration of BTA-EG4 in the plasma and brain at each time point was 
determined by liquid chromatography/MS/MS, and the concentrations of BTA-EG4 in the plasma 
and brain were plotted as a function of time. The following pharmacokinetic parameters for the 
plasma and brain profile of BTA-EG4 were also calculated: the half-life (t1/2) for BTA-EG4 in the 
plasma and brain, the maximum concentration (Cmax) of BTA-EG4 in the plasma and brain, the 
area under the concentration-time curve (AUC), the brain-to-plasma ratio (BB), and the 
logarithmic brain-to-plasma ratio (Log BB). 
Subsection 5: Cell lines  
COS7 cells (Lombardi Co-Resources Cancer Center, Georgetown University) were 
maintained in Opti-MEM (Invitrogen) with 10% fetal bovine serum (FBS; Life Technologies) in 
a 5% CO2 incubator. The cells were transiently transfected with 0.5–1 μg of plasmid in FuGENE 
6 (Roche) according to the manufacturer’s protocol and cultured for 24 h in DMEM containing 
10% FBS. For cotransfections, cells were similarly transfected with 0.5–1 μg of each plasmid in 
FuGENE 6 (Roche) and cultured for 24 h in DMEM with 10% FBS. 
Subsection 6: Primary neuron culture and immunostaining  
Primary hippocampal neurons from E19 Sprague Dawley rats were cultured at 150 
cells/mm2, as previously described (Pak et al., 2001). Neurons were transfected using 
Lipofectamine 2000 (Invitrogen) or calcium phosphate precipitation with GFP + poly-L-lysine 
(PLL), GFP + APP shRNA, or GFP + APP and treated with BTA-EG4. The following antibodies 
were used: mouse anti- GFP (9F9.F9, Novus Biologicals), rabbit anti-GFP (A11122, Invitrogen), 
rabbit anti-GluR1 (PC246, Calbiochem), mouse anti-GluR2 (556341, BD Pharmingen, BD 
Biosciences), mouse anti-postsynaptic density-95 (PSD-95) (NeuroMabs), mouse anti-
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synaptophysin (s5768, Sigma Al- drich), rabbit APP N terminal (A8967, Sigma-Aldrich), anti-
Ras (610001, BD Biosciences), anti-RasGRF1 (C-20, Santa Cruz Biotechnol- ogy; 610149, BD 
Biosciences), anti-ERK1/2 (4695, Cell Signaling Technology), anti-p-ERK1/2 (36880, 
Invitrogen), anti-CREB (D76D11, Cell Signaling Technology), anti-p-CREB (06–519, 
Millipore), and mouse anti-c-Myc (9E10, Novus Biologicals). Cultured hippocampal neuron 
images were acquired by LSM 510 laser scanning confocal microscope (Zeiss). Confocal z-series 
image stacks encompassing entire dendrite segments were analyzed using MetaMorph software 
(Universal Imaging). We transfected cells with GFP to visualize dendrites and dendritic spines, 
followed by immunostaining with synaptophysin or PSD-95. Using MetaMorph software, we 
measured the average puncta number along dendritic segments. 
Subsection 7: GST pull-down assay  
To measure levels of active Ras, brain lysate homogenized with Ral buffer (25 mM Tris-
HCl, pH 7.4, 250 mM NaCl, 0.5% NP40, 1.25 mM MgCl2, and 5% glycerol) from APP 
transgenic, APP knock-out (KO), or wild type mice was incubated with GST-Raf-RBD purified 
protein coupled with glutathione Sepharose (GE Healthcare) overnight at 4°C. After 24 h, pellets 
were washed with Ral buffer and Western blotting was conducted with anti-Ras. 
Subsection 8: Cell surface biotinylation  
COS7 cells were transiently transfected with APP for 24 h in Opti-MEM containing 10% 
fetal bovine serum, and then treated with BTA-EG4 or control (CTRL) for 24 h. After 24 h, 
surface proteins were biotin labeled, immobilized with NeutrAvidin TM Gel and incubated 1 h 
with SDS-PAGE sample buffer, including 50 mM DTT, as described previously (Minami et al., 
2010). Elutes were analyzed for APP by immunoblotting. 
Subsection 9: Live cell surface immunostaining 
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Immunostaining of surface APP in hippocampal neurons was performed as described 
previously (Hoe et al., 2012). Briefly, live neurons were incubated with APP antibodies (10 μg/ml 
in conditioned medium) for 10 min, and then briefly fixed in 4% paraformaldehyde 
(nonpermeabilizing conditions). Surface-labeled APP was detected with Alexa Fluor-555 
secondary antibodies. Cells were then permeabilized in methanol (-20°C, 90 s), and incubated 
with anti-GFP antibody to identify transfected neurons. 
Subsection 10: Animals  
Wild type C57BL/6J and APP knock-out mice (B6.129S7- APPtm1Dbo/J) were obtained 
from Jackson Laboratories. CD1 mice were obtained from Vivasource. All animal experiments 
were approved by the Institutional Animal Care and Use Committees at Georgetown University 
and Johns Hopkins University. All animals were maintained according to protocols approved by 
the Animal Welfare and Use Committee at both institutions. 
Subsection 11: Golgi staining and morphological analysis of dendritic spines  
To analyze dendritic spine density and morphology in the brain, FD Rapid GolgiStain Kit 
(FD NeuroTechnologies) was used. Dissected mouse brains were immersed in Solution A and B 
for 2 weeks in dark conditions at room temperature and transferred into Solution C for 24 h at 
4°C. Brains were sliced using a VT1000S Vibratome (Leica) at 150 μm thickness. Dendritic 
images were acquired by Axioplan 2 (Zeiss) under bright-field microscopy. Spine width, length, 
and linear density of cortical layers II/III and CA1 of hippocampus were measured using Scion 
image soft- ware (Scion). Images were coded and dendritic spines were counted in a blinded 
manner. Spines from 0.2 to 2 μm in length were included for analysis. At least 25 apical oblique 
(AO) and 25 basal shaft (BS) dendrites were measured for spine density from each animal, and 




Subsection 12: Aβ ELISA 
Mouse brains were homogenized in tissue homogenization buffer containing 250 mM 
sucrose, 20 mM Tris base, protease, and phosphatase inhibitors. To measure soluble Aβ, 
diethylamine (DEA) extraction was performed. Crude 10% homogenate was mixed with an equal 
volume of 0.4% DEA, sonicated, and ultracentrifuged for 1 h at 100,000 x g. The supernatant was 
collected and neutralized with 10% 0.5 M Tris, pH 6.8. Sensitive and specific ELISAs to rodent 
Aβ1– 40 was purchased from IBL Transatlantic and conducted per the manufacturer’s protocol. 
Subsection 13: Morris water maze 
To examine the effects of BTA-EG4 on cognitive performance, we injected wild type 
(B6) mice with BTA-EG4 daily for 1 week, and then began behavior testing. We continued daily 
injections for another week, for a total treatment course of 2 weeks. The Morris water maze task 
included training mice to locate a submerged, hidden platform using extramaze visuospatial cues. 
This system consists of a large, white circular pool with a Plexiglas platform painted white and 
submerged below the surface of the water, made opaque by the addition of white nontoxic paint. 
During training, the platform was hidden 14 inches from the side wall in one quadrant of the 
maze. The animals were gently placed at random into one of the four quadrants, separated by 90°, 
and facing the wall. The time required (latency) to locate the hidden platform was recorded by a 
blinded observer and tracked using TOPSCAN, and was limited to 90 s. Animals failing to find 
the platform within 90 s were assisted to the platform. Animals were allowed to remain on the 
platform for 15 s on the first trial and 10 s on subsequent trials. Twenty-four hours after the final 
learning trial, a probe trial of 90 s was given. We recorded the percentage of time spent in the 
quadrant where the platform was previously located. As a control experiment, we tested motor 
impairment or visual discriminative ability. The animals were required to locate a clearly visible 
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black platform (placed in a different location), raised above the water surface, at least 12 h after 
the last trial. 
Subsection 14: Fear conditioning 
Before initiating fear-conditioning tests, wild type mice were injected daily with BTA-
EG4 or vehicle for 2 weeks (n = 8/group). Mice were subsequently trained by exposure to a 
conditioning box (context) for 3 min before administering a tone (18 s) and footshock (2 s), 
which were repeated twice at 1 min intervals. We performed the contextual test 24 h after training 
by re-exposing the mice to the conditioning context. A measurement of freezing behavior was 
recorded every minute for 3 min inside of the conditioning box. The cued test was conducted 3 h 
following the contextual test. Following a 3 min re-exposure to the conditioning box, a tone (18 s) 
was administered and freezing behavior was measured for 1 min. 
Subsection 15: Electrophysiology 
Transverse [for Schaffer collateral (SC) input studies] or horizontal [for temporoammonic 
(TA) input studies] hippocampal slices (400 μm thick) were prepared from adult mice. Slices 
were made using ice-cold dissection buffer (in mM: 212.7 sucrose, 2.6 KCl, 1.23 NaH2PO4, 10 
dextrose, 3 MgCl2 and 1 CaCl2; 5% CO2/95% O2), and recordings were performed in a 
submersion-type chamber perfused with artificial CSF (ACSF; in mM: 124 NaCl, 5 KCl, 1.25 
NaH2PO4, 26 NaHCO3, 10 dextrose, 1.5 MgCl2, and 2.5 CaCl2; 5%CO2/95% O2, 29.5– 30.5°C, 2 
ml/min). For field potential recordings, synaptic responses were evoked using 0.2 ms duration 
pulses delivered through a bipolar glass stimulating electrode at 0.0333 Hz. A train of theta burst 
stimulation (TBS) consisted of a burst of four pulses at 100 Hz repeated 10 times at 5 Hz. For 
4xTBS, four trains of TBS were given at 10 s intertrain intervals. For whole-cell recordings, 
slices were transferred to a submersion-type recording chamber mounted on a fixed stage of an 
upright microscope (E600 FN, Nikon) with infrared (IR) oblique illumination. AMPA receptor 
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(AMPAR)-mediated mEPSCs were pharmacologically isolated by adding 1 μM tetrodotoxin 
(TTX), 20 μM bicuculline, and 100 μM D,L-2-amino-5-phosphonopentanoic acid (APV) to 
ACSF (30 ±1°C, saturated with 95% O2 and 5% CO2), which was continually perfused at a rate of 
2 ml/min. Target cells in CA1 were identified by the pyramid- shaped soma. These neurons were 
patched using a whole-cell patch pipette (tip resistance 3–5 MΩ), which was filled with internal 
solution (in mM: 120 Cs-methanesulfonate, 5 MgCl2, 8 NaCl, 1 EGTA, 10 HEPES, 2 Mg-ATP, 
0.5 Na3GTP, and 0.001 QX-314; pH 7.3, 280–290 mOsm). Recording was initiated 2–3 min after 
break-in, and each cell was recorded for 10 –15 min to collect enough mEPSCs for analysis. The 
Axon patch-clamp amplifier 700B (Molecular Devices) was used for voltage- clamp recordings. 
Cells were held at -70 mV, and the recorded mEPSC data were digitized at 10 kHz with a data 
acquisition board (National Instruments) and acquired through custom-made programs using the 
Igor Pro software (WaveMetrics). The MiniAnalysis program (Synaptosoft) was used to analyze 
the acquired mEPSCs. The threshold for detecting mEPSCs was set at three times the root mean 
square (RMS) noise. There was no significant difference in the RMS noise across the groups 
[BTA-EG4 (30 mg/kg) = 1.6 ±0.09 (n =7), control = 1.6 ±0.05 (n =8); t test, p =0.65]. Recordings 
were excluded from analysis if the RMS noise was <2, the series resistance was <25 MΩ, and 
input resistance was >100 MΩ. To minimize the impact of dendritic filtering, we adopted the 
standard approach of excluding mEPSCs with a rise time of >3 ms, as well as cells showing a 
negative correlation between mEPSC amplitude and rise time (Rall, 1969). Only ~4% of the total 
recorded cells (at most, 1 cell per experimental group) were excluded due to negative correlation 
between mEPSC rise and amplitude. One hundred consecutive mEPSCs that met the rise-time 
criteria were analyzed from each cell. AMPAR- and NMDAR-mediated currents were measured 
at -70 and +40 mV, respectively. AMPAR-mediated EPSC amplitudes were measured at the peak 
of the current at -70 mV. NMDAR-mediated EPSC amplitudes were measured 100 ms after the 
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stimulation artifact. Data are the means ± SE. Student’s t test was used for two-group 
comparisons. For all statistical tests, p =0.05 was considered statistically significant. 
Subsection 16: Slice surface biotinylation 
Hippocampal slices (400 μm thick) were prepared as described above. CA3 and DG 
regions were cut away after the slice preparation to isolate CA1. After 30 min of recovery at room 
temperature, the slices were transferred to 30°C for an additional 30 min of recovery. The slices 
were then transferred to ice-cold ACSF for 10 min, and subsequently to ice-cold ACSF 
containing 1 mg/ml biotin (EZ-Link Sulfo-NHS-SS-Biotin, Pierce) saturated with 5% CO2/95% 
O2 for 15 min. The slices were then washed in TBS (50 mM Tris, 0.9% NaCl, pH 7.4) containing 
100 mM glycine 5 times for 1 min each before homogenized in ice-cold 0.2% SDS/1% Triton X-
100 immunoprecipitation buffer (TX-IPB; 20 mM Na3PO4, 150 mM NaCl, 10 mM EDTA, 10 
mM EGTA, 10 mM Na4P2O7, 50 mM NaF, and 1 mM Na3VO4, pH 7.4; with 1 μM okadaic acid 
and 10 kIU/ml aprotinin) by 30 gentle strokes using glass- Teflon tissue homogenizers (Pyrex). 
The homogenates were centrifuged for 10 min at 13,200 x g, at 4°C. Protein concentration of the 
supernatant was normalized to 0.6 –1.5 mg/ml. Some of the supernatants were saved as inputs, 
and the remaining supernatant was mixed with NeutrAvidin slurry (1:1 in 1% TX-IPB) and 
rotated overnight at 4°C. The NeutrAvidin beads were isolated by brief centrifugation at 1000 x 
g, and washed 3 x 1% TX-IPB, 3 x 1% TX-IPB plus 500 mM NaCl, followed by 2 x 1% TX-IPB. 
The biotinylated surface proteins were then eluted from the NeutrAvidin beads by rotating at 
room temperature for 15 min in gel sample buffer with 2 mM DTT. The input (total homogenate) 
and biotinylated samples (surface fraction) were run on separate gels, and processed for 
immunoblot analysis using GluA1 (sc-55509, Santa Cruz Biotechnology), GluA2/3 (07–598, 
Millipore), GluN1 (a gift from Dr. R.L. Huganir, Johns Hopkins University, Baltimore, MD), 
GluN2A (07– 632, Millipore), and GluN2B (71–8600, Invitrogen) antibodies. NMDAR subunit 
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blots were developed using enhanced chemifluorescence substrate (ECF substrate, GE 
Healthcare). AMPAR blots were probed simultaneously with GluR1 and GluR2/3 antibodies 
followed by second antibodies linked to Cy5 and Cy3. All blots were scanned using Typhoon 
9400 (GE Healthcare), and quantified using Image Quant TL software (GE Healthcare). The 
signal of each sample on a blot was normalized to the average signal from the control group to 
obtain the percentage of average control values, which were compared across groups using 
unpaired Student’s t test. 
Subsection 17: Statistical analyses 
All data were analyzed with GraphPad Prism 4 software using either a two-tailed t test or 
ANOVA with Tukey’s post hoc test for multiple comparisons, with significance determined at p 
=0.05. Cumulative distribution plots were analyzed using the Kolmogorov–Smirnov test. 
Descriptive statistics were calculated with StatView 4.1 and expressed as the mean ± SEM. 
 
Section 3: Results  
 Subsection 1: BTA-EG4 decreases A levels in vitro and in vivo 
We examined the biological and pharmacokinetic properties of BTA-EG4. BTA-EG4 
readily crosses the blood-brain barrier and is rapidly distributed to the brain (Iyer et al., 2002) 
with an estimated Log BB value of 0.43 (Fig 3.1 A&B). While it is clear from these studies that 
BTA-EG4 readily distributes to the brain, we make this conclusion from the analysis of brain and 
plasma samples of only four mice at each time point (two dosed with BTA-EG4 and two dosed 
with vehicle). The quantitative pharmacokinetic parameter values provided (Fig 3.1 B) should, 
therefore, be considered only as estimated values. We further found that daily injections of BTA-
EG4 (50 mg/kg, i.p.) were well tolerated in wild type mice for 16 d, and necropsy revealed no 




Figure 3.1. BTA-EG4 exhibits low toxicity and crosses the blood-brain barrier in vivo.  
 
A. Structure of BTA-EG4 (top) and time-dependent plasma and brain concentrations of BTA-EG4 in wild 
type mice that were injected (10 mg/kg, i.p.; n = 2 per time point). B. Table summarizing the calculated 
pharmacokinetic parameters for the plasma and brain profile of BTA-EG4. Parameters include the t1/2 for 
BTA-EG4 in the plasma and brain, the Cmax of BTA-EG4 in the plasma and brain, the AUC, the BB, and 
the Log BB. C. Primary cortical neuronal cells were treated with control, or 1 or 5μM BTA-EG4 for 24 h. 
Aβ levels in the conditioned media were determined by ELISA (n = 12/group). D. Wild type mice were 
injected with 15 mg/kg, i.p., BTA-EG4 or 30 mg/kg BTA-EG4 daily for 2 weeks, and Aβ levels were 
measured in the brain (n = 12/group). (E-F) Wild type mice were injected with 30 mg/kg BTA-EG4 for 2 
weeks and sAPPα, sAPP, full-length APP, APP C-terminal fragment (CTF), and -actin were measured 
(n = 3). G. Quantification of sAPPα and sAPP from E and F (n = 3/group). The sAPPα and sAPP 
signals for each sample were normalized to -actin. (H-I) COS7 cells expressing APP (H, n = 3) or 
primary cortical neurons (I, n = 3) were treated with BTA-EG4 (5μM) for 24 h. Cell surface proteins were 
biotinylated, isolated with avidin-conjugated beads, and immunoblotted with 6E10 or 22C11 antibody. J. 
Cultured hippocampal neurons (DIV18) were transfected with GFP and APP and treated with BTA-EG4 
for 24 h, and live cell surface staining was conducted. Left panels, GFP; right panels, surface APP (n = 
10/group). K. Cultured hippocampal neurons (DIV18) were transfected with GFP and APP, treated with 
BTA-EG4 for 24 h, and immunostained with anti-APP. Left panels, GFP; right panels, total APP (n = 
10/group). L. Quantification of surface APP intensity from (J) and total APP from (K). *p < 0.05, **p < 




To test whether BTA-EG4 alters A production in vitro, primary cortical neurons were 
treated with BTA-EG4 (1 or 5 μM) or control (10% DMSO), and A levels were measured using 
ELISA. BTA-EG4 significantly decreased A protein levels (Fig 3.1 C). We then examined 
whether BTA-EG4 can alter A levels in vivo by injecting wild type mice daily for 2 weeks with 
BTA-EG4 (15 or 30 mg/kg, 10%DMSO in saline, i.p.). We found that wild type mice injected 
with both doses of BTA-EG4 had significantly decreased A peptide levels compared with 
controls (10% DMSO, i.p.) (Fig 3.1 D), suggesting that BTA-EG4 can also reduce A production 
in vivo. Furthermore, BTA-EG4 altered APP processing in vivo, as monitored by increased sAPPα 
(α-secretase cleavage product) and decreased sAPP (-secretase cleavage product) levels in 
BTA- EG4 injected wild type mice (30 mg/kg, i.p) compared with control-injected mice (Fig 3.1 
E–G). These findings suggest that BTA-EG4 promotes the α-secretase-mediated metabolism of 
APP at the expense of the -secretase pathway, which may explain the reduction in A. It is well 
known that the majority of α-secretase activity occurs on the cell surface, while - and γ-secretase 
activity occurs primarily in the early and late endosomes (Huse et al., 2000; Reiss et al., 2006). 
Thus, if APP is present at the cell’s surface, it is preferentially cleaved by α-secretase, resulting in 
decreased A production. Therefore, we examined whether BTA-EG4 regulates cell surface 
expression of APP. To test this initially, COS7 cells were transfected with human APP and 
treated with BTA-EG4 (5μM) or control (10% DMSO) for 24 h. After performing cell surface 
biotinylation, we found that BTA-EG4 increased cell surface APP (Fig 3.1 H). Furthermore, 
BTA-EG4 increased endogenous cell surface APP levels in primary cortical neurons following 24 
h of BTA-EG4 (5μM) treatment compared with control (10% DMSO) treatment (Fig 3.1 I). In an 
alternative approach to examine the effect of BTA-EG4 on cell surface APP expression, we 
conducted live cell-surface immunostaining in primary hippocampal neurons. BTA-EG4 
treatment (5μM) increased cell surface levels of APP relative to vehicle control without affecting 
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total levels of APP (Fig 3.1 J-L). These results suggest that BTA-EG4 may reduce A production 
by increasing the amount of APP present at the cell surface. 
Subsection 2: BTA-EG4 improves cognitive performance in the absence of enhanced 
long-term potentiation 
 Several studies have shown that A accumulation contributes to cognitive deficits 
(Chang et al., 2011; Chételat et al., 2012). Since we observed that BTA-EG4 decreases A levels 
both in vitro and in vivo (Fig 3.1 C&D), we then examined whether BTA-EG4 affects learning 
and memory.  
The Morris water maze task was used to assess cognitive performance in wild type mice 
injected with BTA-EG4 (30 mg/ kg, i.p.) or controls. BTA-EG4-injected wild type mice exhibited 
significantly reduced escape latency during training (Fig 3.2 A), which was accompanied by an 
increase in swim speed (CTRL = 117 ± 3.1 mm/s, BTA = 130 ± 3.6 mm/s; p < 0.01), but no 
difference in path length to the escape platform (Fig 3.2 B). These findings suggest that the 
apparent reduction in escape latency in the BTA-EG4 group may simply be a reflection of the 
effect of the drug on swim speed. The fact that there is no change in the path length to reach the 
platform, which is a measurement not affected by swim speed, during the training trials suggests 
that BTA-EG4 may not improve the learning process. To test whether BTA-EG4 affects memory, 
we ran probe trials to measure the percentage of time spent in the correct quadrant and the 
number of platform crossings. We found that BTA-EG4-injected wild type mice spent more time 
in the target quadrant and showed a significantly higher rate of platform crossing during probe 
trials (Fig 3.2 C&D), suggesting that BTA-EG4 improves memory in this standard spatial 
memory task. 
Several studies have demonstrated that synaptic plasticity is correlated with learning and 
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(Fig 3.3 A&B). LTP 
was either normal or 
reduced, depending on 
the induction protocol 
Figure 3.2. BTA-EG4 improves cognitive performance. 
  
(A-D) Spatial learning task for BTA-EG4- injected (intraperitoneally) wild 
type mice by Morris water maze paradigm. A. Escape latencies during the 
training phase (n = 15; *p < 0.05 for days 2 and 4; p < 0.001 overall). B. Path 
lengths to the platform during training trials (two-way ANOVA, p = 0.6709). 
C. Percentage of time spent in the target quadrant was measured during the 
probe test on day 5 (*p < 0.05). Individual animal data are shown in gray 
circles. D. Comparison of the number of platform crossings during probe trial 
on day 5 (*p < 0.05). Individual animal data are shown in gray circles. (E-F) 
Associative learning test for BTA-EG4 injected (intraperitoneally) wild type 
mice by fear conditioning. E. Performance of mice treated with BTA-EG4 
(30 mg/kg) daily for 2 weeks before training during the contextual memory 
test (n = 8/group; *p < 0.05). Individual animal data are shown in gray 
circles. F. Mice were re-exposed to the cue component in a novel context 
after 24 h, and their behavior was monitored. Mice treated with BTA-EG4 
exhibited significantly enhanced freezing in response to the cue component 




(Fig 3.3 C&D). Unexpectedly, the summation of synaptic responses during the LTP induction 
protocol was reduced (Fig 3.3 E&F), which suggests that the normal LTP expression is likely due 
to an upregulation of a downstream signaling cascade. Recent evidence suggests that TA inputs to 
CA1, rather than SC inputs to CA1, support water maze-type learning (Nakashiba et al., 2008). 
BTA-EG4 (30 mg/kg, i.p.) treatment reduced the ability to recruit presynaptic axons per 
stimulation intensity at TA inputs to CA1 (Fig 3.3 H, left), but there was no difference in synaptic 
transmission when responses were normalized to the presynaptic fiber volley amplitude (Fig 3.3 
H, right). There was also not a change in presynaptic function (Fig 3.3 I). Similar to SC inputs to 
CA1, LTP at TA inputs also showed a similar reduction in the magnitude of LTP (Fig 3.3 J), 
which occurred in the absence of a change in the response summation during the induction 
protocol (Fig 3.3 K). Collectively, these results support the idea that the benefit of BTA-EG4 to 
improved cognitive performance is not through enhancing LTP.  
Subsection 3: BTA-EG4 increases spinogenesis in vivo 
There is precedence that cognitive performance correlates better with dendritic spine 
Figure 3.3. BTA-EG4 does not enhance LTP in CA1.  
 
(A-F) SC inputs to CA1. A. No significant difference in input-output function. Left, field potential (FP) 
slope plotted against stimulation intensity. CTRL: n = 15 slices, 6 mice; BTA: n = 18 slices, 6 mice. 
Right, FP slope normalized to fiber volley (FV). Top left, Schematic of recording. Top right, 
Representative FP traces. B. No change in presynaptic function. Top, Representative traces at 50 ms 
interstimulus interval (ISI). Bottom, paired pulse facilitation (PPF) ratio at different ISI. (C-D) No 
difference in the magnitude of LTP induced by 1xTBS (CTRL: n = 9 slices, 6 mice, BTA: n = 10 slices, 5 
mice, t test: p = 0.359; C) and are reduction with 4xTBS (CTRL: n = 8slices, n = 4 mice, BTA: n = 11 
slices, 6 mice, t test: *p < 0.01; D) in the BTA-treated group. Top, Representative traces (baseline: thin 
line, post-LTP: thick line). (E-F) Comparison of response integration during 1xTBS (E) and 4xTBS (F), 
*p < 0.05. (G-K) TA inputs to CA1. G. Isolation of TA inputs by stimulating the stratum lucidum-
moleculare (SLM). Left, Schematics of recording. Right, Representative FP traces following stimulation 
of SC inputs by an electrode placed in stratum radiatum (SR) or SLM when recording from SR or SLM. 
H. A reduction in input-output function with stimulation intensity (left), which is normalized when 
corrected for presynaptic recruitment of axons (right) (CTRL: n = 24 slices, n = 5 mice, BTA: n = 23 
slices, n = 5 mice). Top, Representative traces. I. Normal PPF ratio (CTRL: n = 25 slices, n = 5 mice, 
BTA: n = 22 slices, n = 5 mice). Top, Representative traces taken at 50 ms ISI. J. Reduced TA-LTP 
(CTRL: 120 ± 2.1% at 1 h post-LTP, n = 11 slices, n = 5 mice, BTA: 109 ± 1.2%, n = 10 slices, n = 4 




density rather than LTP magnitude (Hayashi et al., 2004; Morgado-Bernal, 2011). Since we 
observed that BTA-EG4 improves memory without enhancing LTP, we hypothesized that BTA- 
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EG4 promotes cognitive performance by increasing spine density. To test this idea, wild type 
mice were injected with BTA-EG4 (30 mg/kg) or control for 2 weeks. Subsequently, we 
Figure 3.4. BTA-EG4 promotes spinogenesis in vivo.  
 
A. Representative Golgi-impregnated wide-field view of the hippocampus (5x magnification). B. 
Representative AO and BS dendrites from hippocampal CA1 neurons from mice treated with control 
and BTA-EG4 (30 mg/kg), as indicated. C. Left, Spine density in hippocampal AO dendrites (n = 5; **p 
< 0.01). Middle, Spine density in hippocampal BS dendrites (n = 5; **p < 0.01). Right, Total averaged 
spine density in hippocampal dendrites (n = 5; **p < 0.01). D. A representative Golgi-impregnated 
neuron from cortical layers II/III. E. Representative AO and BS dendrites from pyramidal neurons of 
mice treated with control and BTA-EG4 (30 mg/kg) as indicated. F. Left, Average dendritic spine 
density for cortical AO dendrites (n = 5, ***p < 0.001). Middle, Average dendritic spine density for 
cortical BS dendrites (n = 5, **p < 0.01). Right, Total average dendritic spine density (n = 5, **p < 
0.01). (G-H) The cumulative distribution percentage of spine head width and spine length in cortical 
layers II/III in mice treated with BTA-EG4 (30 mg/kg) (Kolmogorov–Smirnov test). (I-J) The 
cumulative distribution percentage of spine head width and spine length in the hippocampus CA1 in 





performed Golgi staining and found that BTA-EG4-treated mice showed significantly increased 
dendritic spine density in the CA1 region of the hippocampus and cortical layers II/III (Fig 3.4 A-
F). However, BTA-EG4 did not alter spine morphology, including spine head width and spine 
length, in these areas (Fig 3.4 G-J). These data suggest that BTA-EG4 promotes dendritic spine 
formation without affecting spine morphology. 
Subsection 4: BTA-EG4 requires APP to increase dendritic spine density 
To examine whether BTA-EG4 acts via APP to increase dendritic spine density, we 
acutely knocked down APP using shRNA in primary hippocampal neurons. APP shRNA was 
cotransfected with GFP to visualize dendritic spines, and control cultures were transfected with 
GFP and PLL (control vector for shRNA construct). We then treated both cultures with BTA-EG4 
(5μM) or vehicle. We found that knockdown of APP on its own showed a trend of a decrease in 
dendritic spine density and prevented the increase in dendritic spine density with BTA-EG4 
treatment (Fig 3.5 A&B), which suggests that BTA-EG4 can only increase dendritic spine density 
in the presence of APP. To confirm this finding in vivo, we examined the effect of BTA-EG4 on 
dendritic spine density in APP KO mice. APP KO mice were injected with BTA-EG4 (30 mg/kg) 
or vehicle for 2 weeks, and Golgi analysis was conducted on hippocampal CA1 neurons. In APP 
KOs, we did not find a statistically significant increase in dendritic spine density following BTA-
EG4 treatment (Fig 3.5 C&D). This observation suggests that the ability of BTA-EG4 to promote 
spinogenesis is dependent on APP. 
Subsection 5: BTA-EG4 increases the number of functional excitatory synapses 
Next, we examined whether the increase in dendritic spine density following BTA-EG4 
treatment reflects an increase in the number of functional excitatory synapses. Primary 
hippocampal neurons were treated with BTA-EG4 (5μM) or control, and immunostained with 
synaptic markers. We found that BTA-EG4 increased the number of puncta stained for  
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synaptophysin (presynaptic marker) and PSD-95 (postsynaptic marker) (Fig 3.6 A-C). 
To verify that the increase in dendritic spine density and synaptic proteins reflects an 
increase in functional synapses, we measured mEPSCs from CA1 neurons in hippocampal slices 
Figure 3.5. BTA-EG4 requires APP to increase spine density.  
 
A. Primary hippocampal neurons were transfected with GFP and PLL (top) or GFP and APP shRNA 
(bottom), treated with control or BTA-EG4 (5μM), and spine density was measured. B. Quantification of 
data from A (n = 15, ***p < 0.001). C. Representative images of AO and BS dendrites from APP knock-
out mice treated with control or BTA-EG4. APP knock-out mice were injected with control or BTA-EG4 
for 2 weeks, and Golgi staining was conducted. D. Quantification of data from C (n = 5/group). C, 




following in vivo administration of BTA-EG4 (30 mg/kg, i.p.) for 2 weeks. Consistent with an 
increase in functional synapses, BTA- EG4 significantly increased the frequency of mEPSCs 
compared with vehicle-treated controls (Fig 3.6 D). There was no significant difference in the 
average mEPSC amplitude (Fig 3.6 E), suggesting no postsynaptic alteration in synaptic strength. 
Furthermore, we did not observe a change in the AMPAR/NMDAR ratio (Fig 3.6 F), which 
suggests that the new synapses likely contain both NMDAR and AMPAR at normal levels. 
To test whether the increase in functional excitatory synapses occurs via cell surface 
recruitment of glutamate receptors, we performed steady-state surface biotinylation using acute 
hippocampal slices obtained from mice injected with BTA-EG4 (30 mg/kg) or control vehicle for 
2 weeks. Both the cell surface and total levels of major AMPAR subunits GluA1 and GluA2, as 
well as NMDAR subunits GluN1, GluN2A, and GluN2B, were quantified. There was no 
Figure 3.6. BTA-EG4 increases the number of functional synapses without altering synaptic 
strength.  
 
(A-B) Cultured hippocampal neurons (DIV 18) were treated with BTA-EG4 (5μM) or control for 24 h 
and stained for synaptophysin (A, right) and PSD-95 (B, right). Neurons and dendrites were visualized 
by transfection of GFP (A and B, left panels). C. Quantification of average puncta number of 
synaptophysin and PSD-95 per 20μm length of dendrite (n = 10, *p < 0.05, **p < 0.01). D. BTA-EG4 
(30 mg/kg, i.p.) treated mice showed significantly increased mEPSC frequency in CA1 pyramidal 
neurons. Left, Comparison of average mEPSC frequency (CTRL: n = 7 cells, 5 mice; BTA: n = 8 cells, 5 
mice; t test: *p < 0.05). Values for individual cells are shown in gray circles. Right, Representative three 
consecutive mEPSC traces (1 s each) taken from cells of CTRL and BTA. E. No significant change in 
average mEPSC amplitude (n, the same as in D). Values for individual cells are shown in gray circles. 
Right, Average mEPSC trace from each group. F. No change in the ratio of AMPA/NMDA-mediated 
synaptic responses. Values for individual cells are shown in gray circles. Right, Overlap of AMPAR-
mediated EPSC measured at -70 mV and NMDAR-mediated EPSC measured at +40 mV. Dotted line 
shows where NMDAR responses were measured. (G-J) No change in the total and cell surface levels of 
AMPAR (G, H) and NMDAR (I, J) subunits in microdissected CA1 slices obtained from control and 
BTA (30 mg/kg, i.p.) treated mice. Left, Representative immunoblots. The blots were reprobed for -
actin, which did not show significant difference in signal between control and BTA-EG4- treated groups 
(p = 0.269). Right, Average data of glutamate receptor signal normalized to average control (CTRL: n = 
8 mice, BTA: n = 8 mice, t test: p > 0.1). There was no significant difference when the signal for each 
glutamate receptor antibody was normalized to the actin signal for each total homogenate sample 
(GluA1/-actin ratio: CTRL = 0.96 ± 0.10, BTA = 1.06 ± 0.12, p = 0.5; GluA2/-actin ratio: CTRL = 
0.98 ± 0.09, BTA = 1.27 ± 0.14, p = 0.1; GluN1/-actin ratio: CTRL = 0.98 ± 0.12, BTA = 1.27 ± 0.05, 
p = 0.1; GluN2A/-actin ratio: CTRL = 1.03 ± 0.08, BTA = 1.04 ± 0.14, p = 1.0; GluN2B/-actin ratio: 





significant change in cell surface or total expression of any of these proteins in hippocampal 
slices from BTA-EG4-treated mice (Fig 3.6 G-J). These data suggest that BTA-EG4 does not 
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regulate cell surface or total expression of AMPAR or NMDAR. Hence, the increase in the 
number of functional synapses is likely due to lateral recruitment of existing cell surface 
glutamate receptors to new spines. 
 Subsection 6: BTA-EG4 alters synapse formation through Ras signaling 
We next investigated the molecular mechanism by which BTA-EG4 may alter dendritic 
spine formation. Ras, a small GTPase, is involved in dendritic spine formation and synaptic 
delivery of AMPA receptors (Zhu et al., 2002; Lee et al., 2011). Moreover, abnormal Ras 
signaling is associated with neurodegenerative disease, causing cognitive impairments and 
learning deficits (Stornetta and Zhu, 2011). Thus, we initially investigated the effect of BTA-EG4 
on Ras signaling by treating primary hippocampal neurons with BTA-EG4 (5μM) or control for 
24 h. Interestingly, we found that BTA-EG4 increased levels of RasGRF1, a guanine nucleotide 
exchange factor involved in Ras activation (Lee et al., 2010), as measured by 
immunofluorescence (Fig 3.7 A&H). Further, levels of active Ras were elevated following BTA-
EG4 treatment (5μM) in primary cortical neurons (Fig 3.7 B&H) and following BTA-EG4 
treatment (30 mg/kg) in wild type mice (Fig 3.7 C&H). We also examined whether BTA-EG4 can 
alter the activity of downstream Ras signaling proteins, including p-ERK and p-CREB. We found 
Figure 3.7. BTA-EG4 increases dendritic spine density through Ras signaling.  
 
A. Cultured hippocampal neurons (DIV18) were treated with BTA-EG4 (5μM) or control for 24 h and 
stained for RasGRF1. B. Pulldown of active Ras in primary cortical neurons using GST-Raf1-RBD (n = 
2). C. Pulldown of active Ras in brain lysates from wild type mice intraperitoneally injected with BTA-
EG4 (30 mg/kg) daily for 2 weeks, using GST-Raf1-RBD (n = 3). (D-G) Cultured hippocampal neurons 
(DIV18) were treated with BTA-EG4 (5μM) or control for 24 h, and stained for p-ERK (D), ERK (E), p-
CREB (F), and CREB (G). (A, D-H) Quantification and comparison of RasGRF1 (A, n = 15), p-ERK 
(D, n = 21), ERK (E, n = 30), p-CREB (F, n = 15), and CREB (G, n = 15) intensities (**p < 0.01; *p < 
0.05). I. Primary hippocampal neurons were transfected with GFP and PLL (top) or GFP and RasGRF1 
shRNA (bottom) and treated with BTA-EG4 (5μM) or control. J. Quantification of dendritic spine 
density from I (**p < 0.01; ***p < 0.001). K. Primary hippocampal neurons were transfected with GFP 
and vector, GFP and Ras-WT, and GFP and RasN17, and were treated with BTA-EG4 (5μM) or control. 
L. Quantification of dendritic spine density from K (n = 23, *p < 0.05; **p < 0.01; ***p < 0.001). C, 




that BTA-EG4 (5μM) increased the phosphorylation of ERK and CREB, the active forms of the  




To examine whether the effect of BTA-EG4 on dendritic spine formation is Ras 
dependent, primary hippocampal neurons were transfected with GFP and RasGRF1 shRNA, or 
GFP and PLL. After 24 h, we treated with BTA-EG4 (5μM) or control for another 24 h, and spine 
density was measured using immunofluorescence. Consistent with our findings above, BTA-EG4 
significantly increased dendritic spine density; however, RasGRF1 knockdown prevented the 
effect of BTA-EG4 on dendritic spine formation (Fig 3.7 I&J). In addition, primary hippocampal 
neurons were transfected with GFP and empty vector, GFP and Ras-WT, or GFP and RasN17 
(inactive Ras mutant). After 24 h, we then treated neurons with BTA-EG4 (5μM) or control for 24 
h, and spine density was measured. Ras-WT alone or combined with BTA-EG4 increased 
dendritic spine density compared with control (Fig 3.7 K&L). RasN17 decreased dendritic spine 
density compared with control, and BTA-EG4 could no longer increase dendritic spine density in 
the presence of RasN17 (Fig 3.7 K&L). These results suggest that Ras signaling is necessary for 
mediating the increase in dendritic spine density conferred by BTA-EG4. 
Subsection 7: APP interacts with RasGRF1 and regulates Ras signaling proteins 
Since we observed that BTA-EG4 functions through APP (Fig 3.5) and requires Ras 
signaling to increase spine density (Fig 3.7), we examined whether APP can increase spine 
density through Ras signaling. To test this, we examined whether APP can interact with 
RasGRF1 by immunoprecipitating APP from brain lysates of wild type mice, and probing for 
RasGRF1 (Fig 3.8 A). Interestingly, we found that APP coimmunoprecipitates with Ras-GRF1 
(Fig 3.8 A). Results from immunoprecipitating RasGRF1 and probing for APP also indicated that 
RasGRF1 coimmunoprecipitates with APP (Fig 3.8 B). Our results indicate that RasGRF1 
associates with APP in vivo. 




Figure 3.8. APP interacts with RasGRF1 and regulates Ras signaling proteins. 
  
A. Brain lysates from wild type mice were immunoprecipitated (IP) with IgG or APP, and probed with 
RasGRF1. B. Brain lysates from wild type mice were immunoprecipitated with IgG or RasGRF1, and 
probed with APP. (C-D) Pulldown of active Ras from wild type mice (C, D, n = 5), APP transgenic 
(TG) mice (1 month old, C) or APP knock-out mice (D) using GST-Raf1-RBD. E. Quantification of 
data from C and D. (F-H) Primary hippocampal neurons were transfected with GFP and PLL or GFP 
and APP shRNA, then immunostained with RasGRF1 (F, n = 25), p-ERK (G, n = 25), and p-CREB (H, 




on Ras activity in APP transgenic mice and APP KO mice using a GST pull-down assay (Fig 3.8 
C-E). We found that Ras activity was elevated in 1-month-old APP transgenic mice 
(overexpressing APP without A pathology at 1 month), but decreased in 10-month-old APP KO 
mice, compared with wild type mice (Fig 3.8 C-E). Furthermore, we examined whether APP can 
alter the activity of downstream Ras signaling proteins ERK and CREB. First, to verify the effect 
of APP on Ras signaling, primary hippocampal neurons were transfected with GFP and PLL or 
GFP and APP shRNA, and then immunostained against RasGRF1. Knockdown of APP 
significantly decreased the levels of RasGRF1 compared with control vector (Fig 3.8 F&I). We 
then immunostained primary hippocampal neurons transfected with GFP and PLL or GFP and 
APP shRNA against p-ERK and p-CREB. We found that knockdown of APP decreased the 
phosphorylation of ERK and CREB compared with control vector (Fig 3.8 G-I). These data 
suggest that APP may regulate dendritic spine formation through increases in Ras activity and 
downstream Ras signaling pathways. 
Subsection 8: BTA-EG4 requires APP to alter Ras signaling 
Since we observed that BTA-EG4 and APP could possibly regulate dendritic spine 
density through Ras-dependent mechanisms, we then examined whether BTA-EG4 requires APP 
to modulate Ras signaling. To test this hypothesis, primary hippocampal neurons were transfected 
with GFP and APP shRNA or GFP and APP, treated with control or BTA-EG4 (5μM), then  
immunostained against RasGRF1 (Fig 3.9 A&B). We found that knockdown of APP did not 
increase RasGRF1 following BTA-EG4 treatment compared with control, while overexpression 
of APP significantly increased RasGRF1 following BTA-EG4 treatment compared with control 
(Fig 3.9 A&B). 
Next, we investigated whether BTA-EG4 can alter Ras activity in APP KO mice by 
injecting control or BTA-EG4 for 2 weeks. We found that BTA-EG4-injected APP KO mice did  
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not have altered Ras activity (Fig 3.9 C). Further, we examined the effect of BTA-EG4 on 
downstream Ras signaling in the presence or absence of APP. For this experiment, primary 
hippocampal neurons were transfected with GFP and APP shRNA or APP, treated with BTA- 
EG4 or control, and then immunostained against p-ERK or p-CREB. We found that BTA-EG4 
Figure 3.9. BTA-EG4 requires APP to alter Ras signaling.  
 
A. Primary hippocampal neurons were transfected with GFP and APP shRNA (top) or GFP and APP 
(bottom), treated with control or BTA-EG4 (5μM), then immunostained with RasGRF1. B. 
Quantification of Ras GRF1 levels from A (n = 20, ***p < 0.001). C. Pulldown of active Ras from APP 
knock-out mice using GST-Raf1-RBD (Ras binding domain) following injection of control or BTA-EG4 
(30 mg/kg, i.p.) for 2 weeks. There was no significant difference in the amount of active Ras between 
APP KO mice treated with control or BTA-EG4 [CTRL (C) = 100 ± 1.22%, BTA (B) = 103.2 ± 1.26%, 
n = 5]. D. Primary hippocampal neurons were transfected with GFP and APP shRNA (top) or GFP and 
APP (bottom), treated with control or BTA-EG4 (5μM), then immunostained with p-ERK. E. 
Quantification of p-ERK (n = 20, ***p < 0.001). F. Primary hippocampal neurons were transfected with 
GFP and APP shRNA (top) or GFP and APP (bottom), treated with control or BTA-EG4 (5μM), then 




was ineffective at increasing p-ERK or p-CREB following knockdown of APP, while 
overexpression of APP significantly increased p-ERK and p-CREB with BTA-EG4 treatment 
compared with control (Fig 3.9 D-G). These data strongly support that BTA-EG4 acts via APP to 
activate Ras-dependent signaling. 
 
Section 4: Discussion 
In the present study, we demonstrate that the A-targeting molecule BTA-EG4 reduces 
A levels by facilitating cell surface expression of APP (Fig 3.1). Wild type mice treated with 
BTA-EG4 exhibited improved cognitive performance without enhancement of hippocampal LTP 
(Figs 3.2 & 3.3). Additionally, BTA-EG4 promotes dendritic spine density, which was 
accompanied by an increase in the number of functional synapses as determined by elevated 
mEPSC frequency. Moreover, BTA-EG4 regulates dendritic spine formation, potentially by 
increasing the activity of Ras-ERK signaling proteins through APP (Figs.3.7-3.9). Together, these 
results strongly suggest that BTA-EG4 works through APP to increase dendritic spine density via 
a Ras ERK-dependent mechanism. In addition, BTA-EG4 warrants further investigation to 
determine its effect in mouse models of AD. 
BTA-EG4 treatment regulates APP metabolism, resulting in reduced A levels and 
increased cell surface APP. It is known that -secretase cleavage of APP forms A along the 
intracellular endosomal pathway. Conversely, α-secretase cleavage of APP occurs at the cell 
surface and prevents A production (Hyman, 2011). Because BTA-EG4 did not alter the levels of 
A degradation enzymes (i.e., insulin-degrading enzyme, neprilysin; data not shown), we believe 
BTA-EG4 decreases A levels by specifically increasing cell surface levels of APP, and thus, 
favoring processing of APP by α-secretase cleavage over processing by -secretase. 
Several recent studies have shown that A aggregation is correlated with deficits in 
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learning and memory, and therapies that decrease A can rescue these deficits (Loane et al., 
2009; Chang et al., 2011). For instance, γ-secretase inhibitor (DAPT)-injected mice had decreased 
A levels and improved behavioral performance after traumatic brain injury (Loane et al., 2009). 
Other studies using mouse models of AD showed reduced A levels after treatment with either β-
secretase or histone deacetylase (HDAC) inhibitors (Chang et al., 2011; Ricobaraza et al., 2011). 
These therapies were also able to prevent or improve memory deficits in AD mice. Furthermore, 
γ-secretase and HDAC inhibitors increase LTP, increase dendritic spine density, and improve 
cognitive performance (Townsend et al., 2010; Haettig et al., 2011). In contrast to these results, 
we found that while BTA-EG4 had positive effects on cognitive performance and dendritic spine 
density, it did so without a correlated increase in the magnitude of LTP at both SC and TA inputs 
to CA1 (Fig 3.3). This finding implies that BTA-EG4 improves cognitive performance through an 
LTP-independent mechanism, and suggests that targeting spine density alone may be sufficient to 
improve cognitive function. 
We found that BTA-EG4 specifically acts to increase the number of functional synapses, 
but individual synapses are not stronger. The lack of an increase in LTP magnitude suggests that 
the new synapses are available for synaptic plasticity, but there is no enhancement of LTP due to 
the addition of new synapses. While our LTP findings defy the conventional interpretation of the 
role of LTP in memory formation, it is not an isolated case. Indeed, in the PAK transgenic model, 
decreased dendritic spine density was associated with a decrease in cognitive performance, but an 
enhancement of LTP magnitude (Hayashi et al., 2004). Combined with our results, this suggests 
that an increase in the number of dendritic spines and functional synapses confer benefits to 
cognitive function. The reduction in LTP magnitude seen in some cases may be a homeostatic 
adjustment to the increase in synapse number. For example, higher synaptic density may increase 
the LTP induction threshold to prevent overexcitation of neuronal activity. This presents an 
103 
 
interesting point by implying that creating new synapses may benefit cognitive function not by 
enhancing LTP at individual synapses, but by allowing more synaptic contact points to form 
along the dendrite for potential information storage. It is of interest to note that some of the APP 
transgenic AD mouse models display larger LTP in younger ages (Marchetti and Marie, 2011; 
Wang et al., 2012; Chapter 2). It would be of interest to know whether BTA-EG4 treatment in 
these young AD mouse models would show beneficial effects. While BTA-EG4 significantly 
increased dendritic spine density in cortical layers II/III and the hippocampal CA1 region, this 
occurred without changes in dendritic spine morphology. Longer and thinner dendritic spines are 
characterized as immature “plastic” spines, while shorter and wider dendritic spines are 
characterized as mature “memory” spines (Kasai et al., 2002; Yasumatsu et al., 2008). Thus, 
BTA-EG4 increases dendritic spine density without changing the proportion of immature and 
mature spines. 
Here, we investigated the molecular mechanism by which BTA-EG4 regulates dendritic 
spine density. One possibility is that BTA-EG4 may act through a Ras-dependent mechanism 
because Ras signaling not only plays an important role in dendritic spine formation, but also in 
neuronal degeneration (Saini et al., 2009; Ye and Carew, 2010; Lee et al., 2011; Stornetta and 
Zhu, 2011). For instance, AD mice models have increased synaptic depression, which results in 
decreased activity and levels of RasGRF1, as well as downstream Ras signaling proteins. In 
contrast, AD patients have increased activity of Rap effectors, including p-JNK, which is 
accompanied by the removal of synaptic AMPA receptors (Savage et al., 2002; Zhu et al., 2002; 
Stornetta and Zhu, 2011). Interestingly, we observed that BTA-EG4 promotes Ras-ERK signaling 
(Fig 3.7). BTA-EG4 treatment increased RasGRF1 levels and Ras activity as well as activation of 
downstream Ras signaling proteins, including p-ERK. We found that Ras activity is necessary for 
spinogenesis induced by BTA-EG4, which suggests that one of the main signaling pathways 
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involved in BTA-EG4 action is via its ability to activate Ras. Therefore, BTA-EG4 has the 
potential to reverse the decrease in Ras signaling seen in AD. 
How does BTA-EG4 activate Ras signaling to increase spine density? One possibility is 
that BTA-EG4 binds directly to A to prevent negative functional effects, resulting in protection 
against synapse loss. We also have data to demonstrate that BTA- EG4 promotes cell surface 
expression of APP, which is known to increase dendritic spine formation (Lee et al., 2010b). 
Here, our novel finding provides evidence that APP promotes spinogenesis through direct or 
indirect interaction with RasGRF1 to increase Ras activity and downstream signaling to promote 
spinogenesis (Fig 3.8). Furthermore, the action of BTA-EG4 on dendritic spine formation and Ras 
activity both required APP (Fig 3.9). While this does not rule out the possibility that BTA-EG4 
acts via neutralizing A, the more parsimonious explanation is that BTA-EG4 promotes APP 
signaling to enhance Ras-dependent spinogenesis. Whether the effect of BTA-EG4 on APP 
signaling is strictly through enhancing cell surface APP levels or preventing -cleavage of APP, 
perhaps via direct binding to the A domain of APP, remains to be investigated. Nevertheless, 
there is evidence that A and full-length APP often produce opposite signaling (Hoe et al., 2012); 
hence, the dual role of BTA-EG4 in reducing A and promoting APP signaling is likely 
conferring benefit to synaptic and cognitive function. 
Together, our results strongly suggest that BTA-EG4 treatment decreases A levels and 
improves cognitive performance. Moreover, BTA-EG4 increases dendritic spine density through 
APP- and Ras-dependent mechanisms. Thus, this novel small molecule exhibits potential as a 
drug candidate for AD treatment and warrants further studies to determine its effect in mouse 
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Section 1: Introduction 
Alzheimer’s disease (AD) is the most common form of dementia, characterized by 
dendritic spine loss and progressive impairment of memory (Knobloch and Mansuy, 2008). 
Dendritic spines are small membranous protrusions that provide the sites of excitatory synaptic 
transmission in the central nervous system. The number of dendritic spines correlates with 
synaptic and cognitive function (Kasai et al., 2010). The function of dendritic spines is associated 
with stable LTP regarded as the physiological correlate of memory storage. During LTP 
induction, AMPARs traffic to the plasma membrane and diffuse to synaptic membrane 
compartments, such as those containing PSD-95. Therefore, understanding dendritic spine 
formation and retardation, as well as the synaptic proteins that affect these processes, could be 
important in understanding how synaptic dysfunction during progressive brain diseases, such as 
AD, destroy memory processes.  
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F-spondin is an extracellular matrix protein that has three different domains: N-terminal 
domain (reelin-N domain), spondin domain, and six C-terminal thrombospondin type 1 repeats 
(TSRs) (Tan et al., 2008). A recent study has shown that F-spondin regulates neuronal migration 
during brain development. For instance, F-spondin inhibits the migration of neural crest (NC) 
cells, suggesting that F-spondin regulates the segmental migration of NC cells (Debby-Brafman 
et al., 1999). Several studies have shown that F-spondin may play an important role in neuronal 
outgrowth. Burstyn-Cohen et al., found that the F-spondin TSR domain promotes outgrowth of 
cultured commissural neurons (Burstyn-Cohen et al., 1999). Another study has shown that the 
TSR1-4 fragment inhibits neurite outgrowth and TSR 5-6 fragments promote neurite outgrowth 
(Zisman et al., 2007).  
In addition to the role of F-spondin in neuronal migration and neural outgrowth, our 
collaborators found that F-spondin interacts with APP and ApoE receptor 2 (ApoER2), and 
affects APP processing and Aβ production (Ho and Südhof, 2004). Additionally, a recent study 
found that hippocampal F-spondin overexpression can reduce Aβ levels and enhance learning and 
memory in WT mice (Hafez et al., 2012). Moreover, the same group found that F-spondin 
injected into a mouse model of AD exhibited decreased Aβ plaque deposition (Hafez et al., 
2012). Interestingly, a recent study has shown that a polymorphism in the SPON1 gene locus of 
F-spondin is involved in brain connectivity in humans and implicates the SPON1 gene variant 
with rate of cognitive decline during AD (Jahanshad et al., 2013; Sherva et al., 2014). However, it 
is still unknown whether F-spondin plays a normal role in synaptic function and plasticity and 
whether it can affect dendritic spine formation associated with learning and memory in the adult 
brain. 
In the present study, we examine whether F-spondin is necessary for normal synaptic 
function in the adult brain. Interestingly, we found that the levels of F-spondin were increased in 
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APP Tg mice compared to WT or APP knockout (KO) mice (Megill et al., in preparation). We 
also found that F-spondin can increase dendritic spine formation in vitro and in vivo, and 
increases Ras activity as well as regulating signaling proteins upstream and downstream of Ras, 
which are involved in dendritic spine formation. However, F-spondin did not alter Rap signaling 
protein levels, which are associated with dendritic spine retardation. Taken together, these results 
indicate that F-spondin is important for dendritic spine formation through its interaction with APP 
and regulation of Ras signaling proteins Here we report that F-spondin is necessary, but is not 
sufficient, to promote LTP. 
 
Section 2: Methods 
Subsection 1: Mice 
Wild type mice (C57BL/6J) were obtained from the Jackson Laboratory (Bar Harbor, 
ME, USA). All procedures were performed in accordance with the protocols approved by the 
Institutional Animal Care and Use Committees of the Johns Hopkins University.  
Subsection 2: In vivo viral transfections  
Surgery was done under aseptic conditions. 5-week old male wild type C57BL/6J mice 
were anesthetized using 1-2% isoflurane mixed with O2, and were placed into a stereotactic 
apparatus (with supply of 1-2% isoflurane and O2). Craniotomy was made using a hand-held drill 
under a surgical microscope at the location of -2.54 mm from the Bregma, 2.00 mm lateral for 
CA1. A glass micropipette filled with recombinant lentivirus [the ratio of the virus: F3D(1:2), 
RL(1:6), F-spond-s-GFP(no dilution), GFP(no dilution)]was lowered into the brain 1.125 mm 
from the pia, using stereotactic coordinates. A total of 1.5 µl volume of virus was injected (0.15 
µl/min) using a digital pump. The wound was wiped with sterile PBS (pH 7.4), and the skin was 
sutured. After recovery on a warm thermal blanket (~30˚C), mice were returned to the colony 
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once they were seen to intake water and/or food. The wound was inspected daily, and the mice 
were kept for 2-3 weeks before use. 
Subsection 3: Electrophysiology 
Hippocampal slices (400-µm thick) were prepared (Lee et al., 2003). In brief, hippocampi 
were dissected using oxygenated ice-cold dissection buffer (composition in mM: 212.7 sucrose; 
2.6 KCl; 1.23 NaH2PO4; 26 NaHCO3; 10 dextrose; 3 MgCl2; and 1 CaCl2) and recovered at room 
temperature in artificial cerebrospinal fluid (ACSF, composition in mM: 124 NaCl; 5 KCl; 1.25 
NaH2PO4; 26 NaHCO3; 10 dextrose; 1.5 MgCl2; and 2.5 CaCl2). All recordings were done in a 
submersion recording chamber perfused with ACSF (29–30°C, 2 ml/min) bubbled with 95% O2-
5% CO2. Extracellular field potential responses were obtained by stimulating the Schaffer 
collaterals at about half-maximum intensity and recording from the dendritic field of CA1 using 
glass pipettes filled with ACSF. Synaptic responses were digitized and stored on-line using IGOR 
Pro software (WaveMetrics). LTP was induced using a theta burst stimulation [TBS: four trains, 
each consisting of ten 100-Hz bursts (four pulses) given at 5-Hz, repeated at 10-s intervals]. 10-
Hz stimulation protocol was induced using 10-Hz, 900 pulses. For measurement of paired-pulse 
facilitation (PPF), interstimulus intervals (ISI) of 25, 50, 100, 200, 400, 1000, and 2000 ms were 
used. Input-output curves were generated by measuring extracellular field potential responses 
with varying stimulus intensities. Field potential (FP) slopes were measured, and data are 
expressed as mean ± SE of mean. 
Subsection 4: Statistical analyses  
All data were analyzed using either a two-Tailed T-test or ANOVA with Graphpad Prism 
4 software. Significance determine as p < 0.05. All data is expressed as the mean ± SEM. 
 




F-spondin is necessary 
for hippocampal LTP 
Essentially 
very little is known 
about the role of F-
spondin in the mature 
brain, hence we first 
determined whether F-
spondin was necessary 
for normal synaptic 
transmission and 




control shRNA (RL) or 
F-spondin shRNA 
(F3D) into the CA1 
area of 5-week old WT 
mice. After 2-3 weeks, 
hippocampal slices 
were made and the 
transfection area was 
Figure 4.1. F-spondin is necessary for LTP in CA1.  
A. Confirmation of in-vivo viral injection in CA1 of the hippocampus. CA1 
regions of control shRNA (RL, Top panel) and F-spondin shRNA (F3D, 
Bottom panel) injected mouse.  B. No significant difference in input-output 
function. Top: Representative FP traces. Bottom left: FP slope plotted 
against stimulus intensity (RL: n = 8 slices, 4 mice; F3D: n = 5 slices, 3 
mice). Bottom right: FV amplitude plotted against stimulus intensity. There 
was also no significant difference in the ratio of FP slope to FV amplitude 
(RL: 7.67 ± 2.00; F3D: 5.06 ± 0.86; t test: p = 0.27). C. No change in 
presynaptic function. Left: PPF ratio at different interstimulus interval (ISI) 
(RL: n = 15 slices, 4 mice; F3D: n = 18 slices, 5 mice). Right: 
Representative traces from RL (top) and F3D (bottom) transfected slices at 
50 ms ISI.  D. Reduction in the magnitude of LTP produced by 4xTBS in 
F3D injected mice (RL: 131.4 ± 5.91% at 1 hour post-LTP, n = 10 slices, 4 
mice; F3D: 105.2 ± 3.21% at 1 hour post-LTP, n = 15 slices, 4 mice; t-test: 
*p < 0.01). Right top: Representative traces (baseline: thin line, post-LTP: 
thick line). Right bottom: Normal summation of responses during 4xTBS 




determined by the expression of GFP, which was present in the constructs (Fig 4.1 A). We 
restricted our recordings to slices that expressed GFP. We found that F-spondin shRNA did not 
alter basal synaptic transmission when compared to control shRNA as determined by a lack of a 
change in input-output function (Fig 4.1 B) or PPF ratio at varying interstimulus intervals (Fig 4.1 
C). In contrast, we found that F-spondin shRNA significantly impaired LTP without any change 
in the response summation during the induction protocol (Fig 4.1 D). These results suggest that 
normal expression of F-spondin is necessary for LTP expression.  
Subsection 2: F-spondin is not sufficient to promote LTP 
To determine whether F-spondin is sufficient to promote LTP, we overexpressed F-
spondin into the CA1 area of 5-week old WT mice. After 2-3 weeks, we verified the transfection 
by the expression of GFP, which was co-expressed with F-spondin, and restricted the recordings 
to the slices that showed GFP. We found that similar to F-spondin shRNA, F-spondin 
overexpression did not alter basal synaptic transmission when compared to controls as determined 
by a lack of change in input-output function (Fig 4.2 A) or PPF ratio at varying interstimulus 
intervals (Fig 4.2 B). This suggests that F-spondin levels do not largely affect basal synaptic 
function in CA1 of adult neurons.  
We found that the overexpression of F-spondin did not enhance LTP or alter the 
summation of responses during the induction protocol (Fig 4.2 C), which suggest that endogenous 
levels of F-spondin are likely sufficient for optimal LTP expression. To determine whether the 
lack of an enhancement of LTP with F-spondin overexpression is due to saturation of LTP with 
the maximal induction protocol used, we used a milder form of stimulation (i.e. 10-Hz) that is 
known to produce submaximal levels of LTP. Contrary to our expectation, F-spondin 
overexpression reduced LTP induced at an intermediate stimulation frequency (10-Hz) (Fig 4.2 




Figure 4.2. F-spondin 
overexpression does not 
enhance LTP in CA1 of the 
hippocampus.  
A. No significant difference in 
input-output function. Left: FP 
slope plotted against stimulus 
intensity (GFP: n = 9 slices, 5 
mice; F-spondin-s-GFP: n = 10 
slices, 5 mice). Middle: FV 
amplitude plotted against 
stimulus intensity. Right: 
Representative FP traces. 
There was also no significant 
difference in the ratio of FP 
slope to FV amplitude (GFP: 
3.44 ± 0.70; F-spondin-s-GFP: 
3.89 ±0.55; t test: p = 0.62). B. 
No change in presynaptic 
function. Left: PPF ratio at 
different ISI (GFP: n = 17 
slices, 5 mice, F-spondin-s-
GFP: n = 16 slices, 4 mice). 
Right: Representative traces as 
50 ms interstimulus interval 
(ISI).  C. No difference in the 
magnitude of LTP produced by 
4xTBS (GFP: 127.2 ± 9.87% 
at 1 hour post-LTP, n = 10 
slices, 5 mice; F-spondin-s-
GFP: 117.3 ± 4.21% at 1 hour 
post-LTP, n = 12 slices, 4 
mice; t-test: p = 0.37). Top: 
Representative traces 
(baseline: thin line, post-LTP: 
thick line). Inset: Normal 
summation of responses during 
4xTBS LTP induction 
protocol.  D. Reduction in the 
magnitude of LTP produced by 
10 Hz in F-spondin-s-GFP 
injected mice (GFP: 109.6 ± 
4.20% at 1 hour post-LTP, n = 
10 slices, 2 mice; F-spondin-s-
GFP: 94.7 ± 4.21% at 1 hour 
post-LTP, n = 10 slices, 3 
mice; t-test: *p < 0.05). Right: 
Representative traces 
(baseline: thin line, post-LTP: 




Section 4: Discussion 
We found a novel functional role of F-spondin in regulating LTP in mature neurons. 
Endogenous F-spondin is not only necessary for LTP, but its level is optimal for normal LTP. We 
found that F-spondin knockdown prevents LTP expression, which occurred without significant 
changes in input-output function or response summation during LTP (Fig 4.1). On the other hand, 
F-spondin overexpression did not significantly alter the magnitude of LTP, but increased the 
threshold for LTP induction at an intermediate stimulation frequency (Fig 4.2). These results 
suggest that endogenous levels of F-spondin are optimal for normal LTP and any deviation would 
negatively impact LTP. While F-spondin treatment increases dendritic spine density and specific 
subunits of AMPA and NMDA receptors (data not shown, Megill et al., in preparation), we did 
not observe significant changes in the input-output function with F-spondin overexpression (Fig 
4.2). This may be due to differences in preparation or method of F-spondin overexpression, but 
suggests that increasing F-spondin levels may only marginally affect basal synaptic function 
despite having significant effects on dendritic spine plasticity and LTP induction threshold (Fig 
4.2). The increase in LTP induction threshold following F-spondin overexpression may reflect a 
homeostatic adaptation to the increase in dendritic spine density (data not shown; Megill et al., in 
preparation). A similar reduction in LTP magnitude was also seen in our previous study with an 
Aβ binding chemical, which increased dendritic spine density via Ras signaling (Megill et al., 
2013; Chapter 3). A previous study demonstrated that F-spondin overexpression enhances 
behavioral performance of WT mice in Morris water maze and novel object recognition tasks 
(Hafez et al., 2012). Together with our results, this suggests that improvement of dendritic spine 




 Results from our collaborators provide a signaling pathway in which F-spondin acts on 
APP to activate Ras signaling leading to an increase in dendritic spine density. Furthermore, F-
spondin decreased the levels of a key synaptic Ras inhibitor, SynGAP, without affecting Rap 
signaling molecules. It is of interest to note that SynGAP heterozygotes exhibit similar phenotype 
as F-spondin overexpression, in that there was an increase in surface AMPA receptor clusters but 
no change in basal synaptic transmission and reduced LTP induction (Kim et al., 2003). At this 
point, it is unclear as to whether F-spondin works via direct binding to APP or not, but our study 
provides a molecular signaling mechanism for F-spondin action in mature neurons. The signaling 
of F-spondin via APP also has implications for normal physiological functions of APP. Based on 
our collaborator’s results that F-spondin levels are increased in APP Tg mice, we surmise that F-
spondin may amplify APP signaling. This amplification may not just result from increased F-
spondin activation of APP, but may also result from reduced Aβ production, (Ho and Südhof, 
2004; Hoe et al., 2005) [but see (Rice et al., 2013)] considering that Aβ signaling often opposes 
APP signaling [reviewed in (Hoe et al., 2012)]. F-spondin and APP have been shown to be 
increased in the CSF of symptomatic AD patients compared to non-symptomatic AD patients and 
to normal controls (Zhang et al., 2005; Ringman et al., 2012). Variants in the F-spondin gene 
(SPON1) have also been identified as risk factors for AD and associated with cognitive decline 
(Jahanshad et al., 2013; Sherva et al., 2014). Collectively, our results place F-spondin as a key 
regulator of APP-mediated spinogenesis and necessary for LTP in CA1, which may underlie the 







Chapter 5: Comparing Alzheimer’s disease therapies in a mouse model of AD 
 
This manuscript is in preparation. 
Putative authors: Andrea Megill, Philip C. Wong, Hyang-Sook Hoe, and Hey-Kyoung Lee 
 
My contribution: All of the experiments in this study. 
 
Section 1: Introduction 
It is clear that successful AD treatments will need to do more than just lower Aβ 
production; they will need to rescue cognitive as well as synaptic dysfunction. Increasing 
evidence suggests the cognitive syndromes found in AD patients are preceded by changes in 
synaptic efficacy [reviewed in (Selkoe, 2002; Shankar and Walsh, 2009)]. Therefore, examining 
whether different strategies that target A production and accumulation will rescue synaptic 
dysfunction associated with AD is also important. We decided to compare two therapies, BTA-
EG4 and GRL-8234, in an established AD mouse model (see Chapter 2).  
GRL-8234 is a -secretase inhibitor. Inhibiting APP processing enzymes, like - and γ-
secretase, emerged among the first possible targets of AD therapeutics [reviewed in (Wang et al., 
2012)], in an effort to reduce A production. However, many of these original therapeutics have 
proven unsuccessful due to either widespread toxicity (Vetrivel et al., 2006; Wolfe, 2008; 
Svedružić et al., 2013; D’Onofrio et al., 2012) or their poor results after long-term treatment 
during in vivo studies (Ghosh et al., 2008a, 2008b). GRL-8234 and its derivatives have recently 
been developed and reported to overcome many of these problems, proving to be highly effective 
and potent at inhibiting -secretase activity in vivo (Ghosh et al., 2008c; Chang et al., 2011). In 
Tg2576 AD mice, GRL-8234 was able to recue cognitive decline after long-term treatment. This 
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rescue was also associated with a reduction in soluble A peptides and A plaque number (Chang 
et al., 2011). 
BTA-EG4 was developed in an effort to find a novel small molecule the was able to bind 
A peptides and stop their aggregation, as well as prevent their association with other cellular 
proteins (Inbar et al., 2006; Habib et al., 2010; Capule and Yang, 2012). Recently, with the help 
of our collaborators, we investigated the effects of BTA-EG4 on normal brain activity and 
synaptic function in WT mice. The summary of those results is detailed in Chapter 3. Briefly, we 
found that BTA-EG4 decreased soluble A levels by increasing the cell surface expression of 
APP, thereby altering APP processing. BTA-EG4 also improved memory through an LTP 
independent mechanism that correlated with increased spinogenesis. Finally, we found that BTA-
EG4 required APP to regulate dendritic spine density through a Ras-ERK-dependent signaling 
mechanism (Megill et al., 2013).  
Because BTA-EG4 showed promise as an AD therapeutic, its effects on neural and 
cognitive dysfunction were next studied in 3xTG AD mouse model (Song et al., 2014). There was 
an age specific improvement in 3xTg mice treated with BTA-EG4. Both dendritic spine density 
and Ras activity were increased in CA1 of 6-10 month old 3xTg mice, but not in 13-16 month old 
mice. Increased spine density correlated with improved learning and memory in 6-10 month old 
3xTg mice, as well as a decrease in A levels (Song et al., 2014).   
While both GRL-8234 and BTA-EG4 have been shown to lower A production and 
improve cognitive function, previous studies differ in the AD mouse model used, the duration and 
initiation of treatment, and the mechanism by which treatment proved effective. In addition, and 
most importantly, neither study investigated the effects of treatment on synaptic function and 
plasticity in these AD models. Therefore, the goal of this study is to compare and examine 
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whether short term treatment of BTA-EG4 or GRL-8234 will effectively rescue synaptic deficits 
seen in adult APPswe;PS1deltaE9 Tg mice. 
 
Section 2: Materials and Methods 
Subsection 1: Animals 
Adult 6 to 7-month old WT and APPswe;PS1deltaE9 Tg mice (129/C57BL6 mixed 
background)  were used. Genotypes were distinguished by polymerase chain reaction (PCR) of 
isolated genomic DNA obtained from each pup after weaning. The Institutional Animal Care and 
Use Committees of Johns Hopkins University approved all procedures involving animals 
Subsection 2: Drug administration 
Mice were intraperitoneally (i.p.) injected with either GRL-8234 (33.4ug/g body 
weight/day) or vehicle solvent (50:50 mixture of PEG300 and D5W, v/v); or BTA-EG4 (30 
mg/kg body weight/day) or vehicle solvent (10% DMSO in 1xPBS) for 10 consecutive days.  
Subsection 3: Preparation of acute hippocampal slices  
Acute hippocampal slices were prepared as described previously (Lee et al., 2003). 
Briefly, each mouse was euthanized by decapitation following overdose of isoflurane. 
Hippocampi were rapidly removed and one was sectioned into 400 μm slices on a vibratome 
(Vibratome 3000 series, Ted Pella Inc.), the other was saved for A ELISA. The hippocampus 
was dissected using oxygenated ice-cold dissection buffer (composition in mM: 212.7 sucrose; 2.6 
KCl; 1.23 NaH2PO4; 26 NaHCO3; 10 dextrose; 3 MgCl2; and 1 CaCl2) and recovered at room 
temperature in artificial cerebrospinal fluid (ACSF, composition in mM: 124 NaCl; 5 KCl; 1.25 
NaH2PO4; 26 NaHCO3; 10 dextrose; 1.5 MgCl2; and 2.5 CaCl2).  
Subsection 4: Field potential recording from Schaffer collateral inputs to CA1  
117 
 
All recordings were done in a submersion recording chamber perfused with ACSF (29–
30°C, 2 ml/min) bubbled with 95% O2-5% CO2. For field potential recordings, synaptic responses 
were delivered through a bipolar glass stimulating electrode placed to activate the Schaffer 
collaterals with a 0.2 ms duration pulse (baseline stimulation at 0.0333 Hz), and recorded from 
the dendritic field of CA1. Synaptic responses were digitized and stored on-line using IGOR Pro 
software (WaveMetrics). Input-output curves were generated by measuring extracellular field 
potential responses with varying stimulus intensities. For measurement of paired-pulse facilitation 
(PPF), ISIs of 25, 50, 100, 200, 400, 1000, and 2000 ms were used. LTP was induced using a 
theta burst stimulation [TBS: four trains, each consisting of ten 100-Hz bursts (four pulses) given 
at 5 Hz, repeated at 10-s intervals] (Larson et al., 1986). LTD was induced using a paired-pulse 1 
Hz (50ms ISI), 900 pluses stimulation. Field potential (FP) slopes were measured, and data are 
expressed as mean ± SE of mean. 
Subsection 5: Aβ ELISA 
Each half of the hippocampus was homogenized in tissue homogenization buffer 
containing 250 mM sucrose, 20 mM Tris base, protease, and phosphatase inhibitors. To measure 
soluble Aβ, diethylamine (DEA) extraction was performed. Crude 10% homogenate was mixed 
with an equal volume of 0.4% DEA, sonicated, and ultracentrifuged for 1 h at 47,000 RPM. The 
supernatant was collected and neutralized with 10% 0.5 m Tris, pH 6.8. Sensitive and specific 
ELISAs to Human Aβ1–40 and 42 were purchased from Invitrogen and conducted per the 
manufacturer's protocol.  
Subsection 6: Statistical analyses 
All data were analyzed with GraphPad Prism 4 software using either a two-tailed t test or 
ANOVA with Bonferroni post hoc test for multiple comparisons. Significance was determined as 




Section 3: Results  
Subsection 1: Basal synaptic function and PPF ratio are unaffected in adult WT and 
APPswe;PS1deltaE9 Tg mice treated with either BTA-EG4 or GRL-8234 
 
Figure 5.1. Basal synaptic function is unaffected in adult WT and APPswe;PS1deltaE9 Tg mice 
treated with either BTA-EG4 or GRL-8234. 
 
A. FP slope normalized to FV amplitude in adult (6 to 7-month) WT mice treated with BTA (CTRL: n = 
13 slices, 7 mice; BTA: n =11 slices, 6 mice). Right, Representative FP traces. B. FP slope normalized to 
FV amplitude in adult Tg mice treated with BTA (CTRL: n = 14 slices, 5 mice; BTA: n =11 slices, 4 
mice). Right, Representative FP traces C. FP slope normalized to FV amplitude in adult WT mice treated 
with GRL (CTRL: n = 20 slices, 7 mice; GRL: n = 20 slices, 6 mice). Right, Representative FP traces. D. 
FP slope normalized to FV amplitude in adult Tg mice treated with GRL (CTRL: n = 13 slices, 4 mice; 
GRL: n = 19 slices, 5 mice). Right, Representative FP traces. 
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We conducted electrophysiological experiments on adult, 6 to 7-month old WT and 
APPswe;PS1deltaE9 Tg mice treated with BTA-EG4 (30 mg/kg; i.p.), or GRL-8234 (33.4 mg/kg; 
i.p.), or the appropriate control (BTA: 10% DMSO, GRL: 50/50 PEG 300, D5W) for 10  
Figure 5.2. PPF ratio is unaffected in adult WT and APPswe;PS1deltaE9 Tg mice treated with 
either BTA-EG4 or GRL-8234. 
 
A. PPF ratio at different ISIs in adult WT mice treated with BTA (CTRL: n = 25 slices, 7 mice; BTA: n = 
22 slices, 6 mice) Right, Representative traces at 50 ms ISI. B. PPF ratio at different ISIs in adult WT 
mice treated with BTA (CTRL: n = 20 slices, 5 mice; BTA: n = 19 slices, 5 mice). Right, Representative 
traces at 50 ms ISI.  C. PPF ratio at different ISIs in adult WT mice treated with GRL (CTRL: n = 28 
slices, 7 mice; GRL: n = 30 slices, 6 mice). Right, Representative traces at 50 ms ISI.  D. PPF ratio at 
different ISIs in adult Tg mice treated with GRL (CTRL: n = 21 slices, 4 mice; GRL: n = 25 slices, 6 





consecutive days. Neither BTA-EG4 (Fig 5.1 A&B) nor GRL-8234 (Fig 5.1 C&D) treatment 
effected basal synaptic function in WT (Fig 5.1 A&C) or Tg (Fig 5.1 B&D) mice. Neither was 
there a differential effect of either treatment on PPF ratio (Fig 5.2) at individual ISIs in WT (Fig  
Figure 5.3. LTP in adult WT and APPswe;PS1deltaE9 Tg mice treated with BTA-EG4.  
 
A. BTA treatment has no effect on LTP induced with 4xTBS protocol in adult WT mice (CTRL: 140.34 
± 3.92% at 1 hour post-LTP, n = 12 slices, 5 mice; BTA: 142.74 ± 6.40% at 1 hour post-LTP, n = 11 
slices, 4 mice; t test, p = 0.657). Top, Representative FP traces (baseline: thin line, post-LTP: thick line). 
B. BTA treatment has no effect on LTP induced with 4xTBS protocol in adult Tg mice (CTRL: 167.55 ± 
7.85% at 1 hour post-LTP, n = 16 slices, 5 mice; BTA: 165.31 ± 11.48% at 1 hour post-LTP, n = 12 
slices, 5 mice; t test, p = 0.873). Top, Representative FP traces (baseline: thin line, post-LTP: thick line). 
C. There is a vehicle effect on LTP magnitude seen between WT and Tg mice (values above, Bonferroni 




5.2 A&C) or Tg (Fig 5.2 B&D) mice.  
Subsection 2: Long-term plasticity in adult WT and APPswe;PS1deltaE9 Tg mice 
treated with BTA-EG4. 
Figure 5.4. LTD in adult WT and APPswe;PS1deltaE9 Tg mice treated with BTA-EG4.  
 
A. BTA treatment causes LTP in adult WT mice following a pp-1Hz, 900 pulses LTD protocol (CTRL: 
94.72 ± 2.78% at 1 hour post-LTD, n = 11 slices, 4 mice; BTA: 111.50 ± 2.28% at 1 hour post-LTD, n = 
11 slices, 4 mice; t test, *p < 0.001, gray line). Top, Representative FP traces (baseline: thin line, post-
LTD: thick line). B. BTA treatment has no effect on LTD induced with pp-1Hz, 900 pulses LTD 
protocol in adult Tg mice (CTRL: 100.54 ± 2.87% at 1 hour post-LTD, n = 13 slices, 5 mice; BTA: 
99.72 ± 2.91% at 1 hour post-LTD, n = 11 slices, 4 mice; t test, p = 0.843). Top, Representative FP 
traces (baseline: thin line, post-LTD: thick line). C. LTD is significantly different across WT and Tg 
mice treated with BTA (values above, Bonferroni post test, *p < 0.01, black line). Vehicle treatment 




We have previously reported that adult APPswe;PS1deltaE9 Tg mice show deficits in 
long-term plasticity due to altered expression mechanisms for mediating frequency-dependent 
LTP/LTD (Chapter 2). This deficit resulted from dysregulated metaplasticity and lead to 
decreased LTP and increased LTD at this age. LTP and LTD were measured in adult WT and Tg 
mice treated with BTA-EG4 to investigate whether either treatment would be effective at rescuing 
these deficits. BTA-EG4 treatment did not affect LTP following 4xTBS protocol in WT (Fig 5.3 
A) or Tg (Fig 5.3 B) mice. However, there was a vehicle (10% DMSO) effect seen across WT 
and Tg mice (Fig 5.3 C), as the magnitude of LTP was opposite of what was previously observed 
in non-treated adult WT and Tg mice (Fig 2.6 G). BTA-EG4 treatment produced a small 
potentiation in WT mice (Fig 5.4 A) following pp-1 Hz LTD induction protocol, but did not 
effect LTD magnitude in Tg mice (Fig 5.4 B). In Tg mice, vehicle treatment nearly abolished 
LTD compared to what was previously seen in non-treated Tg mice (Fig 2.6 E). These results 
suggest that vehicle treatment itself reduced LTP in WT mice, enhanced LTP in Tg mice, and 
prevented LTD in Tg mice, hence complicates the interpretation of results with BTA- EG4. 
However, BTA-EG4 treatment did not differ from vehicle treatment in most cases, except that it 
changed the polarity of synaptic plasticity induced by a LTD protocol in WT mice. 
Subsection 3: Long-term plasticity in adult WT and APPswe;PS1deltaE9 Tg mice 
treated with GRL-8234. 
We next measured LTP and LTD in adult WT and Tg mice treated with GRL-8234, using 
the same stimulation protocols as above. GRL-8234 reduced the magnitude of LTP in WT mice 
(Fig 5.5 A) but had no effect on LTP in Tg mice (Fig 5.5 B). The decrease in LTP with GRL-
8234 in WT was not due to a decrease in the summation of synaptic response during LTP 
induction (Fig 5.5 C). There is also a difference in LTP magnitude seen between WT and Tg mice 
treated with vehicle control (50/50 PEG 300, D5W) (Fig 5.5 D), which is similar in magnitude to  
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the LTP deficit that is present in Tg mice at this age (Fig 2.6 G). This suggests that the vehicle 
does not alter LTP in either genotype. GRL-8234 had no effect on LTD in either WT or Tg mice 
(Fig 5.6). However, there was a vehicle effect seen in Tg mice, as LTD was reduced compared to 
what was previously seen in non-treated Tg mice (Fig 2.6 E). 
Figure 5.5. LTP in adult WT and APPswe;PS1deltaE9 Tg mice treated with GRL-8234. 
 
A. GRL treatment negatively affects LTP magnitude induced with 4xTBS protocol in adult WT mice 
(CTRL: 161.60 ± 7.06% at 1 hour post-LTP, n = 14 slices, 4 mice; GRL: 133.71 ± 4.67% at 1 hour post-
LTP, n = 14 slices, 4 mice; t test, *p < 0.01, gray line). Top, Representative FP traces (baseline: thin 
line, post-LTP: thick line). B. GRL treatment has no effect of LTP induced with 4xTBS protocol in 6 to 
7-month Tg mice (CTRL: 143.22 ± 4.75% at 1 hour post-LTP, n = 10 slices, 3 mice; GRL: 141.28 ± 
8.25% at 1 hour post-LTP, n = 10 slices, 4 mice; t test, p = 0.841). Top, Representative FP traces 
(baseline: thin line, post-LTP: thick line). C. Summation of synaptic responses during LTP induction are 
normal in WT mice treated with GRL. D. There is a difference in LTP magnitude in WT and Tg mice 
treated with vehicle control (values above, Bonferroni, *p < 0.05, black line). 
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Subsection 4: Soluble A40 and A42 levels in adult APPswe;PS1deltaE9 Tg mice 
treated with BTA-EG4 or GRL-8234. 
Finally, we measured soluble A40 and A42 levels in adult Tg mice treated with either 
BTA-EG4 or GRL-8234. Our results are consistent with what has previously been observed in  
Figure 5.6. LTD in adult WT and APPswe;PS1deltaE9 Tg mice treated with GRL-8234. 
 
A. GRL treatment has no effect on LTD induced with pp-1Hz, 900 pulses protocol in adult WT mice 
(CTRL: 91.67 ± 1.53% at 1 hour post-LTD, n = 7 slices, 5 mice; GRL: 89.67 ± 2.40% at 1 hour post-
LTD, n = 10 slices, 5 mice; t test, p = 0.491). Top, Representative FP traces (baseline: thin line, post-
LTD: thick line). B. GRL treatment has no effect of LTD induced with pp-1Hz, 900 pulses protocol in 
adult Tg mice (CTRL: 92.12 ± 3.78% at 1 hour post-LTD, n = 9 slices, 4 mice; GRL: 97.74 ± 5.18% at 1 
hour post-LTD, n = 9 slices, 4 mice; t test, p = 0.395) Top, Representative FP traces (baseline: thin line, 
post-LTD: thick line). C. Vehicle treatment reduced LTD magnitude in adult Tg mice compared to non-




studies using Tg mice (Chang et al., 2011; Song et al., 2014). While A levels decreased 
following both treatments, neither reached statistical significance (Fig 5.7 A-B & D-E). Because 
Figure 5.7 Soluble A40 and A42 levels in adult APPswe;PS1deltaE9 Tg mice treated with BTA-
EG4 or GRL-8234.  
 
(A-C) A ELISAs were conducted to compare A levels in adult Tg mice treated with BTA-EG4 
(BTA), vehicle (CTRL), or non-injected control (No inj.). A. BTA does not significantly affect A40 
levels (BTA: 12.96 ± 3.49, n = 6 mice; CTRL: 14.18 ± 3.36, n = 8 mice; No inj.: 18.38 ± 4.02, n = 6 
mice; ANOVA, p = 0.578). B. BTA does not significantly affect A42 levels (BTA: 86.37 ± 22.76, n = 6 
mice; CTRL: 97.91 ± 22.13, n = 8 mice; No inj.: 130.10 ± 29.31, n = 6 mice; ANOVA, p = 0.477). C. 
BTA does not significantly affect the A42/ A40 ratio (BTA: 6.52 ± 0.66, n = 6 mice; CTRL: 7.02 ± 
0.28, n = 8 mice; No inj.: 7.17 ± 0.88, n = 6 mice; ANOVA, p = 0.750). (D-F) A ELISAs were 
conducted to compare A levels in adult Tg mice treated with GRL-8234 (GRL), vehicle (CTRL), or 
non-injected control (No inj.). D. GRL does not significantly affect A40 levels (GRL: 10.70 ± 1.20, n = 
7 mice; CTRL: 14.07 ± 3.07, n = 5 mice; No inj.: same as in A; ANOVA, p = 0.177). E. GRL does not 
significantly affect A42 levels (GRL: 63.66 ± 9.55, n = 7 mice; CTRL: 93.87 ± 19.74, n = 5 mice; No 
inj.: same as in B; ANOVA, p = 0.088). F. GRL does not significantly affect A42/ A40 ratio (GRL: 




this Tg AD model exhibits an increased A42/A40 ratio due to the FAD-linked PS1 mutation 
(Jankowsky et al., 2004), a more effective readout of drug efficacy requires measuring this ratio. 
However, the A ratio was similar between Tg mice of all experimental groups (Fig 5.7 C&F). 
Unexpectedly, we saw that the vehicle alone affected A levels (Fig 5.7). While this effect did 
not reach significance, it suggests that the different vehicles used in this study may be inhibiting 
detection of A proteins by making them inaccessible to the A antibodies or by actually 
decreasing soluble A.  
 
Section 4: Discussion 
In this study we compared BTA-EG4 treatment to a more conventional BACE1 inhibitory 
therapy with GRL-8234. To test the effects of these treatments on synaptic function and plasticity 
in CA1, we used hippocampal slices from adult WT and APPswe;PS1deltaE9 amyloidogenic Tg 
mice, whose deficits have previously been characterized (See Chapter 2). Unforeseen vehicle 
effects largely complicated the interpretation of our results. Overall, it appears that neither BTA-
EG4 nor GRL-8234 is able to rescue the metaplasticity deficits seen in adult Tg mice. 
Subsection 1: Vehicle treatment effects LTP magnitude in WT and 
APPswe;PS1deltaE9 Tg mice 
Our study emphasizes the importance of proper controls and complete understanding of 
the properties of vehicle solvents used. WT mice treated with vehicle control (10% DMSO; i.p.) 
for BTA-EG4 showed significantly reduced LTP compared to non-treated WT mice (Fig 5.3 & 
Fig 2.6; p < 0.05), while Tg mice treated with vehicle control (10% DMSO; i.p.) showed 
significantly enhanced LTP compared to non-treated Tg mice (Fig 5.3 & Fig 2.6; p < 0.05). 
DMSO is a commonly used solvent in experimental drug biology; however, in this study it 
greatly affected synaptic plasticity, which was genotype specific. There are many studies 
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documenting the toxicity and side effects of DMSO (Gross et al., 1993; Hanslick et al., 2009; 
Galvao et al., 2014; Morris et al., 2014; Stevens et al., 2014; Zhou et al., 2014). Two more recent 
studies question the standard 10% DMSO concentration used in many practices and show toxicity 
even at concentrations below 10% DMSO (Galvao et al., 2014; Morris et al., 2014). Although the 
vehicle effects of DMSO seen in this study may not be classified as toxic, our results demonstrate 
that DMSO alters synaptic plasticity mechanisms at the concentration used in many studies.  
The fact that summation of synaptic responses during LTP induction is similar in both 
WT and Tg mice treated with 10% DMSO vehicle (data not shown), suggests that signaling 
downstream of LTP induction and NMDARs is altered. Indeed, numerous studies have shown 
that DMSO has the ability to manipulate various enzymatic activities (Zangar and Novak, 1998; 
McConnell et al., 1999; Rossi and Dianzani, 2000; Grzyska et al., 2002; Ou et al., 2002; Santucci 
et al., 2002; Yokochi and Robertson, 2004; Yoon et al., 2006; Alsafadi and Paradisi, 2013). 
Therefore, it could be suggested that DMSO alters LTP magnitude by affecting signaling 
associated with LTP. For example, DMSO may alter enzymatic activity associated with Ras 
signaling or kinase activity, leading to changed AMPAR phosphorylation and kinetics.  
One unexpected observation is that the effect of DMSO is not uniform between WT and 
Tg mice. We observed a specific reduction in LTP magnitude in WT mice and enhancement of 
LTP in Tg mice with 10% DMSO treatment. Certain plasticity related signals follow a bell 
shaped curve in relation to LTP magnitude. Therefore, an increase in signal strength would 
increase LTP magnitude; however, at a certain point, a peak is reached and any further increase in 
signal strength reduces LTP magnitude. Vehicle treatment in WT mice, with an initial LTP 
magnitude close to the peak, would show a decrease in LTP magnitude in response to increased 
signal strength. In Tg mice, with an initial low LTP magnitude, LTP magnitude would increase 
towards the peak in response to increased signal strength following vehicle treatment. While it 
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would be hard to pinpoint the exact mechanism being manipulated by DMSO, an increase in this 
type of signaling cascade, downstream of LTP induction, would explain the differential effect of 
DMSO on LTP magnitude between the genotypes.  
An alternative explanation to the difference in LTP magnitude between treated and non-
treated mice could simply be that the changes observed are a result of stress caused by the 
injection. However, this is unlikely, as we did not see alterations in LTP phenotype in mice 
injected with GRL-8234 or its vehicle control (50/50 PEG300, D5W) (Fig 5.5). The magnitudes 
of LTP in adult WT or Tg mice treated with vehicle control for GRL-8234 were similar to non-
treated controls (Chapter 2), suggesting that PEG300 itself does not modulate LTP signaling and 
may be a more appropriate biological solvent. 
Subsection 2: Increased susceptibility to environmental stressors decreases LTD 
magnitude in APPswe;PS1deltaE9 Tg mice  
Vehicle effects were most strongly noticed when measuring LTD. The resulting 
phenotype, an almost complete lack of LTD, is seen across drug treatments in treated Tg mice. 
Therefore, we cannot rule out the possibility that this is a direct consequence of daily injections, 
suggesting that LTD magnitudes in Tg mice may be more susceptible to environmental stressors. 
Several recent studies have documented the effect of stress in AD mouse models (Dong et al., 
2008; Escribano et al., 2009; Rothman and Mattson, 2010; Rothman et al., 2012). AD Tg mice 
show increased plasma corticosterone levels compared to WT mice. In addition, stress increases 
A levels and tau phosphorylation, and decreases CaMKII phosphorylation and BDNF levels 
[reviewed in (Rothman and Mattson, 2010)]. This suggests that AD Tg mice are more susceptible 
to the effects of stress, and that stress may worsen cognitive deficits and accelerate the 
progression of AD. Indeed, deficits in LTD have been linked to cognitive dysfunction associated 
with memory retrieval, reversal learning, and behavioral flexibility [reviewed in (Collingridge et 
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al., 2010)]. A decrease in hippocampal LTD following exposure to stress has been observed and 
is thought to be dependent on activation of voltage-gated calcium channels (VGCC) (Maggio and 
Segal, 2007, 2009, 2010). Importantly, during AD, VGCCs provide enhanced Ca2+ influx as a 
result of elevated levels of A peptides, disrupting normal calcium homeostasis (Yagami et al., 
2012; Cataldi, 2013). Therefore, the altered LTD levels reported in this study could be due to a 
differential stress response in WT and Tg mice.  
Subsection 3: LTP magnitudes differ between WT strains: stress and the influence of 
genetic background 
Just as AD Tg and WT mice respond differently to stress, there are also differences in 
stress response seen with genetic background (McCutcheon et al., 2008; Cominski et al., 2012). 
The AD Tg mice used in this study were generated on a 129/C57BL6 (129/B6) mixed 
background, while WT mice originally treated with BTA-EG4 (Chapter 3; Megill et al., 2013) 
were C57BL6 (B6). When comparing plasma corticosterone levels between these strains, the 
mixed 129/B6 mice showed elevated levels of stress-induced corticosterone compared to B6 mice 
(McCutcheon et al., 2008). In addition, mice on a 129S6 genetic background showed elevated 
basal plasma corticosterone levels as well as elevated stress-induced corticosterone (Cominski et 
al., 2012). These findings demonstrate that genetic background influences stress response and 
may explain why LTP magnitudes differ between WT strains treated with vehicle control in this 
study (Chapter 3 vs. Chapter 5). Age, in addition to genetic background, may also cause a 
difference in response to the effect of the DMSO vehicle or injection. Therefore, although 
plasticity may be unaffected by injection stress or 10% DMSO in young B6 WT mice (Chapter 
3), adult 129/B6 WT mice may have a greater susceptibility to stress related factors, which could 
result in a decrease in LTP magnitude (Fig 5.3). 
Subsection 4: BTA-EG4 and GRl-8234 treatment alter LTP/D magnitudes in WT mice 
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Despite the complications of the vehicle effect, overall we did not observe any 
improvement of LTP or LTD in Tg mice with either BTA-EG4 or GRL-8234. To appropriately 
compare between the two treatments, we selected a time course that previously provided 
beneficial functional and structural synaptic changes in WT mice treated with BTA-EG4 (Megill 
et al., 2013). The lack of benefit in this study may be due to the short duration of treatment and 
suggests the possibility that a longer duration, or earlier initiation, of treatment may be needed to 
rescue synaptic deficits. Indeed, previous studies using BTA-EG4 or GRL-8234 treatment in other 
AD models have also shown similar limited effects on lowering A peptide levels (Chang et al., 
2011; Song et al., 2014). Even so, drug efficacy is not determined by A levels alone. Both BTA-
EG4 and GRL-8234 have been previously shown to effectively rescue cognitive function in the 
absence of significantly decreased A levels (Chang et al., 2011; Song et al., 2014), which 
suggests that they may be promoting plasticity independent of reducing A levels. Furthermore, 
the improved cognitive performance observed in 3xTg mice treated with BTA-EG4 in the 
previous study may be through an LTP independent mechanism (Song et al., 2014). Indeed, there 
is existing evidence that cognitive performance does not always correlate with LTP magnitude. 
Specifically, BTA-EG4 treatment in WT mice improved cognitive function in the absence of 
enhanced LTP, and instead better correlated with an increase in dendritic spine density (Chapter 
3; Megill et al., 2013). This provides another line of evidence that cognitive performance may 
better correlate with dendritic spine density rather than LTP magnitude (Chapters 3 and 4). 
Subsection 5: Conclusion 
Although this study was initiated to investigate the potential of current therapeutics to 
rescue metaplasticity deficits in an AD mouse model, it instead provided valuable insights into 
commonly used vehicle controls and the differential effects of stress based on genetic background 
and genotype. It also demonstrates that cognitive rescue following therapeutic treatment in AD 
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mouse models, may occur in the absence of reduced amyloid levels, or changes in frequency-
dependent plasticity. Understanding how commonly used drug therapies and solvents affect 
synaptic function and plasticity in normal and diseased states may give insight into their 




Chapter 6: General discussion and future directions 
 
Alzheimer’s disease (AD) is the most common form of dementia. It is a devastating 
neurological disease, which affects approximately 44% of elderly people 75-84 years of age 
(Hebert et al., 2013). Current theories implicate the production of A as the key molecular event 
that ultimately leads to neurodegeneration and clinical pathologies of AD (Hardy and Selkoe, 
2002). It is clear that successful AD treatments will need to do more than just lower Aβ 
production; they will need to rescue cognitive deficits, but more importantly, the underlying 
synaptic dysfunction. Increasing evidence suggests that the cognitive syndromes found in AD 
patients are preceded by changes in synaptic efficacy (Walsh and Selkoe, 2004; Shankar and 
Walsh, 2009). The overall goal of this project was to target metaplasticity changes associated 
with AD to normalize neuronal function. The results from this project provide a novel 
mechanistic viewpoint in understanding the synaptic dysfunctions seen in AD, which will allow 
development of more effective therapeutics by targeting the fundamental cellular mechanisms 
disrupted by AD progression. This section contains discussion about the significance of the 
results and future directions. 
 
Section 1: Regulation of metaplasticity 
Metaplasticity is a change in the ability of a synapse to produce subsequent synaptic 
plasticity, based on prior synaptic activity (Bear et al., 1987; Bear, 1995). Therefore, 
metaplasticity acts to provide stability to the neural circuit by regulating LTP and LTD. In this 
way, the ability of a neural network to store information is preserved by allowing synapses to 
maintain synaptic weights within a normal range allowing plasticity to be expressed (Abraham, 
2008; Mockett and Hulme, 2008).  
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Alterations in memory networks have been seen early in AD patients, prior to clinical 
pathologies, and manifest as increases in activity within these systems (Sperling et al., 2010). In 
addition, A-induced increases in activity have also been seen in mouse models of AD, 
suggesting that aberrant excitatory neuronal activity may be an early symptom leading to 
cognitive decline seen in AD patients (Palop et al., 2007; Palop and Mucke, 2009). Under normal 
conditions A acts to facilitate presynaptic function (Abramov et al., 2009), which is balanced by 
its ability to act as a negative regulator of postsynaptic function (Kamenetz et al., 2003). During 
AD, this balance can be overridden resulting in disruption of an activity dependent regulatory 
mechanisms (Palop and Mucke, 2010a). Therefore, a decrease in excitatory synaptic transmission 
at the synapse level occurs in concert with aberrant and epileptic form of activity at the circuit 
and network levels, respectively (Palop and Mucke, 2010b). This suggests that A induced 
dysfunction is causing destabilization of neural networks and provides evidence that A or other 
FAD-linked factors may have a role in regulating not only synaptic activity, but also more 
complex patterns of activity both within and across neural networks (Palop and Mucke, 2010a). 
Therefore, understanding how A and the progression of AD effects not only the magnitude of 
LTP/LTD, but the system’s ability to adequately adapt to changes in neural activity to produce 
metaplasticity is worth pursuing.  
Here we investigated the sliding threshold and pull-push models for regulating 
metaplasticity. It is well known that Hebbian synaptic plasticity, such as LTP or LTD can be 
responsible for the strengthening and weakening of synaptic connections in many brain regions 
[reviewed in (Malenka and Bear, 2004)]. Both models suggest that the modification threshold, 
defined as the cross over point from which the postsynaptic activity causes negative synaptic 
modification (LTD) to positive synaptic modification (LTP), is not static but can slide in a 
bidirectional manner based on past neuronal activity. Low level of activity will shift the 
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modification threshold to the left, favoring LTP induction at the expense of LTD. High levels of 
activity will shift the modification threshold to the right, promoting LTD at the expense of LTP 
(Bienenstock et al., 1982; Bear et al., 1987). This indicates that the modification threshold is able 
to slide right or left with changes in activity patterns. A key difference between sliding threshold 
model and pull-push model of metaplasticity is that the former is traditionally supported by 
changes in NMDAR gain that are responsible for changing plasticity induction mechanisms 
(Philpot et al., 2001b; Bear, 2003a; Yashiro and Philpot, 2008; Gray et al., 2011). However, the 
pull-push model states that metaplasticity results from regulating LTP/LTD expression 
mechanisms by effecting signaling that is downstream of NMDAR activation and therefore, 
downstream of plasticity induction mechanisms (Seol et al., 2007; Huang et al., 2012).  
Our data suggests that metaplasticity is altered in both young and adult 
APPswe;PS1deltaE9 Tg mice, but in opposite directions. In young mice the modification 
threshold was shifted to the left, favoring LTP at the expense of LTD (Fig 2.6 D), but in adult Tg 
mice the modification threshold was shifted to the right promoting LTD at the expense of LTP 
(Fig 2.6 H). The parameters responsible for the sliding threshold model of metaplasticity did not 
correlate with observed changes in LTP/LTD (Fig 2.8). Rather we did observe changes in GluA1-
S845 and GluA1-S831 phosphorylation levels (Fig 2.9) which correlate with the pull-push model 
of metaplasticity (Seol et al., 2007; Huang et al., 2012). Hence we propose that changes in 
frequency-dependent plasticity at both ages appear to be mediated by dysregulation of pull-push 
metaplasticity, leading to altered expression mechanisms of LTP/LTD. Additionally, we observed 
that developmental regulation of metaplasticity is altered in Tg mice. While WT mice show a 
developmental increase in frequency-dependent LTP, Tg mice lacked this developmental change 
(Fig 2.7). The observed changes in regulation of AMPAR can account for some, but not all of the 
synaptic phenotypes observed in the Tg mice. We have proposed a model to account for the 
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developmental deficits in Tg mice (Fig 2.10). In WT mice, we observed a developmental increase 
in LTP magnitude (Fig 2.7 C), which we surmise is due to enhanced synaptic recruitment and 
stabilization of AMPARs (Fig 2.10 A). In young Tg mice, the increase in GluA1-S831 
phosphorylation can account for many of the synaptic phenotypes that we observed. GluA1-S831 
phosphorylation is known to selectively increase conductance of GluA1 homomers (Oh and 
Derkach, 2005), which are inward rectifying and Ca2+-permeable (Cull-Candy et al., 2006). 
Inward rectifying AMPARs can summate responses better, because they do not produce outward 
current when the membrane is depolarized (Bowie and Mayer, 1995). In young Tg mice we 
observed enhanced summation of synaptic responses during LTP induction in the absence of 
functional changes in NMDAR ratio (Fig 2.8). However, we did observe an increased in GluA1-
S831 phosphorylation (Fig 2.9 C). If the increase in S831 phosphorylation was found on GluA1 
homomers, this suggests an alternative mechanism to regulate induction mechanisms for 
LTP/LTD leading to the observed increase in LTP magnitude in young Tg mice. Therefore, a 
logical next step would be to determine whether expression of GluA1 homomers is increased at 
the synapses of young Tg mice, using philanthotoxin-433 (PhTx) or Naspm, which are selective 
antagonists of Ca2+-permeable AMPARs. 
GluA2 lacking, Ca2+-permeable AMPARs have been called “plasticity inducers” (Man, 
2011). This is because they are transiently incorporated into the synapse following plasticity 
induction but are later replaced with GluA2 containing AMPARs (Plant et al., 2006). In addition, 
GluA1-S831 phosphorylation has been positively correlated with LTP (Lee et al., 2000a) and 
together with GluA1-S845 phosphorylation, responsible for decreasing the threshold for 
producing LTP (Makino et al., 2011; Hu et al., 2007), as observed in young Tg mice. Thus in 
young Tg mice, the rate at which AMPAR are inserted into the membrane may be increased 
compared to young WT mice, possibly due to the increase in GluA1-S831 phosphorylation, 
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resulting in presumable larger calcium influx, enhanced summation (Fig 2.8 A), and larger LTP 
(Fig 2.6 C). 
In adult Tg mice, there is no developmental increase in LTP magnitude even though the 
levels of AMPAR phosphorylation and the perisynaptic AMPAR pool size are similar to those of 
adult WT mice (Fig 2.9). This suggests that the developmental deficit is not at the level of 
synaptic recruitment of AMPARs or the availability of perisynaptic AMPARs, but is likely due to 
inability to anchor and stabilize the receptors at the PSD following LTP. Previous studies have 
shown that A peptides have the ability to decrease S845 and S831 phosphorylation sites on 
GluA1 (Zhao et al., 2004; Miñano-Molina et al., 2011). In normal conditions, these 
phosphorylation sites correlate with plasticity but their exact role in synaptic plasticity and 
AMPA trafficking remain unknown especially since mice lacking either the S845 or S831 site 
still express normal LTP (Lee et al., 2000a, 2003, 2010a). Another important GluA1-
phosphorylation site is the PKC phosphorylation site S818 (Boehm et al., 2006). Phosphorylation 
at this site mediates GluA1 insertion during LTP and helps to stabilize AMPAR at the surface by 
enhancing the binding of GluA1 to a neuronal actin binding protein 4.1N (Boehm et al., 2006; 
Lin et al., 2009). In addition, preventing phosphorylation of this site diminishes LTP (Boehm et 
al., 2006). Therefore, it may be of interest to compare GluA1-S818 phosphorylation in WT and 
Tg mice, given its role of stabilizing AMPAR to the surface.  
We propose that the main synaptic dysfunction of Tg mice is an inability to 
developmentally regulate LTP/D expression mechanisms due to an initial “off-set” in LTP/LTD 
induction threshold. In other words, the Tg mice are “stuck” at a defective level for producing 
LTP/LTD, and are unable to change as the synapses mature. If this is the case, it may also be 
relevant to compare how AMPAR phosphorylation changes throughout development between 
WT and Tg mice. Perhaps the reason that AMPAR phosphorylation levels are the same in adult 
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WT and Tg mice is that WT mice have undergone a developmental increase that correlates with 
LTP, while Tg levels remain unchanged throughout development.  
 
Section 2: Targeting APP modulation and dendritic spine density in WT mice 
This work also investigates two potential AD therapies in WT mice. To gain a more 
complete understanding of novel therapeutics it is important to investigate their effect on normal 
synaptic function and plasticity, as well as during diseased states. Even though BTA-EG4 and F-
spondin are very different molecules, they exhibit a similar mechanistic approach in conferring 
therapeutic benefits. Both BTA-EG4 and F-spondin increase dendritic spine density through an 
APP dependent increase in Ras signaling that did not correlate with enhanced LTP (Chapters 3 & 
4).  Dendritic spine density and Ras signaling are both disrupted during neurodegenerative 
disease (Knobloch and Mansuy, 2008; Stornetta and Zhu, 2011), therefore finding strategies that 
overcome these deficits are potential useful for the treatment of AD.  
Many leading strategies that seek to alter the long-term progression of AD are limited due 
to wide spread toxicity. These include therapies that target APP processing enzymes, like - and 
γ-secretase (Vetrivel et al., 2006; Wolfe, 2008; Loane et al., 2009; Svedružić et al., 2013; 
D’Onofrio et al., 2012). An alternative approach to alter A peptide production, rather than 
inhibiting the activity of these enzymes, may be the modulation of APP expression. Recently, the 
potential of modulating the steady-state levels of APP was examined in APPswe;PS1deltaE9 Tg 
mice treated with 2-PMAP (Asuni et al., 2014). This group found that steady-state APP levels 
were decreased in Tg mice, with a concomitant decrease in A levels following 2-PMAP 
treatment. They found that 2-PMAP was decreasing the translation of APP to mediate these 
effects. However, the effects of this drug were not tested in WT mice. Since full-length APP has 
been shown to increase synaptic function and dendritic spine density [reviewed in (Hoe et al., 
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2012)], the use of this drug in WT mice may negatively impact synaptic function. This example 
emphasizes the need to study the effects of novel therapeutics on normal neuronal function in 
order to ameliorate unwanted toxicity.  
Even though BTA-EG4 was developed in the hopes of preventing A interactions and 
aggregation, it is able to modulate APP processing by increasing the cell surface expression of 
APP (Fig 3.1). APP present on the cell surface is preferentially cleaved by α-secretase, resulting 
in decreased A production. F-spondin has also been shown to interact with APP and affect its 
processing (Ho and Südhof, 2004). Furthermore, our collaborators found that F-spondin levels 
may be regulated by APP (Chapter 4, Megill et al., in preparation). Previous studies have shown 
that F-spondin interacts with APP signaling by increasing APP on the cell’s surface, preventing 
APP cleavage, and reducing A production (Ho and Südhof, 2004; Hoe et al., 2005; Hafez et al., 
2012) [but see (Rice et al., 2013)]. Regulation of APP signaling by F-spondin is quite similar to 
that of another extracellular matrix protein, Reelin (Hoe et al., 2009). However, regulation of 
Reelin expression by APP is opposite to that of F-spondin. Our collaborators found that F-
spondin levels are increased in APP Tg mice, but Reelin levels are inversely related to APP 
expression such that Reelin is increased in APP KO mice and decreased in APP Tg mice 
(Tg2675) (Hoe et al., 2009). This suggests that unlike Reelin, F-spondin may act to amplify APP 
signaling. While we cannot rule out the possibility that the increase in F-spondin levels in APP 
Tg mice may reflect an increased retention of F-spondin via its direct binding to APP, (Ho and 
Südhof, 2004) rather than an increase in its synthesis, it nonetheless suggests that it would 
enhance APP signaling. This idea is consistent with the observation that the phenotypes seen with 
F-spondin treatment are quite reminiscent of those mediated by full-length APP. For instance, 
full-length APP has been shown to increase dendritic spine density [reviewed in (Hoe et al., 
2012)], similar to what was observed with F-spondin treatment. Our collaborators observation 
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that F-spondin mediated effects require APP, further supports the idea that F-spondin acts via 
APP signaling (Chapter 4, Megill et al., in preparation).  
The reduction in LTP magnitude following certain LTP induction protocol in BTA-EG4 
treatment (Fig 3.3), and F-spondin overexpression (Fig 4.2) in WT mice, suggest a homeostatic 
adjustment to the increase in dendritic spine density. In response to a higher synaptic density an 
increase in LTP induction threshold may prevent overexcitation of neuronal activity. Indeed, 
BTA-EG4 treatment in WT mice provides additional evidence for pull-push regulation of 
metaplasticity. As previously stated, a key feature of the pull-push model is the size of the 
perisynaptic AMPAR population and the regulation of AMPAR phosphorylation. Our data would 
suggest that the perisynaptic pool of AMPARs is decreased in BTA-EG4 treated WT mice 
compared to controls, and could explain the decrease in LTP magnitude. Since we saw no 
difference in cell surface expression of major AMPA- and NMDAR following BTA-EG4 
treatment (Fig 3.6), it suggests that the increase in functional synapses is likely due to lateral 
recruitment of existing cell surface glutamate receptors, thereby potentially decreasing the overall 
size of the perisynaptic pool of AMPARs in BTA-EG4 treated WT mice.  
Therefore, this work not only describes the structural and functional benefits of two 
potential therapeutics, but also an alternative way to provide cognitive benefits, which is to 
increase the number of functional synapses, providing a larger capacity to store information, in 
the absence of enhanced LTP. This suggests that targeting the number of functional synapses 
alone may be sufficient to improve cognitive function and provides an example of how potential 
therapeutics may alter the regulation of metaplasticity.  
Subsection 1: Future directions 
Given the therapeutic potential of BTA-EG4 and F-spondin, their effect on synaptic 
function and plasticity warrant further study in animal models of AD. This section will focus on 
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the potential of F-spondin (BTA-EG4 will be discussed in a later section). However, before F-
spondin is further pursued in AD models, further study in WT mice may be useful to add 
cohesion to the current literature. In this study, the effects of altering F-spondin expression were 
studied in CA1 of the hippocampus (Chapter 4). We found that F-spondin levels do not largely 
effect basal synaptic transmission in adult CA1 (Fig 4.1). We also found that endogenous levels 
of F-spondin were optimal and necessary for producing normal CA1 LTP (Fig 4.1 & 4.2). 
However, since our collaborators found that F-spondin is highly expressed in the DG of adult 
APP Tg mice (Chapter 4, Megill et al., in preparation), asking whether F-spondin is necessary for 
normal LTP in this region would be useful in understanding any alteration that may occur during 
AD. Here the effects of altering F-spondin expression, as a way to rescue synaptic deficits, may 
be more prominent and provide greater beneficial results. It is of interest to note that in a previous 
study, overexpressing F-spondin in the DG, using the same viral construct (Hafez et al., 2012), 
improved spatial learning and memory in WT mice but was not sufficient to improve memory in 
AD Tg mice. While Tg mice did show a decrease in A plaque number and increase in 
synaptophysin staining, the effect of F-spondin overexpression on synaptic function was not 
studied. Since we know that F-spondin is increased in the DG of APP Tg mice, perhaps this 
response is a way to compensate for loss of Reelin expression, or in response to other FAD-linked 
factors. For researchers to have a greater comprehension for why F-spondin was unable to rescue 
spatial memory deficits in Tg mice, we first need to understand the role F-spondin has in normal 
synaptic function and plasticity within the DG. Before the beneficial effect of F-spondin are 
further investigated in AD Tg mice, future studies could include how F-spondin overexpression 
(and knockdown) in CA1 effects spatial learning and memory, and how its overexpression or 




Section 3: The future of AD therapeutics 
In order for the potential AD therapies investigated in the study to be beneficial, the 
current literature and results from this work would suggest that the duration of treatment may 
need to be longer, and/or the initiation of treatment may need to be earlier. It is worth mentioning 
that current therapies tested in this work (Chapter 5) and in their previous counterparts (Chang et 
al., 2011; Song et al., 2014) were unsuccessful at significantly decreasing soluble A levels. This 
demonstrates that drug efficacy is not solely determined by its ability to lower A, nor should a 
drug be considered successful by this measurement alone. During the course of this work, our 
collaborators investigated how BTA-EG4 treatment affects neuronal function in 3xTg mice (Song 
et al., 2014). Collectively, our data suggests that BTA-EG4 treatment may be beneficial during 
early stages of AD. Our collaborators found an increase in dendritic spine density and improved 
cognitive performance in 6-10 month, but not 13-16 month old Tg mice, that occurred in the 
absence of enhanced LTP. This provides evidence that targeting dendritic spine density alone 
may be sufficient to improve cognitive function early in an AD mouse model. Unfortunately, 
conclusions from my work regarding the effects of treatment on synaptic function were largely 
complicated by off-target vehicle effects (Chapter 5) not previously seen in WT treated mice 
(Chapter 3). This raises awareness of commonly used vehicle solvent and their potential to impact 
normal neuronal function. The consequences of vehicle treatment may in part be dictated by the 
current behavioral state of the animal. Therefore, it is possible that these off-target vehicle effects 
were undetected in previous behavioral and structural measurements. Hence, more refined 
behavioral analysis may be needed to strengthen the validity of emerging therapeutics.  
Since BTA-EG4 and GRL-8234 were unable to rescue synaptic deficits and displayed 
either off-target vehicle effects or negative effects on plasticity (Chapter 5), treatments targeting 
regulation of push-pull metaplasticity warrant future investigation. Although it is not exactly clear 
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how altered expression mechanism of LTP/LTD would manifest in an inability to generate slots 
for AMPAR stabilization in the PSD following plasticity induction, treatments that target the 
initial dysfunction in set point may be beneficial by resetting the “stuck” modification threshold. 
These treatments may be found by focusing on some of the normal functions of APP, A, and 
PS1 that are disrupted during AD (Fig 1.2 & 1.4). 
Resetting the modification threshold has been proposed as a therapeutic approach to 
correct amblyopia in adults, and demonstrated to recover function following long-term monocular 
deprivation in the rodent visual cortex (Cho and Bear, 2010; Montey and Quinlan, 2011). By 
reducing the NR2A/NR2B ratio the modification threshold is lowered, promoting LTP, thereby 
promoting synaptic changes that support recovery of function. This demonstrates that sliding the 
modification threshold through a behavioral manipulation can enhance synaptic activity produced 
in response to subsequent sensory experiences (Cho and Bear, 2010). In our study, the threshold 
in adult Tg mice is increased, promoting LTD at the expense of LTP. If the threshold was 
lowered, by reducing the NR2A/NR2B ratio, this could promote recovery of synaptic function. 
Even though we did not measure a change in NR2A/NR2B ratio expression in adult Tg mice, it 
would be interesting to know if changing the subunit composition through genetic or 
pharmacological means would be an effective way to reset the threshold. Lowering the threshold 
could be achieved through decreasing the amount of NR2A, or increasing signaling through 
NR2B. Other questions might be, when would this manipulation be initiated and for how long 
should it be continued? Since these are questions asked of current therapeutics, this would be an 
alternative approach to inhibiting APP processing enzymes by targeting the metaplasticity 
threshold in the hopes of correcting synaptic dysfunction that occurs during AD. 
An alternative approach to resetting the threshold may be in the regulation of 
neuromodulatory systems. The pull-push model provides an example of how important 
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neuromodulators are in regulating plasticity expression mechanisms. Recent papers have 
demonstrated that neuromodulatory systems become disrupted in AD Tg mouse models 
(Coutellier et al., 2014; Nakauchi and Sumikawa, 2014; Wu et al., 2014). These papers focus 
specifically on the cholinergic and adrenergic neuromodulatory systems. Cholinergic signals 
modulate neural excitability of neurons within the hippocampus and have been implicated in 
many physiological function including synaptic plasticity and memory (Yakel, 2013; Molas and 
Dierssen, 2014). Loss of basal forebrain cholinergic innervation during AD and other 
neurodegenerative diseases correlates with cognitive decline (Schliebs and Arendt, 2011). Loss of 
cholinergic innervation, seen as a destruction in cholinergic axons, was seen in 
APPswe;PS1deltaE9 Tg mice, starting as early as 3 months (Wu et al., 2014). Another recent 
study discovered a role for nAChRs in the regulation of LTD induction, such that endogenous 
acetylcholine activating α7-nAChRs during LTD stimulation suppresses LTD induction at the 
Schaffer collaterals to CA1 synapse (Nakauchi and Sumikawa, 2014). Therefore, loss of this 
input during AD, or in AD mouse models, would result in loss of suppression, producing more 
LTD, as seen in adult Tg mice.  
The role of 1- adrenergic receptors in social recognition and memory was also recently 
characterized in a AD mouse model (Coutellier et al., 2014). This study found that memory 
deficits were improved when PKA and p-CREB levels were restored to normal levels by 
pharmacological activation of 1- adrenergic receptors. While synaptic plasticity was not 
measured, perhaps activating PKA signaling was able to enhance plasticity expression 
mechanism by changing AMPAR regulation and phosphorylation states according to the pull-
push model. Indeed, isoproterenol, a non-selective -adrenergic receptor agonist, has been shown 
to activate receptors coupled to AC/PKA signaling cascades and promote LTP in this way (Huang 
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et al., 2012). It would be interesting to know whether restoring the metaplasticity threshold lead 
to the cognitive benefits seen in this study. 
These studies provide evidence that loss of neuromodulatory inputs during the 
progression of AD may lead to deficits in metaplasticity regulation. Therefore, restoring these 
signals in Tg mice could be beneficial in reinstating the modulation of the LTP/LTD threshold. 
Indeed, enhancing cholinergic signaling has been studied as a potential therapeutic to rescue 
cognitive decline, and cholinesterase inhibitors have had some success in mild to moderate AD 
(O’Brien and Burns, 2011). However, methods to restore neuromodulatory systems may be 
complicated due to loss of innervation or death of, in this example, cholinergic neurons. In this 
way, postsynaptic neuron may lose their ability to respond to exogenous neuromodulatory 
signals. This could provide a potential explanation for why cholinesterase inhibitors work only in 
early but not late stages of AD.   
 Finally, understanding how deficits in synaptic activity lead to altered circuit and network 
activity may be important in determining which aspects of neuronal dysfunction most directly 
relate to cognitive decline (Palop and Mucke, 2010a). Understanding how metaplasticity becomes 
altered may provide insights into understanding the relationship between synaptic and network 
dysfunction seen during AD. 
 
Section 4: General conclusions 
It is believed that AD is initiated by synaptic dysfunction, which precedes cognitive 
deficits and neurodegeneration seen in AD patients. Therefore, it is imperative to know the exact 
nature of synaptic dysfunction in AD. In many studies that use AD Tg mouse models, it is unclear 
whether synaptic deficits are at the level of induction or expression of synaptic plasticity 
mechanisms. Here, I present data that suggest synaptic deficits are at the level of expression 
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mechanisms due to defects in pull-push regulation of metaplasticity. Our data uncovered a 
previously undescribed developmental defect in the regulation of metaplasticity causing the AD 
Tg mice to become “stuck” at different set points for inducing plasticity. Therefore these animals 
have lost the ability to adjust their synapses to prior synaptic activity and their synaptic weights 
have been “stuck” within the dynamic range for inducing LTP/LTD. An inability to regulate 
metaplasticity would limit the responsiveness of synapses to further subsequent modification 
causing the observed deficits in LTP/LTD magnitude. Our data suggests that it may not only be 
the change in LTP/LTD magnitude that is driving cognitive deficits, but the inability of the 
system to adequately adapt to changes in neural activity to produce metaplasticity. If 
metaplasticity deficits are universal across different models of AD, it may provide an explanation 
for the similar cognitive deficits in these models despite having varied LTP/LTD phenotypes 
mediated by different FAD-linked factors. In summary, treatments targeting regulation of pull-
push metaplasticity warrant future investigation since currently tested therapies proved 
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